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Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive. It is one of 
the most lethal solid malignancies and has a 5-year survival rate of less the 
3%. There is a high incidence of K-ras mutations in pancreatic cancer and it 
also thought that p21-activated kinase 4 (PAK4) is amplified in pancreatic 
cancer tissue. Studies show that PAK4 was not found in a mutated, 
oncogenic form but rather that its activation was likely to be due to mutations 
in the K-ras gene. It has consequently been hypothesised that K-ras gene 
mutations combined with PAK4 gene amplification could increase ras activity 
within pancreatic cancer. 
 
PAK4 is a member of the PAK family of serine/threonine kinases which act 
as effectors for several small GTPases. They are involved in a wide range of 
signalling pathways including cell motility, survival and proliferation; 
therefore, abnormal PAK signalling can contribute to a number of disease 
states. In particular, PAK4 is oncogenic when overexpressed, promoting cell 
survival, migration and anchorage-independent growth. While the mode of 
PAK4 regulation is not well understood, there is evidence from our lab, and 
others, that PAK4 may lie within a phosphatidylinositol-3-Kinase (PI3K) 
pathway, which is known to be downstream of RAS. This pathway can be 
activated via hepatocyte growth factor (HGF), which signals through the 
receptor tyrosine kinase, c-Met. c-Met acts as a proto-oncogene and 
increased expression of both c-Met and circulating HGF have been observed 
within pancreatic cancer. Such data suggest the potential existence of a c-
Met/RAS/PI3K/PAK4 signalling module. However, a direct in cellulo 
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relationship between PAK4 and RAS has not been reported and the nature of 
the relationship between PAK4 and PI3K remains to be fully elucidated. 
 
I have established that PAK4 expression is elevated in pancreatic cancer cell 
lines and correlated this with c-Met, K-ras and the p85α subunit of PI3K 
expression. Furthermore, I have validated a novel interaction between PAK4, 
K-ras and p85α. Work to date suggests that the PAK4:p85α interaction may 
be dependent on the scaffold protein Gab1. Moreover, I have found that in 
PAK4 deficient cells there is a reduction in the phosphorylation of Akt, a PI3K 
pathway target, further supporting the hypothesis that PAK4 functions 
downstream of PI3K. To complement my biochemical studies, I have 
established that PAK4 knockdown leads to decreased cell migration in 2D 
and demonstrated that this is phenocopied by pharmacological inhibition of 
PI3K. Subsequently, I optimised a pancreatic cancer organotypic model for 
HGF-mediated invasion and used this model to demonstrate that PAK4 
deficient cells have reduced invasive potential. These results implicate a role 
for PAK4 within the RAS/PI3K pathway, which is highly upregulated within 
pancreatic cancer and therefore suggest that PAK4 could be a key player in 




Table of Contents 
Declaration of Authorship………………………………………………… 2 
Acknowledgements………………………………………………………… 3 
Abstract………………………………………………………………………. 5 
Table of Contents…………………………………………………………… 7 
List of Figures……………………………………………………………….. 11 
List of Tables………………………………………………………………… 13 
Abbreviations……………………………………………………………….. 14 
Chapter 1 – Introduction…………………………………………………... 17 
1.1 Pancreatic cancer………………………………………………………. 18 
1.1.1 Pancreatic cancer – the disease…………………………… 18 
1.1.2 Anatomy of the pancreas……………………………........... 19 
1.1.3 Environmental and genetic risk factors………………….... 21 
1.1.4 Cellular origins of pancreatic cancer………………………. 23 
1.1.5 Pathophysiology of PDAC………………………………….. 28 
1.1.6 Stromal contribution to PDAC………………………........... 34 
1.2 Molecular genetics of PDAC…………………………………………... 38 
1.2.1 Signalling overview………………………………………….. 38 
1.2.2 Ras……………………………………………………………. 42 
1.2.3 Oncogenic K-ras signalling in PDAC………………........... 44 
1.2.4 Downstream effector pathways of oncogenic K-ras……... 48 
1.2.5 HGF/c-Met signalling in PDAC…………………………….. 52 
1.3 Cell migration and metastasis………………………………………… 56 
1.3.1 Cell migration…………………………………………........... 56 
1.3.2 Metastasis……………………………………………………. 61 
1.4 PAKs……………………………………………………………………... 66 
1.4.1 PAK overview………………………………………………… 66 
1.4.2 PAK expression and localisation…………………………... 67 
1.4.3 Structure of PAKs……………………………………………. 68 
1.4.4 Regulation of PAK activity………………………………….. 70 
1.4.5 PAK4 and cell migration…………………………………….. 73 
1.4.6 PAK4 and cancer……………………………………………. 75 
1.5 The project………………………………………………………............ 84 
1.5.1 Hypothesis……………………………………………………. 84 
1.5.2 Aims of the project…………………………………………... 84 
 8 
Chapter 2 – Materials and Methods……………………………………... 86 
2.1 Materials…………………………………………………………………. 87 
2.1.1 General materials……………………………………………. 87 
2.1.2 Buffers………………………………………………………… 91 
2.1.3 Plasmids………………………………………………........... 93 
2.1.4 Primers……………………………………………………….. 95 
2.1.5 Antibodies…………………………………………………….. 96 
2.2 Methods – Molecular biology………………………………………….. 99 
2.2.1 Generation of tagged constructs…………………………… 99 
2.2.2 Gel purification of DNA fragments…………………………. 100 
2.2.3 Construction of entry clones………………………………... 100 
2.2.4 Construction of expression clones…………………........... 102 
2.2.5 Site-directed mutagenesis………………………………….. 103 
2.2.6 Transformation of E. coli cells………………………........... 104 
2.2.7 DNA preparation…………………………………………….. 105 
2.3 Methods – Cell biology………………………………………………… 106 
2.3.1 Cell lines and culture conditions……………………........... 106 
2.3.2 Calcium phosphate transfection……………………........... 107 
2.3.3 X-tremeGENE transfection…………………………………. 108 
2.3.4 Hiperfect siRNA transfection……………………………….. 109 
2.3.5 Collagen coating…………………………………………….. 110 
2.3.6 Time-lapse microscopy…………………………………… 110 
2.3.7 Inhibitors………………………………………………........... 111 
2.3.8 MTT assay……………………………………………………. 112 
2.3.9 HGF stimulations…………………………………………….. 112 
2.3.10 Immunofluorescence………………………………………. 113 
2.3.11 Organotypic culture models………………………………. 115 
2.4 Methods – Biochemistry……………………………………………….. 121 
2.4.1 Protein preparations…………………………………........... 121 
2.4.2 GST pulldown assay…………………………………........... 122 
2.4.3 Western blotting……………………………………….......... 122 
2.5 Data and statistical analysis…………………………………………… 125 
2.5.1 Organotypic model…………………………………………... 125 
2.5.2 Densitometry…………………………………………………. 125 
2.5.3 Statistics……………………………………………………… 125 
  
 9 
Chapter 3 – Results Part I Characterisation of pancreatic cell lines 126 
3.1 Introduction……………………………………………………………… 127 
3.2 Results…………………………………………………………………… 130 
3.2.1 E-cadherin expression………………………………………. 130 
3.2.2 Further characterisation of the cell line dechTERT........... 137 
3.2.3 Morphology of pancreatic cell lines………………………... 140 
3.2.4 Characterisation of protein expression……………………. 140 
3.2.5 Characterisation of PAK family kinase expression………. 148 
3.3 Discussion………………………………………………………………. 153 
3.4 Future work……………………………………………………………… 159 
Chapter 4 – Results Part II Characterisation of PAK4 depletion in 
pancreatic cancer cell lines………………………………………………. 
 
160 
4.1 Introduction………………………………………………….…………... 161 
4.2 Results…………………………………………………………………… 164 
4.2.1 HGF leads to increased Akt/Erk phosphorylation.............. 164 








4.2.4 PAK4 knockdown in PaTu8988S and PaTu8988T cells… 170 
4.2.5 Depletion of PAK4 leads to a reduction in cell area and 
rounder cell shape in PaTu8988T cells …………………………. 
 
173 
4.2.6 Depletion of PAK4 reduces PaTu8988T cell migration….. 175 
4.2.7 Production of a PAK4 siRNAi rescue construct………….. 178 




4.3 Discussion………………………………………………………………. 183 
4.4 Future work……………………………………………………………… 189 
Chapter 5 – Results Part III Investigation of the interaction of 
PAK4 with the PI3K pathway……………………………………………... 
 
192 
5.1 Introduction……………………………………………………………… 193 
5.2 Results…………………………………………………………………… 197 
5.2.1 PAK4 interacts with K-ras…………………………………... 197 
5.2.2 PAK4 interacts with the p85α subunit of PI3K……………. 197 













5.2.6 Use of PI3K inhibitor phenocopies PAK4 knockdown…… 206 
5.3 Discussion………………………………………………………………. 211 
5.4 Future work……………………………………………………………… 216 




6.1 Introduction……………………………………………………………… 219 
6.2 Results…………………………………………………………………… 222 




6.2.2 Optimisation of the organotypic model……………………. 226 
6.2.3 HGF increases invasion of pancreatic cancer cells in 3D. 228 
6.2.4 siRNA mediated depletion of PAK4 has no significant 
impact on PaTu8988T cellular proliferation……………………... 
 
232 








6.3 Discussion………………………………………………………………. 244 
6.4 Future work……………………………………………………………… 250 





List of Figures 
Figure 1.1 Anatomy of the pancreas 20 
Figure 1.2 PanIN progression 33 
Figure 1.3 Structure of ras proteins 43 
Figure 1.4 Ras signalling 45 
Figure 1.5 Metastatic process 62 
Figure 1.6 PAK Structure 69 
Figure 1.7 Mechanism of PAK4 autoinhibition 72 
   
Figure 2.1 GatewayTM Technology BP and LR reactions 101 
Figure 2.2 Organotypic model set up 119 
Figure 2.3 Organotypic model analysis 120 
   
Figure 3.1 E-cadherin expression in pancreatic cell lines 131 
Figure 3.2 Calcium nitrate induces the formation of cell-cell 
contacts in HPDE cells 
135 
Figure 3.3 Expression of E-cadherin and β-catenin in pancreatic 
cell lines 
136 
Figure 3.4 Protein expression in the duct epithelial cell line, 
dechTERT 
138 
Figure 3.5 Morphology of pancreatic cell lines 141 
Figure 3.6 Expression of p53 in pancreatic cell lines 146 
Figure 3.7 Expression of c-Met and p85α in pancreatic cell lines 147 
Figure 3.8 K-ras expression in pancreatic cell lines 149 
Figure 3.9 Expression of Group I PAKs in pancreatic cell lines 150 
Figure 3.10 Expression of Group II PAKs in pancreatic cell lines 152 
   
Figure 4.1 Effect of HGF stimulation on the phosphorylation of Akt 
and ERK 
165 
Figure 4.2 Effect of HGF on the phosphorylation of group II PAKs 168 
Figure 4.3 Effect of HGF on PaTu8988S/T cell migration 169 
Figure 4.4 PAK4 knockdown in pancreatic cancer cell lines 171 
Figure 4.5 Effect of PAK4 depletion on PaTu8988T cell area 174 
 12 
Figure 4.6 Effect of PAK4 knockdown on PaTu8988T cell migration 176 
Figure 4.7 PAK4 siRNA rescue construct 180 
Figure 4.8 Reduction in Akt phosphorylation correlates with 
depletion of PAK4 
182 
   
Figure 5.1 PAK4 interacts with K-ras 198 
Figure 5.2 PAK4 interacts with the p85α subunit of PI3K 199 
Figure 5.3 Requirement of SH3 domain of p85α for interaction with 
PAK4 
201 
Figure 5.4 Point mutants of PAK4 reveal no preferential binding site 
within PxxP region 
204 
Figure 5.5 The interaction between PAK4 and p85α is dependent 
on Gab1 
207 
Figure 5.6 Effect of using the PI3K inhibitor LY294002 208 
   
Figure 6.1 Characterisation of PS-1 and PaTu8988T cells 223 
Figure 6.2 Raised air-liquid organotypic model 227 
Figure 6.3 Addition of HGF promotes invasion of pancreatic cancer 
cells in 3D 
230 
Figure 6.4 Depletion of PAK4 has no significant impact on 
PaTu8988T cellular proliferation 
234 
Figure 6.5 PAK4 depletion leads to a reduction in PaTu8988T cell 
invasion in 3D 
236 
Figure 6.6 Cleaved caspase 3 staining of 3D organotypic model 239 
Figure 6.7 Ki67 staining of 3D organotypic model 241 
Figure 6.8 Pharmacological inhibition of PI3K phenocopies invasion 
patterns of PAK4 knockdown cells 
243 
   
Figure 7.1 Proposed model of RAS/PI3K/PAK4/Akt signalling 







List of Tables 
 
Table 1.1 Familial conditions linked with an increased risk of 
pancreatic  
23 
Table 1.2 Classification of pancreatic neoplasms 25 
Table 1.3 Description of PanIN lesions 31 
Table 1.4 Summary of molecular events involved in PDAC 40 
Table 1.5  PAKs in cancer 76 
   
Table 2.1 Mammalian plasmids 93 
Table 2.2 Bacterial plasmids 94 
Table 2.3 Primers 95 
Table 2.4 Primary antibodies 96 
Table 2.5 Secondary antibodies 98 
Table 2.6 PCR conditions for amplification of Ras constructs 99 
Table 2.7 Cycling parameters for the QuikChange Site-Directed 
Mutagenesis method 
103 
Table 2.8 Transformation procedure of chemically competent 
E.coli bacteria 
104 
Table 2.9 Calcium phosphate transfection reaction mix 108 
Table 2.10 X-treme Gene transfection reaction mix 109 
Table 2.11 Sequences of siRNAs used 110 
Table 2.12 Organotypic model matrix preparation 116 
Table 2.13 Components of collagen gel mixture 117 
   





ADM Acinar to ductal metaplasia 
AID Autoinhibitory domain 
Ang-2 Angiopoietin-2 
Arp2/3 Actin related protein 2/3 
Arx Aristaless-related homeobox 
bHLH Basic helix-loop-helix 
BOP Nitrosamine N-nitrosobis-(2-oxopropyl)amin 
Cdc42 Cell division control protein-42 
CDK5RAP3 CDK5 kinase regulatory subunit-associated protein 3 
CRIB Cdc42/Rac interactive binding region 
CSC Cancer stem cell 
CTGF Connective tissue growth factor 
DEspR Dual endothelin1/VEGF signal peptide receptor 
DR Desmoplastic reaction 
ECM  Extracellular matrix 
EMT Epithelial to mesenchymal transition 
FGF Fibroblast growth factor 
GAP GTPase activating protein 
GBD p21-GTPase binding domain 
GDP Guanosine diphosphate 
GEF Guanine nucleotide exchange factor 
GEMM Genetically engineered mouse models 
GID GEH-H1/Gab1-interacting domain 
GTP Guanosine triphosphate 
HMGA1 High-mobility group A1 
Hnf6 Hepatocyte nuclear factor 6 
IL-6 Interleukin-6 
IPMN Intraductal papillary mucinous neoplasm 
JNK c-Jun N-terminal Kinase 
kDa Kilodalton 




MAPK Mitogen activated protein kinase 
MCN Mucinous cystic neoplasm 
MIC Metastatic-initiating cell 
MLC-2 Myosin light chain-2 
MMP Matrix metalloproteinase 
mTORC2 Mammalian target of rapamycin complex-2 
Neurog3 Neurogenin3+ 
Nkx2.2 NK2 homeobox 2  
NMR Nuclear magnetic resonance 
NmU Neuromedin U 
Np-1 Neuropilin-1 
NRP-2 Neuropilin-2 
PAKs p21-activated kinases 
PanIN Pancreatic intraepithelial neoplasia 
PDAC Pancreatic ductal adenocarcinoma 
PDGF Platelet derived growth factor 
PDK-1 3-phosphoinositide-dependent protein kinase-1 
Pdx1 Pancreatic and duodenal homeobox 1 
PH Pleckstrin homology 
PI-4,5-P2 Phosphatidylinositol-4,5-bisphosphate 
PI3K Phosphatidylinositol 3-kinase 
PIP3 Phosphatidylinositol-3,4,5-triphosphate 
PIX PAK-interacting exchange factor 
PKB Protein kinase B 
PKD Protein kinase D 
PP Pancreatic polypeptide 
PSC Pancreatic stellate cell 
PTEN Phosphate and tensin homolog 
Ptf1A Pancreas specific transcription factor 1A 
RTK Receptor tyrosine kinase 
SHH Sonic Hedghog 
SMA Smooth muscle actin 
 16 
SOS Son of sevenless 
SSH-1L Sling-Shot phosphatase-1L 
STAT3 Signal transducer and activator of transcription 3 
TGF-β Transforming growth factor-beta 
VEGF Vascular endothelial growth factor 
WASP Wiskott-Aldrich syndrome protein 
WAVE WASP family verprolin homologous protein 













Chapter 1: Introduction 
1.1 Pancreatic Cancer 
1.1.1 Pancreatic cancer – the disease 
Pancreatic cancer is one of the most lethal solid malignancies; it is the eighth 
most common cancer in the UK and fourth most common cause of cancer 
death in higher-income countries (Kocher and Alrawashdeh, 2010). The five-
year survival rate of patients diagnosed with pancreatic cancer is less than 
5%, with a median survival of less than six months (Bardeesy and DePinho, 
2002). These figures have shown little improvement over the last forty years, 
making a diagnosis of pancreatic cancer carrying one of the most dismal 
prognoses in medicine and highlighting the necessity for increased 
knowledge and novel therapeutics for the diagnosis and treatment of this 
disease.  
 
The prognosis of pancreatic cancer is related to a number of factors such as 
clinical stage at presentation, involvement of lymph nodes and/or formation 
of metastases, tumour size and differentiation (Gobbi et al., 2013). One of 
the factors that leads to low survival rates is that pancreatic cancer often 
lacks specific symptoms, especially during the early phases of the disease. 
However, symptoms can include back pain, vague abdominal symptoms and 
weight loss. The majority of patients are diagnosed after presenting with 
obstructive jaundice, which is usually caused by obstruction of the bile duct 
(Freelove and Walling, 2006). For a small minority of patients (15-20%), 
complete surgical resection (pancreaticduodenectomy/Kausch-Whipple 
procedure or pylorus-preserving pancreaticduodenectomy/Traverso-
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Longmire procedure) offers the only hope for cure and can improve the five-
year survival rate to approximately 20% (Collins and Bloomston, 2009; 
Freelove and Walling, 2006; Kocher and Alrawashdeh, 2010). 
 
There are only a small number of surgical candidates because more than 
half of patients have already developed distant metastases at the time of 
presentation. In addition, poor survival rates can be accounted to aggressive 
local invasion, particularly of major vessels, and resistance to 
chemotherapies (Bardeesy and DePinho, 2002; Collins and Bloomston, 
2009; Freelove and Walling, 2006).  
 
1.1.2 Anatomy of the pancreas 
The mature pancreas contains three main cell lineages and consists of two 
distinctive functional units, which differ in the specific biological roles they 
participate in; the exocrine portion is important in digestion, and the 
endocrine portion plays a significant role in glucose metabolism (Pandol, 
2010). The majority of the pancreas is exocrine tissue and contains two 
different cell types; acinar (exocrine cells) and epithelial duct cells 
(MacDonald et al., 2010; Mastracci et al., 2011). Acinar cells are organised 
into small glands called acini (see figure 1.1A) and are responsible for the 
synthesis and secretion of digestive enzymes such as trypsin, elastase and 
amylase (Hezel et al., 2006; Mastracci et al., 2011), which are stored as 
inactive enzyme forms in zymogen granules (Jura et al., 2005). The duct 
epithelial cells form branching networks, with acini arranged at each 




Figure 1.1: Anatomy of the pancreas. (A) Representation of an acinar 
unit and its relation to the pancreatic ducts. Acini form at the terminal 
ends of the branching ductal network and contain inactive enzymes in 
the form of zymogens. Also shown are the centroacinar cells, which are 
at the junction of the ducts and acini. (B) Pancreatic islet, which is the 
endocrine portion of the pancreas and is embedded in the exocrine 
tissue. Shown are the four main endocrine cells, which are responsible 
for hormone production, controlling glucose metabolism. Figure was 
adapted from: (Bardeesy and DePinho, 2002; Hezel et al., 2006). 
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duct cells are called centroacinar cells and these interface with acini cells 
(Reichert and Rustgi, 2011). 
 
There are five specialised types of endocrine cells; these are organised into 
compact regions called the Islets of Langerhans, which are interspersed 
throughout the exocrine tissue (see figure 1.1B) (Bardeesy and DePinho, 
2002; Hezel et al., 2006). The alpha and beta cells play a significant role in 
glucose metabolism and produce glucagon and insulin, respectively, which 
they release directly into the blood stream. The pancreatic polypeptide (PP), 
delta and epsilon cells modulate the secretory behaviour of the alpha and 
beta cells. They do so through expressing pancreatic polypeptide, 
somatostatin and ghrelin, respectively (Gradwohl et al., 2000; Prado et al., 
2004). 
 
1.1.3 Environmental and genetic risk factors 
Several personal and environmental factors have been associated with the 
development of pancreatic cancer, with smoking being the most well 
established risk factor (Hassan et al., 2007). It has been reported that 
smokers have approximately a 1.74-fold increased risk of developing 
pancreatic cancer, with nitrosamines found in cigarette smoke being potent 
carcinogens; despite these also being present in second-hand smoke, there 
is no increased risk observed as yet to non-smokers exposed to 
environmental tobacco smoke (Iodice et al., 2008; Zhou et al., 2012). 
However, pancreatic cancer is generally considered a disease of the aging 
and is rarely seen before the age of 40, with a 40-fold increased risk by the 
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age of 80 (Bardeesy and DePinho, 2002) and the highest incidence rates 
occurring between the ages of 65-75 (Hariharan et al., 2008; Lowenfels and 
Maisonneuve, 2006). In addition, excessive alcohol consumption and obesity 
also appear to confer an increased risk (Hezel et al., 2006; Jura et al., 2005). 
It has also been reported that those with a benign disease of the pancreas, 
such as chronic pancreatitis or diabetes are also at an increased risk of 
developing pancreatic cancer (Hezel et al., 2006; Jura et al., 2005; Lowenfels 
and Maisonneuve, 2006). In chronic pancreatitis, there is increased cell 
turnover and proliferation as well as defective DNA repair. It has also been 
observed that a loss of p16 expression and KRAS mutations occur frequently 
in chronic pancreatitis and these are found in the high majority of pancreatic 
cancers (Lohr et al., 2005; Lowenfels and Maisonneuve, 2006; Rosty et al., 
2003). In addition, diabetes mellitus is also considered a risk factor of 
pancreatic cancer and diabetes mellitus is considered both an early 
manifestation and an etiologic factor of pancreatic cancer (Ben et al., 2011; 
Everhart and Wright, 1995). 
 
There are several germline mutations that are associated with pancreatic 
cancer, but only approximately 10% are thought to be caused by an inherited 
disorder; the most common inherited genetic disorder is a mutation in 
BRCA2, which can increase the frequency of pancreatic cancer (Couch et 
al., 2007; Lowenfels and Maisonneuve, 2006). There are also a number of 
familial conditions, which can be linked to an increased risk of the 
development of pancreatic cancer. These include; familial atypical mole-
multiple melanoma (FAMMM), Peutz-Jeghers syndrome (PJS), 
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familial/hereditary pancreatitis, cystic fibrosis, Lynch syndrome, familial 
breast/ovarian cancer, Li-Fraumeni syndrome, familial adenomatous 
polyposis (FAP), multiple endocrine neoplasia (MEN) and Von Hippel-Lindau 
syndrome (VHL) (Bartsch et al., 2012; Fill et al., 1979; Hough et al., 1994; 
Landi, 2009) and are summarised in table 1.1. 
 


























































Table 1.1: Familial conditions linked with an increased risk of 
pancreatic cancer. Table adapted from: (Bartsch et al., 2012; Ghaneh et al., 
2007; Landi, 2009) 
 
 
1.1.4 Cellular origins of pancreatic cancer 
Pancreatic cancer can arise in different areas of the pancreas. The most 
commonly afflicted area is within the head of the pancreas, with 
approximately 65% of pancreatic cancers arising in this area. However, 15% 
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originate in the body of the pancreas, 10% are located within the tail and 
10% are multifocal (Ghaneh et al., 2007).  
 
There are several different tumour types that can develop in the pancreas; 
their classification is defined by the histological and molecular resemblance 
to the different pancreatic cell lineages (as described previously) and 
whether they are solid, cystic or intraductal (Bardeesy and DePinho, 2002; 
Hezel et al., 2006; Klimstra et al., 2009). As stated, there are multiple tumour 
types, however, pancreatic ductal adenocarcinoma (PDAC) is by far the most 
common pancreatic neoplasm and accounts for over 80% of cases (Ghaneh 
et al., 2007; Hezel et al., 2006).  Because PDAC is the most commonly 
occurring cancer of the pancreas, the term PDAC and pancreatic cancer are 
often used synonymously but it should be noted that there are a diverse 
range of malignant neoplasms with different characteristics and 
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Table 1.2: Classification of pancreatic neoplasms. Table describes an 
abridged classification of pancreatic neoplasms showing histological features 
and common genetic alterations. Table was adapted from: (Hezel et al., 
2006; Klimstra et al., 2009). 
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Having stated that the majority of pancreatic neoplasms are ductal in origin, 
the actual cellular origin is still an ambiguous subject. There is a significant 
amount of diversity in the turnover of tissue in the pancreas, with a range of 
cells thought to contribute to homeostatic tissue turnover and/or regeneration 
of the pancreas. These include mature epithelial cells, stem cells and bone 
marrow cells (Kong et al., 2011). Due to the histologic appearance of PDAC, 
with a predominantly epithelial cell morphology being observed and dysplasia 
occurring in precancerous ductal lesions, a ductal origin has long been 
suggested (Hernandez-Munoz et al., 2008; Rooman and Real, 2012). 
However, due to the variety of cell types that contribute to normal tissue 
turnover, and with the development of genetic mouse models, it has been 
suggested that PDAC could arise from alternative cellular origins (Stanger 
and Dor, 2006). 
 
With the development of conditionally activatable KRAS alleles in a mouse 
model, which perfectly mimics the point mutations leading to PDAC in the 
human pancreas (Aguirre et al., 2003; Hingorani et al., 2003), further insight 
has been provided into the cellular origins of PDAC. Carcinogens adversely 
impact various cell types in the pancreas, making lineage fidelity difficult to 
preserve (Habbe et al., 2008; Murtaugh and Leach, 2007) and, surprisingly, 
expression of oncogenic K-ras into ductal cell lines has failed to produce 
PDAC or its pre-cursor lesions (see section 1.1.5) (Brembeck et al., 2003). 
Numerous studies have implicated acinar origin due to the frequent 
observation whereby acinar cells expressing mutant K-ras transdifferentiate 
to produce a ductal cell phenotype in a process called acinar to ductal 
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metaplasia (ADM), which has been shown in both humans and mouse 
models (Carriere et al., 2007; De La et al., 2008; Guerra et al., 2007; Habbe 
et al., 2008; Morris et al., 2010a; Shi et al., 2013; Stanger and Dor, 2006). 
For example, it has been demonstrated that ectopic induction of the ductal 
gene Sox9 when expressed with oncogenic K-ras induced the formation of 
PDAC precursors with ductal features (Kopp et al., 2012). In this same study, 
similar results were not observed when using either centroacinar or ductal 
cells. 
 
Alternatively, studies into other possible cellular origins have also been 
published. It has been suggested that deregulated phosphatidylinositol 3-
kinase (PI3K) signalling in centroacinar cells can also contribute to the 
development of PDAC in vivo (Stanger et al., 2005). In addition, centroacinar 
cells have been hypothesised to be pancreatic progenitor cells, contributing 
to maintenance of tissue homeostasis and exhibiting expansion in response 
to injury (Rovira et al., 2010). However, despite this study demonstrating the 
ability of centroacinar cells to differentiate, there is still little research to 
establish whether they play a definitive role in PDAC development (Rooman 
and Real, 2012). In addition, whether islet cells could be the cellular origins 
of PDAC has also been investigated. This hypothesis was based on results 
demonstrating that islet cells were capable of transdifferentiation, act as 
facultative stem cells and redifferentiate into cells with stem cell 
characteristics (Bardeesy and DePinho, 2002; Hennig et al., 2004). It has 
also been shown that after transplantation of islet cells into mice, pancreatic 
cancer with a PDAC-like phenotype developed in response to treatment with 
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the carcinogen nitrosamine N-nitrosobis-(2-oxopropyl)amin (BOP) (El-
Ghamari et al., 2011). Furthermore, a recent study compared the localisation 
of the embryonic stem cell marker, Nanog, and the adult intestine stem cell 
marker, leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), 
in normal and pancreatic cancer samples. This revealed a novel 
colocalisation of the two proteins in beta cells within the islets and also in 
ductal cancer cells (Amsterdam et al., 2013). The authors suggest that the 
beta cells expressing these markers are the initiating cells of PDAC after 
migration and de-differentiation. There is also the question as to whether 
there is a population of stem cells within the pancreas that could give rise to 
PDAC. These cancer stem cells (CSCs) have a high proliferative capacity, 
have the potential to self renew and are pluripotent, with the ability to 
produce differentiated progeny (Bao et al., 2010; Li et al., 2007; Matsuda et 
al., 2012). These CSCs were shown to form tumours in immunocompromised 
mice and several CSC-specific marker have been reported, including CD133, 
CD24, CD44, CXCR4, EpCAM, ABCG2, c-Met, ALDH-1 and nestin, with 
upregulation of the Notch signalling pathway also being apparent. (Abel et 
al., 2014; Amsterdam et al., 2013; Li et al., 2011a; Matsuda et al., 2012; 
Rooman and Real, 2012). However, their use is controversial due the 
expression of these markers in some differentiated cell types of the adult 
pancreas (Rooman and Real, 2012). 
 
1.1.5 Pathophysiology of PDAC 
Over the last decade, knowledge of PDAC precursor lesions has grown and 
the general consensus is that there is a step-wise progression from these 
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lesions to invasive cancer (Distler et al., 2014). Three histologically different 
pancreatic tumour precursor lesions have been described: mucinous cystic 
neoplasms (MCN), intraductal papillary mucinous neoplasms (IPMN) and 
pancreatic intraepithelial neoplasias (PanIN) (Chu et al., 2007; Ghaneh et al., 
2007; Hernandez-Munoz et al., 2008). Early detection and treatment of these 
precursor lesions could help prevent the subsequent development into 
invasive PDAC. PanINs are the most comprehensively studied and are the 
most commonly occurring precursor to PDAC, however, all of these lesions 
exhibit a characteristic step-wise progression towards PDAC and share a 
number of key features (Chu et al., 2007). 
 
IPMNs are characterised by columnar, mucin-producing epithelium (Singh 
and Maitra, 2007), which typically arise within the main pancreatic duct 
and/or the major ductal branches (Werner et al., 2012). Approximately 70% 
of IPMNs are located in the head of the pancreas as opposed to the body or 
tail (Scarlett et al., 2011) and are subdivided into main duct (MD-IPMN) and 
branch duct (BD-IPMN) according to their specific site of origin. Where main 
and branch ducts are involved, mixed-duct or combined-duct terminology is 
applied (Distler et al., 2014; Fritz et al., 2012; Nagai et al., 2008). IPMNs are 
further subclassified depending on the degree of dysplasia into low-grade, 
intermediate-grade, high-grade and IPMN with associated invasive 
carcinoma (Distler et al., 2014) as well as by their histological appearance 
into intestinal, pancreatobiliary, gastric and oncocytic types (Grutzmann et 
al., 2010). Two types of invasive pancreatic cancers typically develop from 
IPMNs, tubular and colloid mucinous noncystic carcinomas (Grutzmann et 
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al., 2010; Xiao, 2012; Yopp and Allen, 2010). Common genetic aberrations 
within IPMNs include mutations in KRAS, CDKN2a, STK11 and a minor 
fraction of cases exhibit alterations to TP53 and SMAD4 (Grutzmann et al., 
2010; Scarlett et al., 2011; Shi and Hruban, 2012). It has also been noted 
that in over 96% of IPMNs there is a mutation in either GNAS or KRAS, with 
a mutation in both genes being observed in half. In addition, GNAS mutations 
occurred more frequently in the intestinal subtype, whereas KRAS mutations 
were more prevalent in the pancreatobiliary subtype of IPMN (Furukawa et 
al., 2011; Kanda et al., 2013; Wu et al., 2011b). 
 
The most infrequent precursor lesions of pancreatic cancer are MCNs and 
the majority are located within the pancreatic body and tail (Distler et al., 
2014). They are typically described as neoplasms composed of mucin-
producing epithelial cells and have an ovarian-type of stroma, with the 
majority being found in women (Scarlett et al., 2011; Testini et al., 2010). 
MCNs are cystic lesions, capable of growing very large, with a fibrous 
pseudocapsule, often with calcifications. Unlike IPMNs, MCNs rarely involve 
the ductal system (Zamboni et al., 1999). They are classified by the degree 
of dysplasia observed, which correlates with patient prognosis (Fernandez-
del Castillo and Warshaw, 1995). KRAS mutations have been observed in 
early MCN lesions, which increase with advancing dysplasia. In more 
advanced MCNs, mutations in TP53, p16, SMAD4 have also been reported 
(Baker et al., 2012; Jimenez et al., 1999; Matthaei et al., 2011; Scarlett et al., 
2011; Singh and Maitra, 2007). 
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PanINs are the most widely studied precursor of pancreatic cancer and were 
originally called by multiple terminologies, such as flat hyperplasia and ductal 
papillary hyperplasia (Scarlett et al., 2011), but the PanIN classification is 
now the accepted system (Hruban et al., 2001; Hruban et al., 2004). PanIN 
lesions are categorised into early and late lesions, progressing from PanIN-
1A and PanIN-1B, which are low grade lesions to PanIN-2 and PanIN-3 
lesions, which are intermediate and high-grade lesions, respectively (Distler 






Develops from normal, flat epithelium and is composed of tall, 
columnar cells with a small amount of overcrowding. Nuclei 
are basally located and appear small and round/oval. There is 




These are very similar to PanIN-1A lesions, but columnar cells 
become increasingly crowded. Cells can also develop papillary 




Architecturally these lesions are comparable to PanIN-1B 
lesions, commonly with papillary/micropapillary architecture. 
However, they demonstrate a moderate degree of architectural 
and nuclear atypia. These abnormalities include some loss of 
polarity, nuclear crowding and enlargement, nuclear 




These lesions demonstrate severe cytological and 
architectural atypia. Cribriform structures and luminal necrosis 
is often observed as small clusters of cells budding off into the 
gland lumen. There is a complete loss of nuclear polarity. They 
are also known as carcinoma in situ as lesions resemble 
carcinoma at the cytonuclear level. There is however, no 
invasion through the basement membrane. 
 
  
Table 1.3: Description of PanIN lesions. PanIN lesions are precursors of 
pancreatic cancer and form a recognised tumour progression model with 
increasing neoplastic potential. Table adapted from: (Biankin et al., 2004; 
Hruban and Fukushima, 2007; Scarlett et al., 2011) 
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PanINs are microscopic lesions, usually less that 5mm, which form in the 
smaller, intralobular pancreatic ducts (Distler et al., 2014; Hruban and 
Fukushima, 2007; Hruban et al., 2004; Scarlett et al., 2011). Pancreatic 
cancer is thought to develop from low-grade to high-grade PanIN lesions, 
then PDAC. The increasingly disorganised cellular architecture and nuclear 
atypia is accompanied by a series of genetic changes (Distler et al., 2014) 
and is summarised in figure 1.2. There are a number of genetic aberrations 
that occur during the development and progression of PanIN lesions. Early 
events that take place include mutations in KRAS (De La et al., 2008), 
telomere shortening (Distler et al., 2014) and overexpression of p21WAF1/CIP1 
(Biankin et al., 2004), which is an important regulator of the cell-cycle 
machinery and its increased expression correlates with PanIN progression 
(Biankin et al., 2004; Scarlett et al., 2011). These early, activating mutations 
of KRAS are observed in over 90% of PDACs and are thought to be the 
driving force behind PDAC formation (Hingorani et al., 2003; Hruban et al., 
1993). As stated, telomere shortening occurs early within PanIN lesion 
progression, this ultimately leads to abnormal fusion of chromosomes, affects 
cell division and increases genomic instability (Koorstra et al., 2008; Maitra et 
al., 2006; van Heek et al., 2002). Telomere shortening is thought to be one of 
the major causes for the gain of oncogenes and other genetic abnormalities 
include inactivation of several tumour suppressor genes (Haugk, 2010). 
These include inactivation of p16/CDKN2A occurring in early PanIN lesions 
and TP53 and SMAD4/DPC4 inactivation occurring later (Hruban et al., 
2004; Koorstra et al., 2008). It has also been shown that aberrant CpG island 
hypermethylation begins in early PanIN lesions and this progressively  
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Figure 1.2: PanIN progression. Diagram demonstrates the different 
theorised cellular origins of PDAC including 1) acinar cells, 2) islet cells, 
3) centroacinar cells and 4) duct cells. Activating KRAS mutations in 
pancreatic cells is able to initiate the development of PDAC. It is 
thought that this develops through a series of stages; progressing from 
PanIN-1A where the normal epithelium becomes tall and columnar to 
PanIN-3, which is also known as carcinoma in situ. With each 
progressive stage, subsequent mutations occur and accumulate 
including mutations in INK4A, TP53 and SMAD4. These mutations, in 
combination with telomere shortening and CpG island hypermethylation 
leads to increased genomic instability and atypical cellular architecture. 
In addition, the progression through these stages is accompanied by 
increasing desmoplasia, a hallmark of pancreatic cancer, whereby 
cancer-associated fibroblasts and activated pancreatic stellate cells 
contribute to an intense stromal reaction, contributing to PDAC 
development. Figure is adapted from: (Bardeesy and DePinho, 2002; 
Distler et al., 2014; Hernandez-Munoz et al., 2008; Morris et al., 2010b; 
Scarlett et al., 2011) 
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increases during PanIN progression (Sato et al., 2008). Furthermore, 
CyclinD1 has been shown to be increasingly overexpression with 
progressing PanIN lesion development, the tumour marker, prostate stem 
cell antigen (PSCA) is expressed in all PanINs, but not normal duct epithelia 
(Argani et al., 2001; Haugk, 2010; Maitra et al., 2003) and matrix 
metalloproteinase (MMP)-7 is expressed in PanIN lesions, which suggests 
the onset of its expression occurs early in PDAC development (Crawford et 
al., 2002). Differential MUC expression is observed in different PanIN lesions 
(Haugk, 2010), cathepsin E has also more recently been identified as a novel 
biomarker of PanIN/PDAC formation (Cruz-Monserrate et al., 2012). It is also 
thought that coordinated overactivation of both Hedgehog and Ras signalling 
pathways contributes heavily to promotion of PanIN lesion formation in the 
early stages of PDAC (Pasca di Magliano et al., 2006). However, there is still 
much that isn’t fully understood about all of these PDAC precursor lesions 
and although they all follow a multi-step progression towards invasive PDAC, 
each lesion is characterised by its own distinct clinicopathologic and genetic 
alterations (Distler et al., 2014; Hernandez-Munoz et al., 2008; Scarlett et al., 
2011). 
 
1.1.6 Stromal contribution to PDAC 
As described in figure 1.2, the desmoplastic reaction (DR) is one of the 
hallmarks of pancreatic cancer and involves the proliferation of fibrotic tissue. 
This DR is composed of extracellular matrix (ECM) proteins - predominantly 
type I collagen and fibronectin - fibroblasts, stellate cells, immune and 
inflammatory cells, lipocytes, endothelial cells and neurons (Bardeesy and 
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DePinho, 2002; Pandol et al., 2009; Rasheed et al., 2012). In addition to the 
characteristic dense bundles of collagen, there is a loss of basement 
membrane integrity and invasion of malignant cells into the interstitial matrix 
(Mahadevan and Von Hoff, 2007). The epithelial and stromal compartments 
communicate and interact, which is known to enhance the aggressive nature 
of PDAC (Chu et al., 2007; Erkan et al., 2012b; Merika et al., 2012; Whatcott 
et al., 2012). Furthermore, it is this desmoplastic reaction and the tumour 
microenvironment that are seen as the major contributors of 
chemoresistance in PDAC (Whatcott et al., 2012), due to deposition of ECM 
components leading to reduced elasticity of tumour tissue, increased tumour 
interstitial fluid pressure and subsequent decreased rate of perfusion of 
chemotherapeutic agents, ultimately reducing drug efficacy (Heldin et al., 
2004).  
 
There are numerous different cell types contributing to desmoplasia; of 
particular interest though, are the reciprocal interactions between tumour and 
stromal cells, which contributes to tumour progression and aggressiveness 
(Erkan et al., 2012b; Tang et al., 2013). In the normal pancreas, pancreatic 
stellate cells (PSCs) have a low proliferative rate (Beacham and Cukierman, 
2005) and can be identified based on their expression of desmin and glial 
fibrillary acidic protein (GFAP) (Rasheed et al., 2012). It is already known 
that PSCs contribute to fibrosis, associated with chronic pancreatitis 
(Masamune et al., 2009) and that they become activated in response to 
oxidative stress and through the secretion of cytokines and growth factors 
from cancer cells (Erkan et al., 2012b). Upon activation, PSCs acquire 
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myofibroblastic characteristics such as α-smooth muscle actin (SMA) 
expression (Apte et al., 2004; Apte et al., 2013; Rasheed et al., 2012) and 
have an increased proliferative capacity. It has been shown that these 
activated PSCs secrete interleukin-6 (IL-6), which activates signal transducer 
and activator of transcription 3 (STAT3) and promotes anchorage-
independent growth and invasiveness in PDAC cells (Guo et al., 2014a) and 
also prevent an effective antitumour response of CD8(+) T cells through 
secretion of CXCL12, which appears to act as a chemoattractant and 
therefore reduces T cell migration to juxtatumoural compartments (Ene-
Obong et al., 2013). Furthermore, in direct coculture PSCs promote 
radioprotection of pancreatic cancer cells and stimulate proliferation (Mantoni 
et al., 2011).  
 
Further interaction between the tumour and stromal compartments occurs 
through the release of several growth factors including transforming growth 
factor-beta (TGF-β), platelet derived growth factor (PDGF), fibroblast growth 
factor (FGF)-2, connective tissue growth factor (CTGF) and Sonic Hedgehog 
(SHH) signalling (Bailey et al., 2008; Damhofer et al., 2013; Gore and Korc, 
2014; Lohr et al., 2001; Mahadevan and Von Hoff, 2007; Whatcott et al., 
2012). A recent study using a well-defined mouse model of PDAC 
demonstrated that SHH-deficient tumours had a reduction in tumour-
associated stroma, as would be predicted. Interestingly, however, these 
tumours were actually more aggressive with increased vascularity and 
proliferative capacity and concluded that SHH-driven stroma formation could, 
in part, act to restrain tumour growth (Rhim et al., 2014). However, the cross-
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talk between tumour and stromal compartments and the activation of 
autocrine and paracrine oncogenic signalling pathways is known to 
contribute heavily in the desmoplastic reaction, which is a hallmark of PDAC. 
A better understanding of this cross talk will help identify possible therapeutic 
strategies.  
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1.2 Molecular genetics of PDAC 
1.2.1 Signalling overview 
Pancreatic cancer is characterised by rapid growth, desmoplasia, early 
invasion and resistance to chemotherapy (Hidalgo, 2010). This can be 
heralded to the accumulation of many genetic alterations/mutations that 
occur in an ordered sequence during the development and multistep 
progression of PDAC. These inherited and acquired (somatic) mutations 
ultimately impact on a number of signalling pathways; genomic analysis in a 
screen of 24 different PDAC samples revealed that there are, on average, 63 
genetic alterations found within each sample. These are thought to impact on 
12 main, overlapping, signalling pathways (Jones et al., 2008; Sakorafas et 
al., 2010), which emphasises the intense nature and complexity of the 
disease (Ottenhof et al., 2011). These pathways involve cellular functions; 
apoptosis, homophilic cell adhesion, invasion, DNA damage repair, G1/S 
phase cell cycle progression and different signalling cascades; Hedgehog, 
integrin, c-Jun N-terminal kinase (JNK), K-ras, TGF-β, Wnt/Notch and small 
GTPase signalling (other than K-ras) (Jones et al., 2008; Ottenhof et al., 
2011). The mutations in these pathways accumulate with increasing genomic 
instability, which occurs primarily due to telomere shortening (van Heek et 
al., 2002). Although PDAC is associated with many mutations in cancer-
associated genes (oncogenes, tumour-suppressor genes and genome-
maintenance genes), genetic and molecular pathways (telomere shortening), 
upregulation and overexpression of growth factors and their associated 
receptors (EGFR, c-Met and TGF-β, for example), angiogenesis and altered 
developmental pathways (Hedgehog) (Sakorafas et al., 2010) for the 
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purposes of this review, the focus will be placed on ras signalling, hepatocyte 
growth factor (HGF) and their downstream pathways including c-Met, PI3K 
and AKT. However, the main genetic/molecular alterations involved in PDAC 









BCL-2, BCL-X(L), MCL-1, caspase inhibitor (survivin) overexpression 
NF-κB and PI3K/AKT signalling 
Hyper-O-GlcNAcylation (maintains NF-κB signalling) 
CASP10, VCP, CAD, HIP1 
 
(Arlt et al., 2013; Hamacher et 




E-cadherin, α/β-catenin – reduced expression 
CDH1, CDH10, FAT, PCDH15, PCDH17 
 





KRAS mutation drives expression of stable mutant of p53 
SDC-2 invasion-associated gene in PDAC – cooperates with K-ras 
ADAM11, DPP6, MEP1A, PCSK6, APG4A, PRSS23 
 
(De Oliveira et al., 2012; Morton 
et al., 2010; Weissmueller et 
al., 2014) 
 
DNA damage repair 
 
TP53 expression lost in 50-75% PDAC 
MLH1, MSH2, MSH6, PMS2 – mismatch repair genes (microsatellite instability) 
BRCA2 – familial and sporadic PDAC (interstrand cross-linking repair) 
ERCC4, ERCC6, EP300, RANBP2 
 




CDKN2A/p16 (FBXW7, CHD1, APC2 – less frequent that CDKN2A) 
Sox2 – aberrantly expressed controls genes involved in transition 
 





Loss of function mutations in activators of JNK, mitogen-activated protein kinase 
(MAPK) kinase 4 (MKK4) and MKK7 impairing JNK signalling 
Interacts with KRAS signalling 
TNF, ATF2, NFATC3 
 
 
(Davies et al., 2014) 




Integrin signalling Mutant p53 drives mutations by promoting integrin recycling 
ITGA4, ITGA9, LAMA1, FN1, ILK 
(Muller et al., 2009; Tuveson 





RalB – invadopodia formation 
Rio kinase 3 (RIOK3) – gene amplification – increases invasiveness through 
activation of rac 
AGHGEF7, CDC42BPA, DEPDC2, PLCB3 
 
(Kimmelman et al., 2008; Neel 




KRAS, MAP2K4, RASGRP3 
30% of early neoplasms and >90% PDAC 
Activates RAF/ERK, PI3K, RalGDS and NF-κB pathways 
 





SMAD4 (loss of heterozygosity (LOH) in 90% PDAC), TGFBR2, BMPR2, SMAD3 
Additional inactivation of remaining allele in 50% PDAC 
Promotes proliferation and epithelial to mesenchymal transition (EMT) 
 





Upregulation/Interacts with Hedgehog, KRAS and NF-κB signalling pathways 
MYC, WNT9A, GATA6, TCF4, MAP2, TSC2 
 
(Froeling et al., 2011; Miyamoto 
et al., 2003; Pasca di Magliano 





Activated in 70% PDAC, essential for CSC viability, paracrine signalling impacts 
stromal cell activity 
Activated by galectin-1 (Gal1) overexpression 
TBX5, SOX3, LPR2, GLI1, BOC, CREBBP 
 
 
(Martinez-Bosch et al., 2014; 
Nolan-Stevaux et al., 2009; 
Seton-Rogers, 2009; Yauch et 
al., 2008) 
 
Table 1.4: Summary of molecular events involved in PDAC. The 12 main signalling pathways affected by genetic mutations in 
pancreatic cancer. Additional references: (Cowley et al., 2013; Hezel et al., 2006; Jones et al., 2008; Mihaljevic et al., 2010; Morris 
et al., 2010b; Ottenhof et al., 2011) 
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1.2.2 Ras 
In humans, there are three RAS genes, which encode four distinct proteins, 
H-ras, N-ras, K-ras4A and K-ras4B; K-ras4A and K-ras4B are alternative 
splice variants of the KRAS gene (Bar-Sagi, 2001; Castellano and Santos, 
2011; Lowy and Willumsen, 1993; Plowman et al., 2003; Pylayeva-Gupta et 
al., 2011). H-, N- and K-ras4A are each 189 amino acids in length while K-
ras4B, which is found more abundantly than K-ras4A, is 188 amino acids; all 
are approximately 21 kilodaltons (kDa) (Bar-Sagi, 2001; Pylayeva-Gupta et 
al., 2011). The structure of all four ras isoforms is very similar and can be 
divided into three main regions (figure 1.3). First, the N-terminus, which is 
identical across the four isoforms, is 86 amino acids in length; with amino 
acids 32-40 constituting a ras effector-protein binding domain (Bar-Sagi, 
2001), which allows interaction with downstream effector proteins and 
enables participation in a wide range of signal transduction cascades. The 
second mid-region is 80 amino acids and although not identical, is still highly 
homologous (Welman et al., 2000). The remaining section, starting at amino 
acid 165, shares no sequence homology between any of the isoforms, 
except for a conserved CAAX motif (C – cysteine, A – aliphatic amino acids, 
X – methionine or serine). This motif plays an important role in directing post-
translational modifications including farnesylation, which affords ras affinity 
for cellular membranes. This association with the cytoplasmic surface of 
cellular membranes is a prerequisite of ras activation and signalling (Ahearn 







Figure 1.3: Structure of ras proteins. There are four ras isoforms, 
which are products of three RAS genes, with K-ras4A and K-ras4B 
being alternative splice variants of the KRAS gene. The N-terminus is 
highly conserved across all four isoforms and includes binding sites for 
GDP and GTP and downstream effector proteins. The C-terminus, from 
amino acid 165-189 (188 for K-ras4B) shares no sequences homology 
between the isoforms, with exception of a conserved CAAX motif. This 
plays an important role in directing post-translational modifications such 
as farnesylation and palmitolation. 
Figure adapted from: (Castellano and Santos, 2011) 
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Under normal cellular conditions, ras is found in guanosine diphosphate 
(GDP)/inactive and guanosine triphosphate (GTP)/active forms. To become 
active, GDP must first dissociate; this is an intrinsically slow process, but is 
accelerated by guanine nucleotide exchange factors (GEFs). Once GDP has 
dissociated, GTP can bind in its place. Within this active conformation, ras 
GTPases are able to interact with various effector proteins to impact on 
different cellular processes including cell growth, proliferation, migration and 
apoptosis (Malumbres and Barbacid, 2003) and this signalling is summarised 
in figure 1.4. The hydrolysis of GTP to GDP, which is mediated through 
intrinsic GTPase activity, reverts ras back to an inactive state; this process is 
accelerated through the action of GTPase activating proteins (GAPs) (Biou 
and Cherfils, 2004; Colicelli, 2004; Vetter and Wittinghofer, 2001). Structural 
changes that occur within the overlapping motile switch I and switch II 
regions in response to guanine nucleotides also affect the interactions of ras 
with GAP and GEF regulators (Castellano and Santos, 2011). The switch 
regions are sensitive to the nature of the bound guanine nucleotide and 
change their structural conformation in response. This increases the affinity 
for the bound nucleotide and ensures the complex remains bound until the 
reaction is complete (Biou and Cherfils, 2004; Hall et al., 2002). 
 
1.2.3 Oncogenic K-ras signalling in PDAC 
The KRAS gene is frequently mutated in PDAC and has been found to be 
present in over 90% of patient tumour samples and occurring in even low-
grade PanIN-1A lesions (Eser et al., 2014; Kanda et al., 2012; Morris et al., 




Figure 1.4: Ras signalling. Ras is found bound to GDP (inactive) and 
GTP (active). The transition between the two states is regulated via 
GEFs and GAPs. GAPs accelerate the intrinsic GTPase activity of ras, 
releasing a phosphate group and converting ras back to its inactive 
state. GEFs mediate the exchange of GDP for GTP, activating ras and 
allowing its interaction with a multitude of effector proteins to participate 
in signalling pathways. Mutations in K-ras occur frequently in PDAC 
leading to continual activation of these downstream signalling 
pathways. Depicted are the three major cascades implicated in PDAC 
progression: RAF/MEK/ERK, PI3K and RalGDS. 
Figure adapted from: (Downward, 2003; Hezel et al., 2006; Hruban et 
al., 2008) 
 46 
inactive (GDP-bound) and active (GTP-bound) form (Malumbres and 
Barbacid, 2003), however, activating mutations that occur within PDAC 
render it constitutively active (Hezel et al., 2006). The most common 
mutation is on codon 12 (Collins et al., 2012; Jones et al., 2008) from GGT to 
GAT or GTT and very rarely CGT, whereby glycine (G) is substituted with 
aspartic acid (D), valine (V) or arginine (R) (Collins and Pasca di Magliano, 
2013; Eser et al., 2014; Hezel et al., 2006; Rachakonda et al., 2013). Glycine 
to aspartic acid (K-rasG12D) substitutions are the most common (Eser et al., 
2014; Pylayeva-Gupta et al., 2011). These mutations compromise the 
intrinsic GTPase activity of ras, meaning it is unable to hydrolise GTP to 
GDP; they can also block the interaction between K-ras and GAPs (Collins 
and Pasca di Magliano, 2013; Eser et al., 2014). This ultimately means that 
K-ras is locked in an active state and leads to persistent activation of 
downstream signalling pathways, many of which are key drivers of PDAC 
initiation and progression (Pylayeva-Gupta et al., 2011). 
 
Although KRAS mutations are sufficient for the initiation of pre-cursor lesions, 
additional genetic aberrations are required for disease progression (Morris et 
al., 2010b) and K-ras driven genetically engineered mouse models (GEMM) 
of PDAC can be accelerated through introduction of inactivating mutations of 
the tumour suppressor genes CDKN2A, TP53 and/or DPC4/SMAD4 (Biankin 
et al., 2012; Eser et al., 2014). Indeed, sustained K-ras signalling is an 
essential requirement for maintenance of metastatic lesions, PDAC 
progression and growth; genomic analysis has revealed a fundamental role 
for K-ras in reprogramming tumour metabolism through selective activation of 
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biosynthetic pathways, which support tumour growth (Ying et al., 2012). 
Knowing that K-ras is crucial in PDAC progression, and with cell line studies 
suggesting an oncogenic KRAS addiction (Zimmermann et al., 2013), it 
makes K-ras an attractive therapeutic target. However, attempts in producing 
potent and direct inhibitors to target ras have not been successful and have 
lead to the perception that ras is undruggable (Bryant et al., 2014). However, 
there have been some advances, with on-going research showing that 
targeting ras may still hold promise. These studies have focused on selected 
compounds have been used to inhibit son of sevenless (SOS)-mediated 
nucleotide exchange, therefore inhibiting SOS-catalysed K-ras activation. 
Another strategy has implemented small-molecule inhibitors that target Ras-
GTP directly, which blocks ras interactions with downstream effector proteins 
(Maurer et al., 2012; Shima et al., 2013; Sun et al., 2012). It is known that 
PDAC shows high dependency on K-ras and sustained K-ras signalling is a 
requirement for PDAC maintenance (Ying et al., 2012). Recently, several 
studies have demonstrated a link between K-ras and the transcriptional 
coactivator Yes-associated protein-1 (YAP1). It was shown that in a GEMM 
of PDAC, following K-ras suppression there was initial tumour regression. 
However, the majority of tumours relapsed and it was shown that activating 
mutations in YAP1 were able to compensate for K-ras suppression. It has 
also been noted that YAP1 can induce EMT and proliferation in PDAC 
independently of K-ras (Greten, 2014; Kapoor et al., 2014; Seton-Rogers, 
2014; Shao et al., 2014; Zhang et al., 2014b). These studies therefore 
provide evidence for the ability of YAP1 to substitute K-ras signalling in 
oncogenic K-ras dependent PDAC. However, to date, research has focused 
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on downstream effector pathways of oncogenic K-ras in PDAC as more 
optimistic therapeutic targets to combat the disease. 
 
1.2.4 Downstream effector pathways of oncogenic K-ras 
Within PDAC, it is believed that there are three main effector pathways 
downstream of K-ras; these are the MAPK, PI3K and RalGEF pathway. 
Through the activation of these various signalling cascades, active ras is able 
to impact multiple cellular processes that are critical to PDAC progression 
including, but not limited to, proliferation and survival, as well as cell polarity 
and migration (Downward, 2003). These pathways are summarised in figure 
1.4. MAPK signalling is present in both early and late stage PDAC, in both 
mouse models and human tumours. It involves the activation of Raf kinases, 
by K-ras, which then activate MEK1/2. This results in phosphorylation and 
activation of ERK1/2 and subsequently affects cell-cycle progression, 
transcription, cell migration etc (Collins and Pasca di Magliano, 2013; 
Downward, 2003; Hingorani et al., 2003). RalGEFs are required for ras-
induced transformation and activate ras-like small GTPases such as ral-A or 
ral-B, which promote PDAC growth and metastasis. In addition activation of 
CDK5, downstream of K-ras and increases malignant progression, migration 
and invasion in vitro is linked to ras-ral signalling (Eggers et al., 2011; Eser et 
al., 2014; Feldmann et al., 2010; Lim et al., 2005; Lim et al., 2006). However, 
the main focus of this study is the PI3K pathway, which is what will now be 
covered in depth. 
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Among the different oncogenic K-ras activated effector pathways that are 
involved in PDAC, the PI3K pathway is a key mediator of ras-driven 
oncogenesis and is emerging as one of the most critical (Eser et al., 2013); it 
has been estimated that approximately 50% of cancers have deregulation of 
this pathway involved in their tumorigenesis (Ferro and Falasca, 2014; Yuan 
and Cantley, 2008). PI3Ks are lipid kinases of which there are multiple 
isoforms; these can be divided into three classes, which is based on 
structural features and substrate preferences. Class I PI3Ks comprise a p110 
catalytic subunit and a regulatory subunit. Class II PI3Ks share 
approximately 45% homology with the catalytic subunit of class I PI3Ks but 
have a C-terminal region that mediate calcium and lipid binding. Class III 
PI3Ks are thought to regulate vesicle trafficking (Cantrell, 2001). PI3Ks 
phosphorylate the 3’-hydroxyl group on the inositol ring of phosphoinositides 
to generate secondary messengers such as phosphatidylinositol-3,4,5-
triphosphate (PIP3), using phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) 
as a substrate. PIP3 recruits and coordinates downstream effectors, such as 
Akt, also known as protein kinase B (PKB), which then stimulates various 
effector pathways (Cantrell, 2001; Franke, 2008; Vanhaesebroeck et al., 
2010; Yuan and Cantley, 2008). Class I PI3Ks are the best understood, 
which are further subdivided into Class IA (α, β and δ), which bind the p85 
type of regulatory subunit and Class IB (γ), which binds either the p101 or 
p87 regulatory subunit (Vanhaesebroeck et al., 2010). It is the class IA 
PI3Ks, which are more heavily implicated in cancer (Yuan and Cantley, 2008; 
Zhao and Vogt, 2008), however, more recently it has been hypothesised that 
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p110γ overexpression could be a key player in PDAC progression (Edling et 
al., 2010). 
 
Ras interacts with the P110 subunit via a RAS binding domain (RBD) and 
this is independent of p85 (Castellano et al., 2013; Gupta et al., 2007; Organ 
and Tsao, 2011). Upon activation, PI3Ks catalyse the phosphorylation of 
PIPs, which promotes recruitment of downstream effectors such as 3-
phosphoinositide-dependent protein kinase-1 (PDK1) and Akt (Ferro and 
Falasca, 2014). The activity of PI3K is negatively regulated by the tumour 
suppressor phosphate and tensin homolog (PTEN) (Georgescu, 2010). 
Although mutations in PTEN are rare in PDAC, the disease is associated 
with a loss of PTEN function and this, in association with constitutively active 
K-ras leads to sustained PI3K signalling (Hill et al., 2010). In addition, PI3K 
signalling in the tumour microenvironment has been shown to significantly 
enhance PDAC progression (Ferro and Falasca, 2014) and activation of this 
pathway also increases NFκB signalling to promote tumour-enhancing 
changes to the tumour microenvironment (Ying et al., 2011). 
 
As stated, PI3K signalling leads to the activation of Akt, which is a known 
indicator of aggressiveness in PDAC (Kennedy et al., 2011a; Kennedy et al., 
2011b; Yamamoto et al., 2004) and correlates with outcome (Baer et al., 
2013; Parsons et al., 2010; Schlieman et al., 2003). Akt is a member of the 
‘AGC’ superfamily of protein kinases, of which there are 80 members; there 
are three isoforms of Akt (α, β, γ; Akt 1,2,3), which have differential 
expression patterns, with recent data suggesting they may have over-lapping 
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and distinct roles in cancer (Engelman, 2009; Franke, 2008; Scheid and 
Woodgett, 2003).  Akt is activated by PIP3, through PIP3 binding via the 
pleckstrin homology (PH) domain, which causes a conformational change, 
unmasking the kinase domain and allowing phosphorylation to occur 
(Georgescu, 2010). Phosphorylation at two sites is required for full activation 
of Akt (Higuchi et al., 2008); PDK1 phosphorylates Thr308 in the activation 
loop and the mammalian target of rapamycin complex-2 (mTORC2) 
phosphorylates Ser473 in the C-terminal hydrophobic motif (Case et al., 
2011; Georgescu, 2010; Higuchi et al., 2008; Moore et al., 2011; Sarbassov 
et al., 2005; Tato et al., 2011). There are two classes of phosphatases that 
are known to dephosphorylate and therefore inactivate Akt, protein 
phosphatase 2A (PP2A) and PH domain leucine-rich repeat protein 
phosphatases (PHLPP) 1 and 2 (Georgescu, 2010). 
 
Activation or overexpression of Akt1 has been observed in human pancreatic 
tumour samples and Akt2 is also thought to be amplified or overexpressed in 
a small percentage of PDACs (Asano et al., 2004; Michl and Downward, 
2005; Ruggeri et al., 1998; Semba et al., 2003). Activated Akt is known to 
promote cell survival, which it does through antagonisation of key apoptotic 
machinery components such as Bad (Datta et al., 1997; Fang et al., 1999), 
caspase-9 (Zhou et al., 2000) and forkhead transcription factor family 
members (Brunet et al., 1999). Within PDAC, Akt signalling has been shown 
to play heavily in chemoresistance through crosstalk with the chromatin 
modulator, BRG1 (Liu et al., 2014) and through regulation by the multi-
functional cell membrane protein, RLIP76 (Leake et al., 2012). Furthermore, 
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pharmacological inhibition of components of the PI3K signalling module, 
including PI3K, PDK1 or Akt have been shown to inhibit PDAC cell 
proliferation in vitro (Baer et al., 2013) and genetic inactivation of PDK1 
blocks oncogenic K-ras induced PDAC formation in vivo (Eser et al., 2013). 
However, although typically the PI3K/AKT pathway has been considered 
primarily to be responsible for survival signalling and proliferation, there is 
accumulating evidence to suggest that Akt signalling contributes to cellular 
motility (Kim et al., 2001; Xue and Hemmings, 2013; Xue et al., 2012). Akt 
has been shown to induce tumour metastasis through Twist1 
phosphorylation-driven EMT and crosstalk between TGF-β and PI3K 
signalling (Xue et al., 2012) and activated Akt was found to promote 
phosphorylation/activation of components important cell migration including 
actin filaments (Ho et al., 2011). Furthermore, phosphorylation of Akt was 
required for motility of lung endothelial cells downstream of HGF (Usatyuk et 
al., 2014). It has also recently been reported that the Wnt family member, 
Wnt5A, promotes phosphorylation of Akt at Ser473 downstream of PI3K to 
promote osteosarcoma cell migration (Zhang et al., 2014a). However, 
although a role for Akt in cell migration, including in metastatic cancer cells, 
has been documented, whether Akt contributes pancreatic cancer cell 
migration has yet to be fully established. 
 
1.2.5 HGF/c-Met signalling in PDAC 
It is known that the PI3K pathway can be activated downstream of Ras. 
However, PI3K is also activated through association with receptors such as 
c-Met. The c-Met proto-oncogene codes for the c-Met protein, which is a cell 
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surface receptor tyrosine kinase (RTK). It is found expressed in a range of 
epithelial cells including those of the prostate, liver and pancreas both during 
development and throughout adulthood (Organ and Tsao, 2011). Post-
translational, proteolytic processing produces a single-pass, disulphide-linked 
α/β heterodimer (Comoglio et al., 2008; Organ and Tsao, 2011). c-Met acts 
as a high affinity receptor for HGF, which is also known as scatter factor 
(Naldini et al., 1991; Weidner et al., 1991). Upon binding, HGF induces c-Met 
receptor dimerisation and acts as a pleiotropic factor and cytokine to initiate a 
phosphorylation cascade. Signalling through this receptor is key to a number 
of important biological and cellular processes, including development, wound 
healing and morphogenesis and promotes proliferation, cell survival, motility 
and cell scattering (Blumenschein et al., 2012; Boros and Miller, 1995; 
Brinkmann et al., 1995; Maulik et al., 2002; Zhu et al., 1994). HGF/c-Met 
signalling is known to play an important role in embryogenesis and wound 
repair through induction of cell scattering involving the dissolution of 
cadherin-based cell junctions and increased cellular motility (Chmielowiec et 
al., 2007).  
 
HGF/c-Met signalling has been shown to play a significant role in pancreatic 
tumorigenesis too, acting upstream of several signalling pathways including 
PI3K and MAPK (Maehara et al., 2001; Patel et al., 2014; Tan and Yang, 
2010). Under physiological conditions, both c-Met and HGF are expressed at 
low levels in acinar and stromal cells of the pancreas (Di Renzo et al., 1995). 
In many cancers, c-Met is mutated, but this is rare in PDAC; more often there 
is a marked increase in c-Met expression observed in PDAC tumour samples 
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(Di Renzo et al., 1995; Ebert et al., 1994; Furukawa et al., 1995; Yu et al., 
2006), which correlates with poor prognosis (Zhu et al., 2011). It is also 
known that there are increased levels of circulating HGF in pancreatic cancer 
patients (Kemik et al., 2009).  
 
The regulatory p85 subunit of PI3K serves three main roles: stabilisation, 
inactivation and recruitment (Vanhaesebroeck et al., 2010). To initiate PI3K 
signalling, in response to growth factor stimulation, the p85 subunit 
associates with the c-Met receptor. This interaction can either be direct, 
whereby the p85 subunit associates with phosphorylated tyrosine residues 
via its SH2 domain, or indirectly via the scaffold protein Gab1 (Engelman, 
2009; Organ and Tsao, 2011; Rocchi et al., 1998; Yu et al., 2001). After this 
association of the SH2 domain on p85 and the phosphorylated tyrosine 
residues takes place, p85-mediated inhibition of the catalytic P110 subunit is 
relieved enabling p110 to transfer phosphate groups to initiate downstream 
signalling after being brought into contact with their lipid substrates at the cell 
membrane (Vanhaesebroeck et al., 2010). This is described in section 1.2.4 
and summarised in figure 1.4. In addition, c-Met mediated invasiveness and 
HGF-induced scattering have been shown to be enhanced through the 
bioactive peptide Neuromedin U (NmU), which is also found overexpressed 
in PDAC samples (Ketterer et al., 2009). Neuropilin-1 (Np-1) is also 
overexpressed in PDAC; Np-1 is a receptor for semaphorin 3A and vascular 
endothelial growth factor (VEGF), however, this has also shown to associate 
with c-Met in an HGF-induced manner to aid c-Met activation and promote 
PDAC cell invasiveness (Matsushita et al., 2007). Taken all together, these 
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data show the extreme complexity of the signalling pathways and cross talk 
involved in PDAC progression and the need to gain a better understanding of 







1.3 Cell migration and metastasis 
1.3.1 Cell migration 
Cell migration is central to a number of physiological processes occurring in 
many organisms. It is important in both embryonic development and for 
normal functioning within the adult organism (Kurosaka and Kashina, 2008; 
Ridley et al., 2003; Vicente-Manzanares et al., 2005). Cell migration plays a 
key role in gastrulation and in the formation of various tissues and organs of 
the embryo (Chuai et al., 2012; Solnica-Krezel and Sepich, 2012). 
Comparable cell migration occurs in adult organisms, contributing to the 
renewal of the skin and intestinal lining (Heath, 1996), morphogenesis 
(Juliano and Haskill, 1993), wound healing (Schneider et al., 2010) and 
immune responses (Ding et al., 2012; Madri and Graesser, 2000; Tomura et 
al., 2010). However, cell migration can also factor into various pathological 
processes including vascular disease and cancer (Chaffer and Weinberg, 
2011; Lauffenburger and Horwitz, 1996; Vicente-Manzanares et al., 2005). 
 
Migration of cells begins when the cells become polarised in response to 
external stimuli. This can take the form of various signals including chemical 
gradients of dissolved or surface-attached molecules (chemotaxis and 
hapotaxis) (Carter, 1965; Carter, 1967), light intensity (phototaxis) (Jekely, 
2009; Saranak and Foster, 1997), electrostatic potential (galvanotaxis) 
(Erickson and Nuccitelli, 1984), gravitational potential (geotaxis) (Lowe, 
1997) or matrix stiffness (durotaxis) (Lo et al., 2000). 
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There are a number of key steps involved in cell migration. Initially 
polarisation of the cell must occur in order for directional migration to 
commence, followed by a cyclical process combining adhesion to the ECM 
with protrusion, elongation, contraction and detachment of the rear of the cell 
(Huttenlocher and Horwitz, 2011; Lauffenburger and Horwitz, 1996; Ridley et 
al., 2003). Polarisation occurs in response to environmental stimuli and 
defines the leading and trailing edges of the cell. It is a complex process, 
requiring a high level of coordination between a number of key regulatory 
molecules. PI3K and its lipid products PIP3 have been heavily implicated in 
control of cell polarity and migration. In response to environmental signals, it 
has been reported that PI3K becomes activated and causes the 
accumulation of PIP3 at the leading edge of the cell. A concentration gradient 
of PIP3 is reinforced due to the localisation of PTEN at the rear of the cell 
(Merlot and Firtel, 2003; Raftopoulou and Hall, 2004; Webb and Horwitz, 
2003). There are a number of elegant studies in Dicytostelium discoideum 
demonstrating the requirement for a PIP3 concentration gradient in cell 
migration (Funamoto et al., 2002; Iijima and Devreotes, 2002), however, 
more recent data has suggested that it may not be necessary for chemotactic 
cell migration in either Dicytostelium discoideum or neutrophils (Hoeller and 
Kay, 2007; Veltman et al., 2014), as previously described (Cai and 
Devreotes, 2011; Leslie et al., 2005). Despite this, a central role for 
PI3K/PTEN regulated PIP3 gradient is still frequently cited. 
 
Ras functions as an essential part of the cell migratory machinery, acting 
upstream of PI3K at the leading edge of the cell to initiate the formation of 
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this concentration gradient; a positive feedback loop then amplifies the 
concentration of PIP3 to promote actin polymerisation (Sasaki and Firtel, 
2005). This gradient leads to the activation of Rho GTPases such as Rho, 
Rac and cell division control protein-42 (Cdc42), which are known to play a 
central role in controlling the cellular responses required for cell migration. It 
has been reported that Rho promotes actin/myosin contraction in both the 
cell body and at the rear of the cell, Rac induces the formation of membrane 
protrusion at the leading edge through regulation of actin polymerisation and 
integrin adhesion complexes and Cdc42 mediates the direction of cell 
movement (Parri and Chiarugi, 2010; Raftopoulou and Hall, 2004; Ridley, 
2001). Rac and Cdc42 target the Wiskott-Aldrich syndrome protein/WASP 
family verprolin homologous protein (WASP/WAVE) family of proteins; these 
in turn activate the actin related protein 2/3 (Arp2/3) complex (Friedl and 
Wolf, 2010; Ridley et al., 2003; Webb and Horwitz, 2003). This cascade of 
events subsequently leads to reorganisation and polymerisation of the actin 
cytoskeleton, which is needed to cause the cell to change shape and 
generate the forces required to drive cell migration (Hall, 1998). Cell 
migration requires the protrusion of cellular processes such as 
lamellopodium, filopodium, pseudopodia or invadopodia; although these 
structures are diverse in morphology, they all contain filamentous actin. 
 
 Actin is the most abundant protein found within all eukaryotic cells. It is 
found in two forms: monomeric, globular G-actin; and polymeric, filamentous 
F-actin, which forms from the polymerisation of G-actin into double helical 
filaments (Dominguez and Holmes, 2011; Holmes, 2009; Oda et al., 2009), a 
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reaction that is catalysed by ATP hydrolysis (Pollard and Borisy, 2003). 
Nucleation, whereby three G-actin monomers must associate to create a 
filament nucleus, is the process by which new actin filaments are created; 
this is the rate limiting step in actin polymerisation (Krause and Gautreau, 
2014). Each actin monomer is orientated in the same direction, resulting in a 
polarised structure, with discernibly different ends. This is due to association 
of myosin, which creates an arrowhead pattern. The ends are defined, based 
on this pattern, as barbed (plus) or pointed (minus) (Pollard and Borisy, 
2003). The nucleation of G-actin monomers occurs more readily at the 
barbed end of the actin filaments, which are orientated strongly with respect 
to the cells surface with barbed ends outwards and this rapid polymerisation 
pushes the membrane forward (Pollard and Borisy, 2003; Small et al., 1978), 
which is facilitated by a decrease in membrane tension (Raucher and 
Sheetz, 2000). In lamellipodia, Cdc42, Rac and/or WASP/WAVE proteins 
activate the Arp2/3 complex and cause nucleation of actin into a branching 
network, providing lamellipodia with their characteristic flat and broad 
morphology. Behind the dynamic lamellipodia is a region called the lamella. 
This is much more stable and couples the actin network to myosin II-
mediated contractility (Ponti et al., 2004). In contrast, filopodia can be 
recognised by fine, finger-like projections, which are formed through 
promotion of linear actin polymerisation by the action of Cdc42 via formins, 
vasodilator-stimulated phosphoprotein (VASP) and fascin (Faix and Rottner, 
2006; Jaffe and Hall, 2005; Mattila and Lappalainen, 2008; Ridley, 2011; 
Small et al., 2002; Vicente-Manzanares et al., 2009). Within the cell body, 
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actin filaments are arranged as anti-parallel ‘stress’ fibers, which create the 
contractile forces required during cell movement (Katoh et al., 2001).  
 
In addition to actin polymerisation being a vital aspect of cell migration, cell-
substratum adhesions also play an important role. Integrin-mediated 
signalling helps regulate cell attachment to the ECM during migration 
(Huttenlocher and Horwitz, 2011). Integrins are transmembrane glycoprotein 
receptors, which are composed of an α and β subunit. They couple the 
cytoskeleton, via adapter proteins, to components of the ECM including 
collagens, laminins and fibronectin (Hood and Cheresh, 2002). Integrins 
cluster in a small area, developing into a focal complex, which mature into 
more stable focal adhesions. These adhesions remain in contact with the 
ECM while the cell moves, until they reach the rear of the cell, where they 
disassemble. Disassembly is mediated either through enzymatic action 
(calpain, for example) or a reduction in integrin affinity for ECM components. 
This allows the trailing edge to retract and for the cell to move forward (Friedl 
and Wolf, 2003; Hood and Cheresh, 2002; Huttenlocher and Horwitz, 2011; 
Lauffenburger and Horwitz, 1996). Integrins are ubiquitously expressed, but 
overexpression and aberrant behaviour is observed in some cancer types, 
promoting metastasis, including within PDAC (Hosotani et al., 2002). Taken 
together, it is clear that cell motility is a highly complex process, which is 
highly regulated. Orchestrating the process is a wide range of receptor, 
bundling, capping, adhesion and motor proteins (Ananthakrishnan and 
Ehrlicher, 2007); however, the formation of these cellular protrusions is a key 
process in cell migration, which is true of both normal and cancerous cells. 
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1.3.2 Metastasis 
Although there are many cellular processes that require cell migration, this 
study has focused on pancreatic cancer cell migration. In cancer, 
deregulated cell migration results in metastasis of tumour cells to distant 
sites around the body. In these instances, cells gain an invasive capacity, 
changing from a benign to a malignant state. In order for cells to metastasise, 
there are a number of key steps: detachment from the primary tumour, local 
invasion, intravasation into the blood or lymphatic system, dissemination and 
extravasation and subsequent outgrowth at distal, secondary sites (figure 
1.5) (Valastyan and Weinberg, 2011; Yilmaz and Christofori, 2009). As 
stated, they must first break away from the primary tumour, often undergoing 
EMT. A loss of E-cadherin is characteristic of this process, leading to the loss 
of intercellular junctions and is initiated through the repression of 
transcriptional regulators such as Snail and Twist (Brabek et al., 2010; Liu et 
al., 2008b), which are known to be upregulated in PDAC (Dangi-Garimella et 
al., 2012). This then enables cells to adopt a more motile phenotype (Yilmaz 
and Christofori, 2009). In order to invade locally, cancer cells must breach 
the basement membrane, a specialised ECM known to organise epithelial 
tissues and maintain tissue architecture (Yurchenco, 2011). Cancer cells are 
thought to use similar molecular programmes that are used during 
development to produce gaps in the basement membrane in order to spread, 
such as proteolytic degradation (Hotary et al., 2006; Ihara et al., 2011). 
MMPs are the most prominent proteinases that allow cancer cells to 
metastasise and while basement membrane and ECM degradation is their 
primary function, they also regulate pathways associated with cell growth and  
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Figure 1.5: Metastatic process. Metastasis requires several steps 
including (1) reduced adhesion to neighbouring cells and detachment 
from the primary tumour. (2) Local invasion and invasion through the 
basement membrane into the stroma. (3) Intravasation into the 
vasculature. (4) Cancer cells travel around the body, often protected 
from immune cells by platelets. (5) Cancer cells get trapped and bind to 
receptors on endothelial cells and extravasate. (6) Cancer cells then 
invade, proliferate and subsequently form secondary tumours at distal 
sites around the body. 
Figure adapted from: (Schroeder et al., 2012) 
 63 
angiogenesis (Kessenbrock et al., 2010). Overexpression of several MMPs, 
including MMP2 and MMP9 is well documented in pancreatic cancer (Haq et 
al., 2000; Jimenez et al., 2000; Zervos et al., 1999; Zhang et al., 2011b).  
 
Once the basement membrane has been breached, cancer cells are then 
able to invade locally and disseminate from the primary tumour and enter the 
stroma (Valastyan and Weinberg, 2011). Here they interact with stromal 
cells, which can contribute to tumour progression (see section 1.1.6). 
Cancer cells can migrate by a variety of different mechanisms; either by 
amoeboid or mesenchymal type movement, or collectively in clusters or 
strands. Attempted inhibition of one mode of migration can result in cancer 
cells converting to another form (Brabek et al., 2010; Friedl and Wolf, 2003). 
Cells moving via mesenchymal type migration have a characteristic 
elongated, fibroblast-like appearance. Molecules such as MMPs are recruited 
to aid in developing a pathway through the dense ECM meshwork (Brabek et 
al., 2010). In amoeboid migration, cells remain in a more rounded shape and 
movement is generated through repeated cycles of expansion and 
contraction of the cell body. Cells are extremely deformable and are able to 
squeeze through vey narrow regions within the matrix. This type of cell 
migration requires the activation of the Rho/ROCK pathway and subsequent 
phosphorylation of myosin light chain-2 (MLC-2) (Brabek et al., 2010; Sahai 
and Marshall, 2003; Webb and Horwitz, 2003). Collective cell migration can 
take place in the form of sheets/strands of cancer cells, which stay in contact 
with the primary tumour but invade into the local area, or in the form of 
clusters/groups of cells that detach from the primary tumour and often enter 
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the blood or lymphatic system in order to metastasis (Friedl and Wolf, 2003; 
Ilina and Friedl, 2009). 
 
Entry of cancer cells into the stroma provides opportunities to access the 
circulation, which is achieved through a process called intravasation 
(Valastyan and Weinberg, 2011). Compared to other tumours, PDACs are 
poorly vascularised, making a very hostile environment that the cancer cells 
must adapt to; this is thought to contribute to the intense chemoresistance 
observed in PDAC (Bartholin, 2012). Lymphatic metastasis is an early even 
in PDAC progression and is an independent poor prognosis factor (Xiao et 
al., 2014). Indeed, the angioregulatory growth factor, angiopoietin-2 (Ang-2), 
was found expressed in transformed PDAC cell samples. This was found to 
promote lymphatic metastasis through binding to the corresponding receptor 
on blood and lymphatic epithelium (Schulz et al., 2011). Accumulating 
evidence supports the theory that the accumulating mutations in PDAC and 
microenvironment lead to the formation of metastasis-initiating cells (MIC), 
which initiate lymphatic metastasis through chemokine guidance 
mechanisms (Xiao et al., 2014). The ability of cancer cells to evade anoikis is 
essential for survival in the circulatory systems. Several mechanisms have 
been proposed to promote anchorage independent growth in PDAC. This 
includes upregulation of Wnt/β-catenin signalling (Arensman et al., 2014), 
expression of protein kinase D-1 (PKD-1) (Ochi et al., 2011), overexpression 
of the architectural transcription factor, high-mobility group A1 (HMGA1)(Liau 
et al., 2007) and expression of dual endothelin1/VEGF signal peptide 
receptor, DEspR (Herrera et al., 2014). Furthermore, it is thought that PAK4 
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(see section 1.4) could promote anchorage independent growth in PDAC 
(Kimmelman et al., 2008). Cancer cells must then arrest within the vessels 
and extravasate in order to form distal metastases (Gupta and Massague, 
2006). In PDAC expression of neuropilin-2 (NRP-2) has been shown to 
mediate vascular adhesion and extravasation through interaction with α5 
integrin on endothelial cells (Cao et al., 2013). The metastasis-associated 
gene S100P has also been shown to facilitate both intravasation and 
extravasation in PDAC in vitro and in vivo using a zebrafish embryo model 
(Barry et al., 2013), which is mediated through cytoskeletal changes and 
regulation of cathepsin D (Whiteman et al., 2007). Once cells extravasate, if 
the secondary sites microenvironment is conducive to supporting cancer cell 
growth, micrometastases will be generated; these can then proliferate and 
form macroscopic lesions (Saxena and Christofori, 2013). The most common 
secondary sites for metastasis in PDAC are the liver and peritoneal cavity; 
less common sites include the lung, bone and brain (Borad et al., 2009). 
These findings are recapitulated in genetically engineered mouse models of 
PDAC using Pdx1-Cre/Lox-Stop-Lox (LSL)-Kras or p48Cre/LSL-Kras mice. 
In these models the LSL regulates active K-ras and additional deletions in 
various tumour suppressor genes are often incorporated (Grippo and 
Tuveson, 2010; Hingorani et al., 2003; Saxena and Christofori, 2013). The 
ability of cancer cells to invade and metastasise is an area of extensive 
research and studies of factors, proteins and signalling networks contributing 
to this process are continuing to expand knowledge. One such group of 
proteins shown to contribute heavily to cell migration and metastasis are the 
family of p21-activated kinases (PAKs). 
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1.4 PAKs 
1.4.1 PAK overview 
The p21-activated kinases (PAKs) are serine/threonine kinases, of which 
there are six isoforms and are known to be downstream effectors of the Rho 
GTPases, Rac and Cdc42. They can be sub-divided into two groups, based 
on structural similarities, sequence homology and regulation: group I PAKs 
(PAK1-3) and group II PAKs (PAK4-6) (Arias-Romero and Chernoff, 2008; 
Bokoch, 2003; Jaffer and Chernoff, 2002). Nearly all eukaryotes, with the 
exception of plants, encode one or more of the PAK genes and various 
experimental systems have been utilised in order to determine the multitude 
of PAK functions (Hofmann et al., 2004). It is well documented that PAKs act 
as effectors for a wide range of signalling pathways. Activated PAKs are able 
to relocalise to the nucleus, where they manipulate gene transcription (Li et 
al., 2012; Tao et al., 2011) or to the leading edge of cells to influence 
cytoskeletal organisation and contribute to cellular motility (Arias-Romero 
and Chernoff, 2008; Bagrodia and Cerione, 1999; Sells and Chernoff, 1997). 
In addition, PAKs are known to play a role in hormone signalling (Eswaran et 
al., 2008; Lee et al., 2002; Rayala et al., 2006; Schrantz et al., 2004), 
apoptosis/cell survival (Cotteret et al., 2003; Ong et al., 2011; Schurmann et 
al., 2000; Ye et al., 2011) and changes in cell morphology (Cau et al., 2001; 
Manser et al., 1997; Zeng et al., 2000).  
 
Of the group II PAKs, PAK4 was the first to be identified and is the most 
widely studied. It was originally identified as a cytoskeletal regulatory protein, 
controlling filopodia formation downstream of active Cdc42 (Abo et al., 1998). 
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However, more recent research has also highlighted its requirement in 
embryonic development, with PAK4 knockout in mice resulting in embryonic 
lethality (embryonic day 11.5) (Qu et al., 2003). Moreover, the number of 
substrates and binding partners for PAK4 is rapidly and continually 
expanding, it has been found to be fundamental in a plethora of cellular 
processes, highlighting PAK4 as a central signalling molecule (Dart and 
Wells, 2013). Indeed, because PAK4 plays a key role in cell signalling, it is 
not surprising that deregulation of PAK4 activity contributes to a number of 
disease states, including oncogenic transformation and cancer progression 
(Kumar et al., 2006; Kumar and Vadlamudi, 2002; Wells and Jones, 2010). 
Although an overview of all PAK members will be provided, PAK4 will remain 
the main focus. 
 
1.4.2 PAK4 expression and localisation 
It is known that PAK4 is required for embryonic development, being 
important for foetal heart and nervous system development (Qu et al., 2003; 
Tian et al., 2009; Tian et al., 2011b). PAK4 has a much lower level of protein 
expression in adult tissues (Minden, 2012); it is still found ubiquitously 
expressed in a wide range of tissue, but detected at particularly high levels in 
the prostate, testis and colon (Abo et al., 1998; Callow et al., 2002). Inactive 
PAK4 is predominantly found in the perinuclear region, however, 
coexpression with active Cdc42 leads to PAK4 localisation at the Golgi (Abo 
et al., 1998; Baldassa et al., 2010). Relocalisation of PAK4 to the cell 
periphery is observed in breast cancer cells and in response to HGF 
signalling in epithelial cells (Wells et al., 2002; Zhang et al., 2002). In 
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addition, PAK4 has been observed in cell substratum adhesion complexes in 
migrating macrophages and prostate cancer cell lines (Gringel et al., 2006; 
Wells et al., 2010); with recently identified nuclear import/export signals also 
contributing to the subcellular localisation of PAK4 (Li et al., 2012). 
 
1.4.3 Structure of PAKs 
PAKs show significant sequence homology to the Ste20 protein kinase, 
which is involved in the pheromone/mating factor pathway in the budding 
yeast, Saccharomyces cerevisiae. PAK related kinases have also been 
described in both Drosopila and Caenorhabditis elegans (Bagrodia and 
Cerione, 1999; Sells and Chernoff, 1997). Outside of the kinase domain, the 
sequences of PAKs and Ste20 protein kinase diverge except for a 60 amino 
acid sequence at the N-terminal, known as the p21-GTPase binding domain 
(GBD) (Sells and Chernoff, 1997). All PAKs contain this N-terminal GBD and 
a highly conserved C-terminal catalytic serine/threonine kinase domain 
(figure 1.6). Within the GBD of group I PAKs, there is also a Cdc42/Rac 
interactive binding region (CRIB), which overlaps with an autoinhibitory 
domain (AID) (Arias-Romero and Chernoff, 2008; Eswaran et al., 2007; 
Whale et al., 2011). With the exception of PAK5 (also known as PAK7) 
(Ching et al., 2003), the group II PAKs were not thought to contain an AID. 
However, more recently a putative AID has been identified in PAK4 
(Baskaran et al., 2012), in a region that is conserved across all group II PAKs 
(Dart and Wells, 2013). In addition, all PAK proteins contain a variable 
number of core proline motifs (PxxP), which are putative binding sites for 




Figure 1.6: PAK structure. There are 6 PAK family kinases, which are 
divided into two group based on structural similarities and sequence 
homology. However, all PAKs have an N-terminal p21-GTPase binding 
domain (GBD) and a C-terminal kinase domain. Group I PAKs (PAK1-
3) contain an autoinhibitory domain (AID), whereas group II PAKs 
contain a putative AID sequence. All PAKs contain a variable number of 
core PxxP motifs (proline rich regions), which are putative binding sites 
for SH3 domain containing proteins. Group I PAKs also contain a 
Nck1/2 binding site at the N-termini and a PIX binding site in the central 
region (indicated in yellow and green, respectively). Specific to PAK4 
are a β5 integrin binding site (although this region is highly homologus 
among the other PAK family members) and a GEF-H1/Gab1 interacting 
domain (GID), which lies adjacent to the kinase domain. 
Figure adapted from (Dart and Wells, 2013; King et al., 2014). 
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yet been identified. The sequence N-terminal to the GBD is smaller in group  
II PAKs, which in group I PAKs binds to the SH3 domains of Nck1/2 and 
Grb2. Another structural feature unique to group I PAKs is a non-classical 
SH3 domain, which is a specific binding site for the guanine nucleotide 
exchange factor, PAK-interacting exchange factor (PIX) (Arias-Romero and 
Chernoff, 2008; Bokoch, 2003; Chong et al., 2001; Howe, 2001; Whale et al., 
2011; Zhao et al., 2000). 
 
Specific to PAK4, upstream of the kinase domain, there is a GEF-H1/Gab1-
interacting domain (GID), which binds to PDZ-RhoGEF (Barac et al., 2004) in 
addition to GEF-H1 (Callow et al., 2005) and Gab1 (Paliouras et al., 2009). 
PAK4 has also been shown to interact with the integrin αvβ5 via a binding 
site located within the kinase domain (Li et al., 2010c; Zhang et al., 2002), 
although it is hypothesised that all PAKs could potentially bind integrins. 
Although there are conserved structural motifs within the PAK family of 
proteins, all isoforms are structurally distinct and there is considerable 
variation. It is thought that this could provide substrate specificity, distinct 
functional roles and allow recognition of specific target sequences on binding 
partners (Arias-Romero and Chernoff, 2008; Rennefahrt et al., 2007; Wells 
and Jones, 2010). However, despite these structural differences PAK4 
shares a number of substrates with PAK1 (Dart and Wells, 2013). 
 
1.4.4 Regulation of PAK activity 
Inactive group I PAKs form unphosphorylated homodimers, whereby the AID 
binds to the kinase domain and prevents its activity (Buchwald et al., 2001; 
 71 
Eswaran et al., 2007; Parrini et al., 2002). Group I PAKs bind to both Rac 
and Cdc42 (King et al., 2014), this association between active Rac/Cdc42 
with the GBD of group I PAKs disrupts the dimerisation; conformational 
changes destablilise the AID structure, leading to dissociation from the 
kinase domain and allowing autophosphorylation to occur (Arias-Romero and 
Chernoff, 2008; Chong et al., 2001). Autophosphorylation happens at several 
serine residues and at a single threonine residue (corresponding to Thr423 in 
PAK1), located within the activation loop of the kinase domain, which allows 
full kinase activity (Chong et al., 2001; Gatti et al., 1999; Wang et al., 2011). 
 
In contrast to group I PAKs, binding of active Rho GTPases had no 
significant impact on PAK4 kinase activity (Abo et al., 1998). With the 
exception of PAK5 (Ching et al., 2003), it was originally thought that group II 
PAKs had no AID present and there has been much speculation over the 
regulation of PAK4 kinase activity. Recently, however, two possible 
mechanisms of PAK4 activity regulation have been put forward. The first 
identifies a potential AID in the N-terminal, composed of amino acids 20-68. 
This it is thought could hold PAK4 in an inactive conformation until binding of 
active Cdc42 leads to structural changes allowing PAK4 activation (Baskaran 
et al., 2012). The second study revolves around a newly identified 
pseudosubstrate, which contains a critical proline residue (R49PKPLV). They 
concluded that this sequence was necessary and sufficient to inhibit PAK4 
kinase activity, but also that there were potentially other regions that may 
facilitate complete inhibition. They noted binding of a SH3 domain-containing 





Figure 1.7: Mechanism of PAK4 autoinhibition. PAK4 has been 
identified as having an autoinhibitory pseudosubstrate (RPKP). It has 
been reported that GTPases binding to the GBD does not activate 
PAK4, but is important for subcellular localisation. However, a 
secondary signal from binding of a SH3 domain-containing protein 
causes a conformational change, releasing pseudosubstrate 
autoinhibition and allows kinase activity. This interaction may be 
through direct binding to the pseudosubstrate sequence or via another 
proline region within the N-terminus. 
Figure adapted from: (Ha et al., 2012). 
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Additionally, they reported that autoinhibition was relieved upon mutation of 
this region (Ha et al., 2012), which compliments previous studies 
demonstrating that there is increased kinase activity in N-terminally truncated 
PAK4 (Wells et al., 2002). Further to the two studies, the entire AID 
sequence of PAK was elucidated through nuclear magnetic resonance 
(NMR) studies. It was found to comprise 20 residues with an N-terminal α-
helix and the previously identified pseudosubstrate motif, which occupied the 
kinase cleft to achieve full autoinhibition (Wang et al., 2013). These studies 
do all conclude that PAK4 is likely to be constitutively phosphorylated at 
Ser474, a site previously used as a marker of PAK4 kinase activity; rather 
than being regulated by phosphorylation of residues within the activation 
loop, PAK4 activity is modulated via conformational changes mediated by N-
terminal regions. They further postulate that this newly identified AID could 
be conserved across all group II PAKs, providing a common mechanism of 
autoregulation (Baskaran et al., 2012; Ha et al., 2012; Wang et al., 2013) 
 
1.4.5 PAK4 and cell migration 
PAK4 was originally identified as a cytoskeletal regulatory kinase, 
relocalising to the Golgi downstream of activated Cdc42 and inducing actin 
polymerisation and formation of filopodia in both endothelial cells and 
fibroblasts (Abo et al., 1998; Qu et al., 2001). Subsequent to this, PAK4 has 
been the focus of intense study and multiple cell migrational functions have 
been identified. It has been shown that overexpression of PAK4 leads to 
dissolution of stress fibers, a loss of focal adhesions and cell rounding (Barac 
et al., 2004; Qu et al., 2001; Wells et al., 2002), which is thought to be, at 
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least in part, due to the interaction of PAK4 with GEF-H1. Interaction 
between the two proteins, leads to phosphorylation GEF-H1 and inhibition of 
its stress fiber formation functions. In addition, this study provided a 
mechanistic insight into the role of PAK4/GEF-H1 interaction and crosstalk 
between microtubules and the actin cytoskeleton (Callow et al., 2005).  
 
Cofilin is a regulator of actin filament disassembly; LIM-kinase (LIMK) has 
been shown to target cofilin, and through phosphorylation reverse cofilin-
induced actin depolymerisation (Yang et al., 1998). PAK4 has been shown to 
interact and phosphorylate LIMK, enhancing its ability to phosphorylate cofilin 
to further inhibit actin disassembly (Ahmed et al., 2008; Dan et al., 2001). 
This is thought to be due to inhibition of Sling-Shot phosphatase-1L (SSH-1L) 
by PAK4, relieving the SSH-1L-induced down-regulation of LIMK 
(Soosairajah et al., 2005). Upregulation of LIMK activity by PAK4 is further 
enhanced by protein kinase D (PKD) mediated phosphorylation of PAK4 at 
Ser474 (Doppler et al., 2014; Spratley et al., 2011). In addition to the LIMK-
mediated pro-migratory function of PAK4, it has been shown to regulate cell 
adhesion dynamics, which are a key component of cell migration. Both PAK4 
knockout mice, and PAK4 depleted cells have an increase in the number of 
focal adhesions (Qu et al., 2003; Wells et al., 2010), which is thought to be 
linked to the reduction in PAK4-mediated phosphorylation of paxillin at 
Ser272 (a marker of adhesion dynamics); this phosphorylation is thought 
could promote adhesion disassembly (Wells et al., 2010; Zhang et al., 2008). 
It is known that PAK4 interacts with the cytoplasmic tail of integrin αvβ5 
(Zhang et al., 2002), phosphorylating the β5 subunit at two sites (Ser759 and 
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Ser762), which are located within a membrane-proximal integrin beta5-
SERS-motif (Li et al., 2010c). These phosphorylation events serve to 
accelerate integrin αvβ5 turnover within adhesions through inhibition of 
integrin αvβ5 clustering, connections to F-actin and preventing adhesion 
maturation (Li et al., 2010b), which is dependent on PAK4 kinase activity and 
promotes cell motility. PAK4 has also been shown to interact with the 
scaffold protein, Gab1, leading to relocalisation to the cell periphery 
(specifically within lamellipodia), an interaction that occurs downstream of c-
Met, in response to HGF (Paliouras et al., 2009). 
 
1.4.6 PAK4 and cancer 
Overexpression and/or mutational activation of different PAK isoforms has 
been observed in many different tumour types, data suggest that aberrant 
PAK activity drives many cellular processes, which are central features of 
cancer (King et al., 2014; Radu et al., 2014). In this study, the mechanisms of 
PAK4-driven oncogenesis and its role in cancer progression are discussed. 
However, alterations of both group I and group II PAKs is summarised in 
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Table 1.5: PAKs in cancer. Table demonstrating the range of cancers different PAK isoforms are involved in and the type of 
alterations involved. Table adapted from King et al, 2014 including some newly published data. Of note are the different studies of 
PAK1 involvement in pancreatic cancer, demonstrating the complexities involved in this disease and the requirement for further 
investigation. 
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With regards to PAK4, it is the most widely studied group II PAK, especially 
in respect to cancer. The PAK4 gene maps to a region on chromosome 19 
(19q13.2), which is commonly amplified in cancer (Begum et al., 2009; Chen 
et al., 2008; Minden, 2012; Parsons et al., 2005; Yu et al., 2009). PAK4 has 
been shown to be overexpressed or genetically amplified and/or mutated in a 
number of cancer cell lines and tumour samples including breast (Callow et 
al., 2002; Liu et al., 2010b; Minden, 2012; Wong et al., 2013), ovarian (Davis 
et al., 2013; Siu et al., 2010a), colon (Parsons et al., 2005; Tabusa et al., 
2013), prostate (Ahmed et al., 2008; Park et al., 2013; Wells et al., 2010; 
Whale et al., 2013), gastric (Ahn et al., 2011), lung (Callow et al., 2002), 
glioma (Kesanakurti et al., 2012), gallbladder (Kim et al., 2008), squamous 
cell carcinoma (Begum et al., 2009; Zanivan et al., 2013) and pancreatic 
(Chen et al., 2008; Kimmelman et al., 2008; Mahlamaki et al., 2004). 
 
It is known that PAK4 plays a key role in cellular proliferation in the 
developing embryo (Qu et al., 2003; Tian et al., 2009; Tian et al., 2011b), but 
also controlling key aspects of normal cellular proliferation. PAK4 regulates 
both the G1 (Nekrasova and Minden, 2011) and G2/M phase (Bompard et al., 
2010) of the cell cycle and is important in spindle positioning during mitosis 
(Bompard et al., 2013). However, the impact of PAK4 on proliferation has 
also been reported in cancer, which allows cells to rapidly expand in number. 
PAK4 was found to regulate the expression of both cyclin D1 and CDC25A in 
ovarian cancer cells, with shRNA-mediated depletion of PAK4 resulting in a 
significant reduction in proliferation (Siu et al., 2010a). It is also thought that 
PAK4 could balance the expression of CDK6 and p16 (a tumour suppressor 
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that inhibits CDK6) to favour an increased proliferative rate in 
choriocarcinoma cells (Zhang et al., 2011a). Further evidence shows that 
increased PAK4 expression in gastric cancer correlated with cell cycle 
progression via PAK4 phosphorylation of Smad2/3 and subsequent inhibition 
of TGF-β1 signalling (Wang et al., 2014). Conversely, cell cycle arrest is 
observed in PAK4 knockdown laryngeal carcinoma cells through activation of 
the ATM/Chk1/2/p53 pathway (Sun et al., 2013). Additionally, PAK4 
knockdown in colon carcinoma cell lines resulted in significantly reduced 
proliferation; this was, however, found not to involve either the MAPK or 
PI3K/Akt signalling pathways and was irrespective of PAK4 protein levels 
(Tabusa et al., 2013). These data provide strong evidence to support a role 
for PAK4-driven cell cycle progression in tumourogenesis. 
 
Evasion of apoptosis is another hallmark of cancer and PAK4 has been 
shown to promote cell survival through both kinase-dependent and kinase-
independent mechanisms (King et al., 2014). Cells overexpressing either wild 
type or constitutively active PAK4 were able to avoid apoptosis after 
exposure to pro-apoptotic stimuli through prevention of caspase activation 
(Gnesutta et al., 2001). PAK4 protection from apoptosis requires both kinase-
independent antagonism of caspase 8 activation and prevents recruitment to 
death domain receptors (Gnesutta and Minden, 2003) and PAK4 kinase-
dependent phosphorylation of the proapoptotic protein, Bad (Gnesutta and 
Minden, 2003). Cells lacking PAK4 are more susceptible to apoptosis, with 
cells requiring PAK4 to activate TNF-α mediated pro-survival pathways (Li 
and Minden, 2005) Additionally, PAK4 has been found to associate with 
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keratinocyte growth factor (KGF) receptor, which is an important protective 
factor for epithelial cells. Expression of a dominant-negative PAK4 blocks 
KGF-mediated inhibition of caspase 3 activation (Lu et al., 2003), which 
further demonstrates a role for PAK4 in cell survival mechanisms. 
Furthermore, PAK4 gene amplification observed in ovarian cancer has 
recently been shown to be essential for cell viability (Davis et al., 2013). 
 
PAK4 is also heavily implicated in cancer cell metastasis, a process that is 
reliant on reorganisation of the actin cytoskeleton. PAK4 is a known 
cytoskeletal regulatory kinase (see section 1.4.5). PAK4/LIMK interactions 
are known to contribute to cell migration (Dan et al., 2001) and this has been 
shown to be downstream of HGF in prostate cancer cells (Ahmed et al., 
2008). Indeed, PAK4 depleted prostate cancer cells are less responsive to 
HGF, demonstrating a significant reduction in cell migration (Wells et al., 
2010). This PAK4/LIMK signalling has also been shown to contribute to 
gastric cancer cell migration in vitro. LIMK phosphorylation by PAK4 is 
enhanced via interaction of DiGeorge critical region 6L with the PAK4 kinase 
domain (Li et al., 2010a). Additional pro-migratory signalling of PAK4 in 
gastric cancer metastasis is mediated through PAK4 dependent 
phosphorylation of superior cervical ganglia 10 (SCG10), a microtubule 
destabiliser, at Ser50. This serves to regulate microtubules and promote 
gastric cancer cell migration for in vitro and in a xenograft mouse model (Guo 
et al., 2014b). Further to the role of PAK4 in normal cell adhesion dynamics 
via integrins, PAK4 was shown to contribute to focal adhesion turnover and 
directional cell migration in prostate cancer through interaction with a β1 
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integrin/Trop-2 complex (Trerotola et al., 2013). PAK4 enhances endometrial 
cell invasion and PAK4 knockdown in both endometrial and glioma cells 
produces a significantly reduced migratory phenotype (Kesanakurti et al., 
2012; Kim et al., 2013). Overexpression studies of PAK4 in ovarian cancer 
demonstrate the ability of PAK4 to enhance ovarian cancer cell migration in a 
c-Src/MEK-1/MMP-2 kinase-dependent manner, with the level of c-Src and 
MMP-2 expression correlated with PAK4 knockdown (Siu et al., 2010a). In 
addition, in the MCF10 breast cancer progression cell series, the level of 
PAK4 expression is observed as correlating with tumourogenicity in the cell 
lines (So et al., 2012). PAK4 is known to trigger transformation of mammary 
epithelial cells (Liu et al., 2010b), with PAK4 depletion in MDA-MB-231 
breast cancer cells leading to both reduced migration in vitro and decreased 
tumour formation in nude mice in vivo (Wong et al., 2013) and also 
contributing to oncogene ErbB2-induced breast cancer cell invasiveness 
(Rafn et al., 2012). There was a marked decrease in the invasive capacity of 
PAK4-depleted skin cancer cell lines (A431 and SCC9) in a collagen-based 
3D organotypic model, which may be due to ablation of PAK4-mediated 
phosphorylation of RAF1 and Src, at Ser43 and Ser17 respectively (Zanivan 
et al., 2013). Overexpression of PAK4 has also been documented in 
hepatocellular carcinoma tissue; this correlates with the known pro-
metastatic protein, CDK5 kinase regulatory subunit-associated protein 3 
(CDK5RAP3), which also enhanced PAK4 kinase activity (Mak et al., 2011). 
Interestingly, PAK4 has also been shown to be overexpressed in pancreatic 
cancer (Chen et al., 2008; Mahlamaki et al., 2004). Constitutively active 
PAK4 increases pancreatic duct cell invasion and siRNA-mediated depletion 
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of PAK4 in the highly invasive PaTu8988T PDAC cell line resulting in both a 
reduction of anchorage-independent growth and a decreased migratory 
phenotype (Kimmelman et al., 2008). However, the mechanisms of PAK4-
mediated invasion and pro-migratory signalling in PDAC have yet to be 
elucidated. With the wealth of data published, it strongly implicates the 
effects of aberrant PAK4 signalling and its key role in invasive oncogenesis.  
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1.5 The project 
1.5.1 Hypothesis 
PAK4 is overexpressed in pancreatic cancer cell lines and in primary tumour 
samples. In addition, KRAS gene mutations occur frequently in pancreatic 
cancer; it is thought that these mutations could lead to PAK4 activation. HGF 
and its receptor c-Met are also upregulated in pancreatic cancers, these in 
combination with oncogenic K-ras lead to continual signalling of downstream 
pathways, including the PI3K pathway. PAK4 has been shown to be 
activated downstream of PI3K in an HGF dependant manner, leading to 
increased cell migration. In addition LY294002, a phosphoinositide 3-kinase 
(PI3K) inhibitor, inhibits HGF-induced PAK4 kinase activation (Wells et al., 
2002). PAK4 has also been shown to be amplified in PDAC cell lines and 
tumour samples and that oncogenic K-ras can activate PAK4 (Chen et al., 
2008). It was therefore hypothesised that PAK4 could lie within the PI3K 
pathway in pancreatic cancer downstream of K-ras and/or HGF/c-Met to 
promote pancreatic cancer cell migration and invasion. 
 
1.5.2 Aims of the project 
The aim of this project was to investigate the importance of PAK4 signalling 
in pancreatic cancer cell invasion, and the pathways involved in its activation 
and downstream effector functions. To facilitate the studies of PAK4 biology, 
knockdown cell lines would be used to demonstrate a requirement for PAK4 
in pancreatic cancer cell migration downstream of HGF. This would be done 
both in random 2D migration assays and using an already established 
organotypic model of pancreatic cancer in order to study 3D invasion. In 
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parallel, PAK4 interacting partners, relevant to the pathways involved in 
PDAC progression will be isolated using GST pulldown assays. These 
interactions will be further explored using pharmacological inhibition of PI3K 
in order to determine if the effects of PAK4 knockdown are phenocopied. 
Finally, potential downstream effectors of PAK4 signalling in PDAC will also 
be investigated in order to provide a additional insight as to the nature of 












Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 General Materials 
10X Dulbecco’s modified Eagle’s medium (DMEM) (VWR International, UK) 
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) (Cayman 
Chemical, USA)  
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris)-Base/Hydrochloric acid 
(HCL) (Sigma-Aldrich, UK) 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) (Sigma-
Aldrich, UK) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (GIBCO®, 
Invitrogen, UK) 
4’, 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, UK) 
Acrylamide (30%) (Severn Biotech Ltd, UK) 
Agarose (Invitrogen, UK) 
Ammonium persulfate (APS) (Sigma-Aldrich, UK) 
Ampicillin (Sigma-Aldrich, UK) 
Aprotinin (Sigma-Aldrich, UK) 
BD MatrigelTM Matrix (BD Biosciences, UK) 
Beta (β)-mercaptoethanol (Sigma-Aldrich, UK) 
Bovine pituitary extract (BPE) (GIBCO®, Invitrogen, UK) 
Bovine serum albumin (BSA) (VWR International, UK) 
Bromophenol blue (Bio-Rad, UK) 
Calcium phosphate transfection kit (Invitrogen, UK) 
cOmplete, EDTA free protease inhibitor cocktail tabets (Roche, UK) 
Concentrated rat tail collagen, type I (BD Biosciences, UK) 
Coomassie brilliant blue (Thermo Scientific, USA)  
Deoxyribonucleotide triphosphate (dNTPs) (New England Biolabs UK) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, UK) 
Dithiothreitol (DTT) (Sigma-Aldrich, UK) 
DMEM F:12 media (Lonza, UK) 
DMEM+GlutaMAXTM (GIBCO®, Invitrogen, UK) 
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DNA ladder (New England Biolabs, UK) 
Dulbecco’s phosphate-buffered saline (DPBS) (Lonza, UK) 
Epidermal growth factor (EGF) (GIBCO®, Invitrogen, UK) 
Ethanol (BDH Laboratory Supplies, UK) 
Ethidium bromide (Thermo Fisher Scientific, UK) 
Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, UK) 
Fibronectin (Sigma-Aldrich, UK) 
Fish skin gelatin (Sigma-Aldrich, UK) 
FluorSaveTM Reagent (Calbiochem, UK) 
Foetal bovine serum (FBS) (GIBCO®, Invitrogen, UK) 
Formalin solution (neutral buffered) (Sigma-Aldrich, UK) 
Fuji Medical X-ray film, Super RX (Fuji Film, Japan) 
GatewayTM BP ClonaseTM Enzyme Mix (Invitrogen, UK) 
GatewayTM LR ClonaseTM Enzyme Mix (Invitrogen, UK) 
Gentamycin (Sigma-Aldrich, UK) 
Glacial acetic acid (Sigma-Aldrich, UK) 
Glutathione SepharoseTM 4B Fast Flow beads (GE Healthcare, UK) 
Gluteraldehyde (Sigma-Aldrich, UK) 
Glycerol (Sigma-Aldrich, UK) 
Glycine (Sigma-Aldrich, UK) 
HCl (VWR International, UK) 
HGF (Recombinant Human) (R&D systems, USA) 
HiPerfect (Qiagen Ltd, UK) 
IllustraTM GFXTM PCR DNA & Gel Band Purification Kit (GE Healthcare, UK) 
Isopropanol (VWR International, UK) 
Kanamycin (Invitrogen, UK) 
Keratinocyte serum free media (KSFM) (GIBCO®, Invitrogen, UK) 
L-Arabinose (Sigma-Aldrich, UK) 
Lemo21 (DE3) chemiclally competent E.coli cells (New England Biolabs, 
UK) 
Leupeptin (Sigma-Aldrich, UK) 
Luria-agar (L-agar) (Sigma-Aldrich, UK) 
Luria-broth (L-broth) tablets (Sigma-Aldrich, UK) 
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MAX Efficiency® DH5αTM Competent Escherichia coli (E. coli) cells 
(Invitrogen, UK) 
Methanol (VWR International, UK) 
Milk powder (Marvel, UK) 
NEB-10 beta chemically competent E. coli cells (New England Biolabs, UK) 
Nuclease-free water (Fisher Scientific, UK) 
Nylon membrane (Millipore, UK) 
Octylphenoxypolyethoxyethanol/NonidetTM P40 (NP-40) (Sigma-Aldrich, 
UK) 
One Shot® BL21-A1 Competent E. coli cells (Invitrogen, UK) 
One Shot® TOP10 Chemically competent E. coli cells (Invitrogen, UK) 
OptiMEM (GIBCO®, Invitrogen, UK) 
Paraformaldehyde (PFA) (Sigma-Aldrich, UK) 
pDESTTM15 (Invitrogen, UK) 
pDESTTM207 (Invitrogen, UK) 
Penicillin/Streptomycin (Sigma-Aldrich, UK) 
Phenylmethylsulfonylfluoride (PMSF) (Sigma-Aldrich, UK) 
Phosphate buffered saline (PBS) tablets (Oxoid Limited, UK) 
Phusion DNA polymerase (Finnzymes, UK) 
Phusion HF Buffer (New England Biolabs, UK) 
Pierce® ECL western blotting substrate (Thermo Scientific, USA) 
Precision Plus ProteinTM All Blue Standards (Bio-rad, UK) 
PurelinkTM HiPure Plasmid Filter Maxi-prep kit (Invitrogen, UK) 
PurelinkTM HiPure Plasmid Filter Mini-prep kit (Invitrogen, UK) 
Puromycin (Sigma-Aldrich, UK) 
QIAfilterTM Plasmid Midi-prep kit (Qiagen, UK) 
QuikChangeTM Site-directed mutagenesis kit (Stratagene, USA) 
Rat tail collagen, Type I (BD Biosciences, UK) 
Rat tail collagen, Type I (Millipore, UK) 
Roswell Park Memorial Institute (RPMI)-1640 medium (GIBCO®, Invitrogen, 
UK) 
Sodium borohydride (Sigma-Aldrich, UK) 
Sodium chloride (NaCl) (Sigma-Aldrich, UK) 
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Sodium dodecyl sulphate (SDS) (Sigma-Aldrich, UK) 
Sodium fluoride (NaF) (Alfa Aesar, UK) 
Sodium hydroxide (NaOH) (Sigma-Aldrich, UK) 
Sodium orthovanadate (Na3VO4) (Sigma-Aldrich, UK) 
Sodium pyrophosphate (BDH Chemicals, UK) 
Spectinomycin (Sigma-Aldrich, UK) 
Sucrose (Sigma-Aldrich, UK) 
Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, UK) 
Tri-sodium citrate dihydrate (Sigma-Aldrich, UK) 
Tris acetate (Sigma-Aldrich, UK) 
Tris-base (Sigma-Aldrich, UK) 
Tris-EDTA (TE) Buffer (Invitrogen, UK) 
TritonX-100 (VWR International, UK) 
Trypsin/EDTA (GIBCO®, Invitrogen, UK) 
Tween20 (VWR International, UK) 
Whatman PROTRAN nitrocellulose membrane (Perkin Elmer, USA) 
X-tremeGENE HP transfection reagent (Roche, UK) 






Blocking solution: 5% w/v milk powder or 5% BSA in TBS-Tween 
 
Coomassie blue stain: 50% v/v methanol, 10% v/v acetic acid, 0.025% w/v 
coomassie blue 
 
Coomassie destain solution: 12.5% v/v isopropanol, 10% v/v acetic acid 
 
DNA loading buffer: 40% w/v sucrose, 0.25% w/v bromophenol blue 
 
Freeze down buffer: (for GST proteins): 50% v/v glycerol, 20mM Tris-HCl 
pH7.6, 100mM NaCl plus protease inhibitor cocktail 
 
Harsh stripping buffer: 62.5mM Tris pH6.8, 2% w/v SDS, 100mM β-
mercaptoethanol  
 
Laemmli buffer (2X): 100mM Tris-HCl pH6.8, 4% w/v SDS, 20% v/v glycerol, 
0.2% w/v bromophenol blue, 1:50 β-mercaptoethanol 
 
Laemmli buffer (6X): 375 mM Tris-HCl pH 6.8, 6% SDS, 48% glycerol, 9% β-
mercaptoethanol, 0.03% bromophenol blue 
 
Mild stripping buffer: 25mM Glycine pH2, 1% w/v SDS 
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NP-40 lysis buffer: 0.5% v/v NP-40, 30mM sodium pyrophosphate, 50mM 
Tris-HCl pH7.6, 150mM NaCl, 0.1mM EDTA plus protease inhibitor cocktail 
 
Protease inhibitor cocktail: 50mM NaF, 1mM Na3VO4, 1mM PMSF, 10μg/ml 
leupeptin, 1μg/ml aprotinin and 1mM DTT 
 
Pulldown lysis buffer: 20mM Tris-HCl pH7.6, 150mM NaCl, 2mM EDTA, 
0.01% v/v TritonX-100, 10% v/v glycerol plus protease inhibitor cocktail 
 
Pulldown wash buffer: 20mM Tris-HCl pH7.6, 300mM NaCl, 2mM EDTA, 1% 
v/v TritonX-100, 10% v/v glycerol plus protease inhibitor cocktail 
 
SDS-PAGE running buffer (10X): 250mM Tris-base, 1.92M Glycine, 1% w/v 
SDS. Dilute to 1X with distilled water for use. 
 
SDS-PAGE transfer buffer (10X): 250mM Tris-base, 1.92M Glycine. Dilute to 
1X with distilled water and methanol (to a final concentration of 20% v/v) 
 







Construct Vector backbone Source 
   
Myc:H-ras V12  pDONR223 Addgene, USA 
(31201) 
 
Generated by author 
Myc:K-ras V12 pDONR223 Addgene, USA 
(31200) 
 
Generated by author 
Myc:N-ras V12 pDONRTM207 
Kind gift from Dr. Matthias 
Krause, King’s College 
London. 
 




pEGFP-C1 (Clontech, UK) 
modified for use in 
GatewayTMTechnology by 
Kerry Shea, King’s College 
London 
 
Generated by author 
GFP:K-ras pEGFP-C1 (Clontech, UK) 
modified for use in 
GatewayTMTechnology by 
Kerry Shea, King’s College 
London 
 
Generated by author 
GFP:p85α pEGFP-C1 (Clontech, UK) 
modified for use in 
GatewayTMTechnology by 
Kerry Shea, King’s College 
London 
 
Generated by author 
GFP:p85α SH3 pEGFP-C1 (Clontech, UK) 
modified for use in 
GatewayTMTechnology by 
Kerry Shea, King’s College 
London 
 
Generated by author 
GFP:p85α ΔSH3 pEGFP-C1 (Clontech, UK) 
modified for use in 
GatewayTMTechnology by 
Kerry Shea, King’s College 
London 
 
Generated by author 
 
Table 2.1: Mammalian Plasmids 
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Construct Vector backbone Source 
   
GST pGEX 2A1 Kind gift from Professor Anne 






























Generated by author 
 
 































































































Table 2.3: Primers 
N.B. Gateway denotes primers that contain the specific att sequences, which 
lies before the template specific sequence within the primer.  
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2.1.5 Antibodies 
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Table 2.4: Primary Antibodies 
 
























































































Table 2.5: Secondary Antibodies  
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2.2 Methods – Molecular Biology 
2.2.1 Generation of tagged constructs 
The GatewayTM Technology system was used to generate tagged constructs. 
(N.B. This was only necessary for Ras constructs). Wild-type H-, K-, and N-
ras constructs (a kind gift from Dr. Matthias Krause, King’s College London) 
were used as templates in the production of Ras DNA flanked by attB sites; 
the addition of these sites is necessary in order to generate PCR products 
that were suitable for subsequent cloning into the GatewayTM vectors. Ras 
DNA flanked by the attB sequences were produced by PCR amplification 
using Phusion DNA polymerase. Each reaction was set up using 10μl 
reaction buffer, 500ng template DNA, 3% v/v DMSO, 200μM of 
deoxyribonucleotide triphosphate (dNTPs) and 500nM of each forward and 
reverse primer (see table 2.3). This was made up to a total reaction volume 
of 50μl, with nuclease-free water, in a sterile 0.2ml PCR tube. The PCR 
reaction was performed under the conditions described in table 2.6.  
 
Number of cycles (& Process) Temperature Time 
1 (initial denaturation) 95oC 4 minutes 
30 95oC 30 seconds 
 68oC 30 seconds 
1 (final extension) 68oC 5 minutes 
 





2.2.2 Gel purification of DNA fragments 
PCR products were resolved on a 1.3% w/v TAE agarose gel supplemented 
with 0.5μg/ml ethidium bromide to allow detection of DNA products. The DNA 
was then visualised under a low intensity UV light and could then be excised 
from the agarose gel using a scalpel. The DNA fragment was then purified 
using the IllustraTM GFXTM PCR DNA and Gel Band Purification kit according 
to the manufacturers protocol. In short, capture buffer was added to the 
sample to denature protein and/or dissolve agarose gel. The sample mixture 
was then applied to the IllustraTM GFXTM microspin column and DNA bound 
to the membrane. A wash buffer was applied and the membrane bound DNA 
was washed to remove any salts or contaminants and DNA dried. The 
purified DNA was then eluted from the column using sterile nuclease-free 
water and stored at -20oC for subsequent use. (N.B. It was found that due to 
the formation of strong secondary structures, the H- and K-ras DNA given 
could not be used in a PCR reaction despite substantial optimisation 
attempts. For these reasons, the pDONR vectors were purchased from 
Addgene, as stated). 
 
2.2.3 Construction of entry clones 
To facilitate the transfer of the PCR product (attB sequence flanked N-ras 
DNA) into an attP containing donor vector (pDONRTM207 vector), resulting in 
the formation of an entry clone, a GatewayTM BP recombination reaction was 
performed. This was in accordance with the manufacturers instructions and 
summarised in figure 2.1. The BP reaction mix, containing the PCR product, 
donor vector and BP clonase, was incubated at 25oC for 1 hour. After this  
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Figure 2.1: GatewayTM Technology BP and LR reactions. (A) 
Diagramatric summary of BP reaction for production of entry clone. (B) 
Summary of the LR recombination reaction, which is carried out in order 
to create an expression clone containing the gene of interest. 
 
Image is from GatewayTM Technology Manual (Invitrogen, UK). 
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incubation, proteinase K was added, the reaction mix incubated at 37oC for 
10 minutes, which terminated the reaction. This reaction mix was then 
transformed into competent E. coli and entry clones selected for using the 
appropriate antibiotic (10μg/ml gentamycin for N-ras and 100μg/ml 
spectinomycin for purchased H- and K-ras). Bacteria were plated out onto 
LB-agar supplemented with the appropriate antibiotic and incubated 
overnight at 37oC. Individual colonies were subsequently selected, purified 
and sequenced (by Eurofins MWG Operon) before continuing to LR reaction 
for production of expression clones. 
 
2.2.4 Construction of expression clones 
The GatewayTM LR recombination reaction was used to transfer the gene of 
interest into an attR-containing destination vector to create an attB-containing 
expression clone. This reaction was used to generate GST, GFP and Myc-
tagged expression clones using pDESTTM15, pEGFP-C1 and pDESTTMMyc 
respectively. This reaction was carried out in accordance with the 
manufacturers instructions and summarised in figure 2.1. The purified entry 
clone was incubated with the chosen destination vector and the LR 
ClonaseTM reaction buffer at 25oC for 1 hour. The subsequent addition of 
proteinase K and incubation for 10 minutes at 37oC terminated the reaction. 
This reaction mix was then used to transform chemically competent E. coli, 
the expression clones selected for using the appropriate antibiotic and the 
plasmid DNA isolated and purified. The DNA obtained was sequenced by 
Eurofins MWG Operon prior to any subsequent use in further assays. 
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2.2.5 Site Directed Mutagenesis 
Site directed mutagenesis was used to construct two point mutants of full 
length PAK4 (P105,108A and P287,289A) and a PAK4 RNAi rescue 
construct (see Table 2.3 for primer sequences). 
 
The PCR reactions were performed using the Stratagene QuikChange® Site-
Directed Mutagenesis kit which uses PfuTurbo® DNA polymerase and a 
temperature cycler. The reaction was set up in a 0.2ml PCR tube as follows: 
5μl of 10x reaction buffer (100mM KCl, 100mM (NH4)2SO4, 200mM Tris-HCl 
pH 8.8, 20mM MgSO4, 1% Triton
® X-100, 1mg/ml nuclease-free BSA), 50ng 
of template DNA (PAK4 entry clone), 1μl dNTP mix and 125ng of mutagenic 
forward and reverse primers. The total reaction volume was made up to 50μl 
with ddH2O. To this 1μl PfuTurbo
® DNA polymerase (2.5U/μl) was added. 
The specific thermo cycling parameters are described in table 2.7.  
 
Number of cycles Temperature Time 
   
1 Cycle 
 
95oC 30 seconds 
18 Cycles 95oC 30 seconds 





Table 2.7: Cycling Parameters for the QuikChange Site-Directed 
Mutagenesis method. 
 
*1 minute/kb of plasmid length. 
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Following the temperature cycling 1μl of the Dpn I restriction enzyme (10U/μl) 
was added to the amplification reaction in order to digest the parental (non 
mutated) supercoiled dsDNA template and select for the newly synthesized 
DNA containing the mutations. The reaction mixture was mixed by pipetting 
up and down several times, spun down in a microcentrifuge for one minute 
and then incubated at 37oC for precisely one hour. Following this, 5μl of the 
reaction mixture was transformed into chemically competent E. coli bacteria. 
 
2.2.6 Transformation of Escherichia coli cells 
The heat shock method was used to transform E. coli bacteria, the strain 
used varied between different assays. Vials of bacteria, which were stored at 
-80oC, were thawed for 10 minutes on ice prior to transformation. Typically, 
5μl of plasmid DNA was added to the bacteria and mixed by tapping. These 
cells were then incubated of ice for 30 minutes. Following this, bacteria were 
heat shocked by incubating the vials containing the reaction mix at 42oC. The 
length of heat shock varied slightly between E. coli strains (see table 2.8 for 
variations in the procedures). The reaction mix was then placed on ice for 5 
minutes. A volume of L-broth was then added to the reaction mix (see table 
2.8) and then vials were incubated at 37oC in a shaking incubator for one 
hour at approximately 225rpm.  
 
Bacteria 
Length of Heat 
Shock 








30 seconds 2 minutes 250μl 
BL21-A1TM One 
Shot® 





20 seconds 2 minutes 950μl 
NEB 10-beta 
 
30 seconds 5 minutes 950μl 
Lemo21 (DE3) 
 
10 seconds 5 minutes 950μl 
 
Table 2.8: Transformation procedure of chemically competent E. coli 
bacteria 
 
Subsequently, 200-300μl of the transformation reaction was plated onto pre-
warmed LB plates containing the appropriate antibiotic for plasmid selection. 
The plates were inverted and incubated at 37oC overnight. The following day, 
colonies were picked and grown in L-broth containing the appropriate 
selection antibiotic and either grown up for use in various procedures or 
made into a glycerol stock. 
 
2.2.7 DNA Preparation 
Plasmid DNA was isolated and purified from E.coli bacteria using either the 
Invitrogen PurelinkTM HiPure plasmid DNA purification maxiprep kit, the 
QIAfilterTM Plasmid Midi-prep kit or the PurelinkTM HiPure Plasmid Filter Mini-
prep kit, dependent on the DNA yield required. L-broth, with the appropriate 
selection antibiotic added, was inoculated with the transformed bacteria and 
grown overnight at 37oC in a shaking incubator. DNA was purified as per the 
manufacturers protocol and resulting DNA resuspended in TE buffer and 




2.3 Methods - Cell Biology 
2.3.1 Cell Lines & Culture Conditions 
Several difference cancerous and non-cancerous pancreatic cell lines were 
used and described here. Two epithelial cell lines included: HPDE cells 
which are a human papillomavirus (HPV)-16 E6E7 immortalised cell line, 
which were derived from normal adult pancreatic tissue (Furukawa et al., 
1996) and dechTERT cells, which are primary cells collected and hTERT 
immortalised previously (Li et al., 2009) but have not been widely used. 
Three cancer cell lines were also used, including; Capan1, a well 
differentiated, colony forming cell line which was sourced from a liver 
metastasis, with mutations is KRAS, TP53, INK4A, SMAD4 and BRCA2 
(Deer et al., 2010; Sipos et al., 2003). Also used, was another colony forming 
cell line, PaTu8988S that was isolated from a liver metastasis of a primary 
pancreatic adenocarcinoma together with PaTu8988T, which is a poorly 
differentiated, highly invasive cell line. These carry mutations in KRAS and 
TP53 with methylation of the 5’ CpG island of INK4A (Dammann et al., 2003; 
Elsasser et al., 1992). For use in the organotypic model of pancreatic cancer, 
PS-1 cells which were immortalised using ectopic human telomerase reverse 
transcriptase (hTERT) by members of Dr Hemant Kocher’s laboratory 
(Froeling et al., 2009; Li et al., 2009). The strain was verified as being of 
stellate origin based on the expression of characteristic stellate cell markers. 
These included presence of lipid droplets in the cytoplasm and expression of 
various cytoskeletal proteins such as GFAP, desmin, vimentin and αSMA. 
They have been shown to grow well in culture, without the loss of phenotypic 
characteristics during continuous passage. 
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All cell lines were cultured as adherent monolayers in sterile tissue culture 
flasks. They were incubated in a humidified atmosphere of 5% CO2 at 37
oC 
and maintained with regular media change. PaTu8988S and PaTu8988T 
(from Dr. Frank Ulrich Weiß, Department of Medicine, Ernst Moritz Arndt 
Universität Greifswald, Greifswald, Germany), HEK293 (ATCC) and 
DechTERT (from Mr Hemant Kocher, Barts Cancer Institute, UK) cells were 
maintained in Dulbecco’s modified Eagle’s media (DMEM) supplemented 
with 10% v/v fetal bovine serum (FBS) and 1mM penicillin/streptomycin. 
Capan1 (from Mr Hemant Kocher, Barts Cancer Institute, UK) cells were 
maintained in Roswell Park Memorial Institute-1640 (RPMI-1640) media 
supplemented with 10% v/v FBS with 1mM penicillin/streptomycin. HPDE 
cells (from Mr Hemant Kocher, Barts Cancer Institute, UK) were maintained 
in keratinocyte serum-free media (K-SFM) supplemented with 5ng/ml 
epidermal growth factor (EGF), 0.1mg/ml bovine pituitary extract (BPE) and 
1mM penicillin/streptomycin. PS-1 cells (from Mr Hemant Kocher, Barts 
Cancer Insitute, UK) were maintained in DMEM:F12, supplemented with 10% 
v/v FBS, 1mM penicillin/streptomycin and 1μg/ml puromycin as a selection 
agent. To passage, cells were first washed with sterile phosphate buffered 
saline (PBS) and trypsinised with 0.5% Trypsin/Ethylenediaminetetraacetic 
acid (EDTA). 
 
2.3.2 Calcium Phosphate Transfection 
The calcium phosphate transfection kit was used to transfect HEK293 cells. 
Cells were seeded at a density of 1x105/ml and incubated at 37oC overnight. 
On the day of transfection, 3-4 hours prior to the addition of the reaction mix, 
 108 
the media was aspirated and replaced with fresh, warmed media. The 
reaction mix was set up using the conditions described in table 2.9. 
 
 
2cm tissue culture plate 
(2ml total volume) 
10cm tissue culture plate 










7.2μl 2M CaCl2 
4μg DNA 
Make up to 60μl with sterile 
water 
 
60μl 2x Hepes buffered saline 
 
30μl 2M CaCl2 
20μg DNA 
Make up to 300μl with sterile 
water 
 
300μl 2x Hepes buffered saline 
 
Table 2.9: Calcium phosphate transfection reaction mix. 
 
The contents of tube A (CaCl2, DNA and water mix) was added 100μl at a 
time, dropwise, to the 2x HBS in tube B, with aeration. This transfection 
mixture was then incubated at room temperature for 30 minutes, before 
being added dropwise to the cells and dispersed. 
 
2.3.3 X-treme Gene Transfection 
Cells were plated at the optimal seeding density (depending on application) 
of either 2x104/ml or 1x105/ml 24 hours prior to transfection in full growth 
media (10% FBS). On the day of transfection, the media was aspirated from 
the cells, which where then washed once with sterile PBS before the media 
was replaced with serum free OptiMEM media, free from antibiotics. The 
transfection mixture was then made up in OptiMEM serum free media, details 
of which are outline in table 2.10. To the OptiMEM the XtremeGENE HP 
transfection reagent and DNA were added at a ratio of 6:2 and incubated at 
room temperature for 30 minutes before being added dropwise to the cells 
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and dispersed. Cells were then returned to the incubator and maintained at 
37oC for 6 hours, after which the OptiMEM was aspirated and replaced with 

































Table 2.10: X-treme Gene transfection reaction mix. 
 
2.3.4 Hiperfect siRNA transfection 
Cells were plated at an appropriate density (2x104/ml) the day before 
transfection in full growth media (10% FBS). The next day, the reaction mix 
was set up as follows: 60nM of siRNA (table 2.11) was diluted in 100μl 
serum-free OptiMEM media. Equal concentrations of a control siRNA were 
used in each experiment. To the reaction mix, 12μl of HiPerfect was added. 
(Note: these volumes were for cells seeded in a 6 well plate in a total volume 
of 2ml; volumes were scaled up accordingly for larger experiments). This was 
then incubated at room temperature for 30 minutes before being added 
dropwise to the cells. Cells were then incubated at 37oC for various time 
frames depending on the assay. For longer periods of time i.e. in excess of 
















































Table 2.11: Sequences of siRNAs used. 
 
2.3.5 Collagen Coating 
Type I rat tail collagen was diluted to 50μg/ml in 0.02M glacial acetic acid, 
which had been filter sterilized. The dilute collagen solution was added and 
left on a level surface at room temperature for 60 minutes. The collagen was 
then aspirated and washed twice with sterile PBS before cells were seeded 
as usual.  
 
2.3.6 Time-lapse Microscopy 
Cells were seeded onto collagen coated wells of a 6 well plate at a density of 
2x104/ml. Where siRNA was used prior to movie acquisition cells were plated 
onto plastic, treated with the siRNA and then trypsinised and replated onto 
collagen coated plated on the day of the time-lapse. Immediately prior to 
time-lapse acquisition, the media was supplemented with 20mM Hepes 
before plates were sealed with parafilm and placed on the automated and 
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heated stage of an Olympus IX71 inverted time-lapse microscope. Images 
were collected using a Retiga SRV CCD camera with images being captured 
at 5-minute intervals for a total time period of 12 hours using Image-Pro Plus 
software.  
 
Following acquisition the movie files were extracted and saved as AVI files. 
These were then imported into the ImageJ software programme and cells 
could be manually tracked using the manual tracking plugin, MTrackJ. This 
resulted in the generation of a sequence of position coordinates, which could 
then be imported into the chemotaxis and migration tool from Ibidi. This 
allowed further analysis; the generation of migration plot profiles and the 
mean velocity and distance values to be calculated. In general, 
approximately 60-100 cells were tracked over at least three independent 
experiments per condition.  
 
2.3.7 Inhibitors 
LY294002 (molecular formula: C19H17N3) is known to be a highly selective 
inhibitor of PI3K and has been shown to block PI3K-dependent AKT 
phosphorylation and kinase activity. A stock solution, at a concentration of 
10mM, was made by diluting the lyophilized powder in DMSO. Aliquots were 
stored at -20oC until required. For use in all assays the stock solution was 
diluted further in culture medium to establish a working concentration of 





Prior to performing the MTT assay, PaTu8988T cells were treated with 
siRNA to transiently knockdown PAK4. A non-targeting siRNA was also used 
as a control. A 24 well sterile tissue culture plate was coated with collagen as 
described in section 2.3.5. Cells were seeded at a density of 5x103 and then 
incubated for 72 hours. The MTT powder was made up to a working 
concentration of 500μg/ml in DMEM media, fresh before each experiment. 
Culture media was carefully aspirated from each well and cells washed twice 
with sterile PBS before 1ml MTT:DMEM solution was applied. Cells were 
incubated in the presence of the MTT at 37oC for 3 hours. After this 
incubation, the MTT:DMEM was carefully removed and 500μl DMSO was 
used to solubilize the converted dye. This was pipetted up and down several 
times and then incubated at 37oC for a further 10 minutes. Each sample was 
then mixed again by pipetting and transferred to an Eppendorf tube. 
Subsequently, the absorbance was measured at a wavelength of 562nm 
using a Nanodrop.  
 
2.3.9 HGF Stimulations 
Cells were seeded at densities appropriate for the subsequent assay and 
subsequently maintained at 37oC in a humidified atmosphere with 5% CO2. 
The night before the HGF stimulation, the culture media was removed and 
cells were washed twice in sterile PBS. They were then maintained in media 
containing 0% FBS (starve media). The next day for lysates HGF was added 
at various time points at a concentration of 10ng/ml before cells were lysed 
and subsequently stored at -20oC. For use in migration assay, HGF was 
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added immediately prior to commencing time-lapse microscopy, also at a 
concentration of 10ng/ml. 
 
2.3.10 Immunofluorescence 
Cells cultured on coverslips. 
When seeding cells on coverslips, these were sterilized prior to use. 
Coverslips were incubated overnight at room temperature in a solution of 
40% 1M hydrochloric acid and 60% ethanol (96% solution). The coverslips 
were then rinsed three times in distilled water and boiled, rinsed a further six 
times in distilled water and then autoclaved. 
 
Cells were seeded onto collagen-coated coverslips and left to settle 
overnight. They were then washed twice in PBS and fixed in 4% 
paraformaldehyde (PFA) for 20 minutes at room temperature. Cells were 
then washed three times in PBS and permeabilised in 0.2% TritonX-100 for 5 
minutes at room temperature, washed a further three times in PBS and then 
blocked with 3% BSA for 30 minutes. The coverslips were then incubated in 
primary antibody, diluted in 3% BSA for 2 hours at room temperature in the 
dark, washed three times in PBS and incubated with the appropriate 
secondary antibody for one hour at room temperature in the dark. To 
visualize the nucleus, cells were also incubated with DAPI diluted in 3% BSA 
for 10 minutes before a final three washed in PBS and one with distilled 
water. Coverslips were then mounted onto microscope slides using 
FluorSave, left at room temperature in the dark overnight and stored at -20oC 
until being imaged. Cells were visualised using an Olympus IX71 inverted 
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microscope, using a 40X lens, and images analysed using ImageJ software.  
 
Organotypic Culture Models 
For paraffin embedded samples, the sections were de-waxed and rehydrated 
prior to staining. Slides were de-waxed using xylene twice for 5 minutes each 
time. To rehydrate the sections an alcohol gradient was used. Each wash 
was incubated at room temperature for 2 minutes as follows: 
 
2 x 100% Ethanol 
1 x 90% Ethanol 
1 x 70% Ethanol 
1 x 50% Ethanol 
1 x double distilled water 
 
Samples were then soaked in PBS (with calcium and magnesium). Antigen 
retrieval was then completed in order to break the protein cross-links, which 
are formed through formalin fixation. To do this, 0.01M tri-sodium citrate 
(dihydrate) at pH6 was brought to the boil. The slides were then immersed in 
the buffer and boiled for 10 minutes.  
 
Following antigen retrieval slides were dried quickly and sections outlined 
with a wax pen, being careful not to touch the sections. The sections were 
then permeabilised through incubation in 0.2% TritonX-100 in PBS for 5 
minutes at room temperature. Sections were washed twice in PBS and then 
quenched in a 1mg/ml sodium borohydride/PBS solution for 10 minutes. 
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Sections were then washed twice in PBS before being blocked for 30 
minutes at room temperature. A blocking solution containing 2% BSA, 0.02% 
fish skin gelatin and 10% FBS was used. Sections were then incubated 
overnight at 4oC in the dark with the appropriate primary antibody. The 
following day, sections were washed three times with PBS before being 
incubated for 1 hour at room temperature in the dark with the appropriate 
secondary antibody, followed by 10 minutes with DAPI. The sections were 
washed another three times in PBS and twice in ddH20. A small amount of 
fluorsave mounting medium was then pipetted onto a square coverslip. This 
was inverted onto the sections and gently pressed down to remove any air 
bubbles. The slides were then kept in the dark at room temperature overnight 
in order for the fluor save to set. Slides were stored at -20oC until imaged. 
Images were collected on a Carl Zeiss LSM510 META laser scanning 
confocal microscope or a Nikon Eclipse Ti-E inverted A1R Si confocal 
microscope. 
 
2.3.11 Organotypic Culture Models 
On day one, the organotypic gel matrix was prepared. First, a cell 
suspension of PS-1 cells was made to get a final concentration of 2.5x105 
cells in a volume of 100ul per gel. The gels were made up in the ratios in 
table 2.12. Prior to use, all components were filter sterilized through a 20-
micron syringe-top filter to remove any precipitate and were maintained on 




The gel was mixed thoroughly with care not to introduce any air bubbles. If 
yellow, the gel was neutralized through the addition of filter sterilized 0.1M 
sodium hydroxide (NaOH) until pink. Once mixed, 1ml was added dropwise  
to each well of a 24-well tissue culture plate, being careful not to introduce 
any air bubbles. The plate was then placed in an incubator for 1 hour at 37oC 
until the gel had polymerized. After this, 1ml of DMEM with 10% FBS was 




Collagen:MatrigelTM (1:1) 7 volumes (3.5:3.5) 
10X DMEM 1 volume 
FCS 1 volume 
Fibroblast suspension 1 volume 
 
Table 2.12: Organotypic model matrix preparation 
 
On day 2, a cell suspension was prepared containing 5x105 PaTu8988T cells 
mixed with 2.5x105 PS-1 cells per gel in 1ml DMEM containing 10% FBS. In 
order to study the effect of PAK4 knockdown on pancreatic cancer cell 
invasion, PaTu8988T cells had previously been treated with siRNA and to 
look at the effect of the PI3K inhibitor (LY294002) cells were seeded in the 
presence of the inhibitor. Once the cell suspension was prepared, the media 
was aspirated carefully from on top of each gel and 1ml of cell suspension 
then added dropwise to the centre of the gel. The gels were incubated at 
room temperature for 5 minutes to allow the cells to settle before being 
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returned to the incubator and maintained at 37oC for 48 hours. 
 
On day 3, the nylon sheets were prepared in the following manner. The 
required number of nylon sheets, which had previously been autoclaved to 
sterilize, were placed in a sterile petri dish. A collagen gel was then prepared 
(see table 2.13), with all components being maintained and mixed on ice. 
 
Component Quantity 
Collagen 7 volumes 
10X DMEM 1 volume 
FBS 1 volume 
DMEM containing 10% FBS 1 volume 
 
Table 2.13: Components of collagen gel mixture 
 
The gel was mixed carefully to prevent the introduction of air bubbles and 
neutralized with the addition of filter sterilized 0.1M NaOH until it was pink in 
colour.  Once mixed, 250μl of the collagen mix was added dropwise to the 
centre of each sheet and the petri dish was incubated at 37oC for 30 minutes 
to allow the collagen to polymerise. To crosslink the collagen, a 1% 
gluteraldehyde solution was prepared in sterile PBS. After 30 minutes, 10ml 
of the gluteraldehyde solution was added to the petri dish and then incubated 
at 4oC for one hour. The nylon sheets were then washed three times in sterile 
PBS, once in DMEM containing 10% FBS and then left in 10ml DMEM with 
10% FBS. The petri dish was sealed with parafilm and left at 4oC overnight. 
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On day 4, the organotypic gels were raised onto steel grids to create an air-
liquid interface. To do so, steel grids were placed into each well of a 6 well 
tissue culture plate. Onto each grid, a gel-coated nylon sheet was carefully 
placed. Then, using a sterile spatula, each gel was carefully removed from 
the 24 well culture plate and placed on top of the nylon sheet. The well of the 
plate was then filled until it reached the undersurface of the grid. This was 
then classed as day 1 of the organotypic invasion assay. The gels were then 
returned to the incubator and maintained at 37oC. The culture media was 
replaced every two days and the gels were harvested after 14 days of 
culture, with day one being counted as the day gels were raised onto grids. A 
diagrammatic summary of the organotypic model set up is displayed in 
figure 2.2. 
 
After 14 days, the gels were harvested by removing the whole gel and the 
nylon membrane from the grid. Gels were then carefully cut in half and 
placed in a universal tube. Gels were fixed in formal saline for 24 hours. The 
formal saline was then replaced with 70% ethanol and then maintained at 
4oC and sent for processing (paraffin embedding and sectioning) at the 
Pathology laboratory at St Thomas Hospital, London. Sectioned samples 
were then stained (as described in section 2.3.10) and analysed (as 








Figure 2.2: Organotypic model set up. A collagen:matrigelTM matrix 
was produced containing pancreatic stellate cells. The next day a 
mixture of pancreatic cancer cells and stellate cells (ratio 2:1) were 
seeded on top. 48 hours later, the matrix was raised onto a collagen-
covered nylon membrane on top of a steel grid. Culture media was 
used to create an air-liquid interface to promote invasion of cells down 
into the matrix. Culture media was replaced every two days for a total of 
fourteen days. Gels were then formalin fixed overnight, maintained in 






Figure 2.3: Organotypic model analysis. After the organotypic gels 
had been processed and sectioned, they were stained as above for 
DAPI (blue), pan-cytokeratin (green) and SMA (red). For analysis of 
invasion depth, three randomly selected points were measured using 
ImageJ. This is indicated by the white arrow. A total number of at least 
30 measurements were taken per condition over three independent 
experiments. Any obvious areas of artifactual invasion (i.e. at the edges 
of gel sections or through processing) were excluded. * Indicates PS-1 
cell stained for SMA, which was pre-mixed into the matrix before a 2:1 
ratio of cancer (PaTu8988T): stellate (PS-1) cells were seeded on top. 
Therefore total number of cells per gel is equal. 
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2.4 Methods - Biochemistry 
2.4.1 Protein Preparations 
For the purification of GST-fusion proteins, E. coli BL21-A1 cells were 
transformed with GST expression plasmids. The transformed bacteria were 
cultured in 5ml L-broth to which 100μg/ml of the antibiotic ampicillin was 
added. These cultures were incubated overnight at 37oC. The next day 2ml 
of this culture was added to 200ml of L-broth inoculated with ampicillin, 
forming a 1 in 200 dilution. These were incubated at 37oC for approximately 2 
hours until the optical density reached 0.6. In order to induce the bacterial 
cultures, 2ml of a 20% L-Arabinose solution was added before the cultures 
were incubated overnight at 20oC. The following day, the cultures were 
harvested by centrifuging at 6000 rpm for 15 minutes. The supernatant was 
discarded and the pelleted bacteria were resuspended in 15ml PBS 
containing protease inhibitor cocktail. To disrupt the cells, the bacteria were 
subjected to sonication for 3 minutes with a pulse every second and at a 70% 
amplitude. Cell debris was removed by centrifugation for 10 minutes at 4800 
rpm and the supernatant retained. During this time, GST beads were pre-
washed using the PBS plus inhibitor cocktail solution three times. Beads 
were then added to the supernatant before incubation for 2 hours at 4oC on a 
rotating wheel. Following this incubation period, the beads were pelleted by 
centrifugation at 500 x gravity for 5 minutes. Beads were washed three times 
in the PBS plus protease inhibitor cocktail solution before a freeze down 




2.4.2 GST Pulldown Assay 
HEK293 cells were used within these assays and plated at a density of 
1x105/ml into 10cm tissue culture plates and incubated overnight at 37oC. 
The next day the cells were transfected with the appropriate GFP-tagged 
construct using the calcium phosphate transfection kit (see section 2.3.2). 
After 24 hours cells were lysed using an optimized pulldown lysis buffer (see 
section 2.1.2 Buffers). GST beads, which had been pre-washed in the lysis 
buffer, were used to pre-clear the lysates. These were incubated for one hour 
at 4oC on a rotating wheel. Lysates were centrifuged at 2000 rpm for 2 
minutes and the supernatant transferred to a fresh eppendorf tube. GST 
purified protein beads, which had also been pre-washed in the lysis buffer, 
were then added to the lysates which were incubated for a further two hours 
at 4oC on a rotating wheel. Subsequently the lysates were centrifuged at 
2000rpm for 2 minutes and the unbound fractions were discarded. The beads 
were then washed three times using pulldown wash buffer and 30μl of 2x 
SDS gel sample buffer added. Samples were then boiled for 3 minutes and 
stored at -20oC until used in immunoblotting.  
 
For each experiment a GST alone expression plasmid was used as a control 
and approximately equal amounts of GST alone and GST fusion proteins 
were used in each assay. For plasmids see table 2.2. 
 
2.4.3 Western Blotting 
Isolation of Protein 
When cells were approximately 70% confluent, they were washed twice in 
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PBS and lysed for 10 minutes on ice in 0.5% NP-40 lysis buffer 
supplemented with 1mM DTT, 1μg/ml aprotinin, 10μg/ml leupeptin, 1mM 
PMSF, 50mM sodium fluoride and 1mM sodium orthovanadate. Cells were 
scraped and transferred to eppendorf tubes. Cell debris was collected by 
centrifuging the lysates at 13,000 x g for 10 minutes at 4oC. The supernatant 
was then collected and transferred to a fresh eppendorf and samples 
prepared through the addition of a 6 X Laemmli buffer (diluted to 1 X) before 
samples were boiled for 3 minutes. Whole cell lysate samples were then 
subsequently stored at -20oC until use. 
 
Gel electrophoresis and immunoblotting 
Lysates were boiled for 3 minutes prior to use. An equal amount of 
denatured, cellular proteins were then separated on 7.5-12.5% sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels. 
Proteins were then electroblotted onto nitrocellulose membrane at 70-100 
volts for 1-2 hours (dependent on the percentage gels used). Non-specific 
binding was blocked through incubation of the membrane in 5% skimmed 
milk in 0.1% TBS-Tween20 or 5% BSA in 0.1% TBS-Tween20, followed by 
overnight incubation in the primary antibody at 4oC (see table 2.4). 
Membranes were then washed three times, for 10 minutes, in 0.1% TBS-
Tween20 prior to incubation with the appropriate horseradish peroxidase-
conjugated secondary antibody (see table 2.5) for one hour at room 
temperature. Membranes were then washed a further three times, for 10 
minutes, in 0.1% TBS-Tween20. Specific protein bands were then visualised 
using an ECL chemiluminescence detection kit. 
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Stripping of Nitrocellulose Membranes 
If membranes were to be reprobed, they were incubated in stripping buffer 
twice for 15 minutes each (at room temperature for mild stripping or at 50oC if 
a harsh stripping buffer was used) with constant agitation. Membranes were 
then washed twice for 10 minutes in PBS and twice for 10 minutes in TBS-





2.5 Data & Statistical Analysis 
2.5.1 Organotypic model 
For organotypic cultures, three gels from three independent experiments 
were analysed and several randomly selected areas imaged by an 
independent observer. The invasion depth was measured at three points in 
each sample using ImageJ. The areas of invading cells were calculated after 
exclusion of non-uniform invasion at the edges of the gel. Any areas where 
obvious artifactual invasion had occurred in identifiable areas (that could be 
due to processing) were also omitted.  
 
2.5.2 Densitometry 
For western blotting, densitometric analysis of specific bands was performed 
using ImageJ software. In order to obtain a semi-quantitative measurement 
of the level of total protein, all band densities were normalised to a loading 
control. In all circumstances, GAPDH was used as a loading control and was 
detected on the same membrane as the protein of interest. 
 
2.5.3 Statistics 
Where appropriate, results were subjected to statistical analysis using 
unpaired student t-tests. Values were considered statistically significant if the 












Results: Part 1 




Chapter 3: Characterisation of pancreatic cell lines 
 
3.1 Introduction 
This project aimed to understand the role of PAK4 in pancreatic cancer, so it 
was first necessary to characterise a range of cell lines. Five cell lines were 
chosen for initial investigation. This included two epithelial cell lines; HPDE 
cells which are a human papillomavirus (HPV)-16 E6E7 immortalised cell line 
which were derived from normal adult pancreatic tissue (Furukawa et al., 
1996) and dechTERT cells, which were primary cells collected and hTERT 
immortalised previously (Li et al., 2009), but have not been widely used. 
Three cancer cell lines were also selected; Capan1, a well differentiated, 
colony forming cell line which was sourced from a liver metastasis, with 
mutations is KRAS, TP53, INK4A, SMAD4 and BRCA2 (Deer et al., 2010; 
Sipos et al., 2003). Another colony forming cell line, PaTu8988S, isolated 
from a liver metastasis of a primary pancreatic adenocarcinoma together with 
PaTu8988T, which is a poorly differentiated, highly invasive cell line. These 
sister cell lines carry mutations in KRAS and TP53 with methylation of the 5’ 
CpG island of INK4A (Dammann et al., 2003; Elsasser et al., 1992). 
 
It has been well established that the PI3K pathway is upregulated in 
pancreatic cancer (Eser et al., 2013) and contributes to disease development 
and progression. It is also known that this pathway can be stimulated either 
through c-Met downstream of HGF or through Ras (Ebi et al., 2011). c-Met is 
known to have increased expression within pancreatic cancer (Herreros-
Villanueva et al., 2012; Li et al., 2011a) and mutations in K-ras are found in 
more than 90% of pancreatic cancers (Collins et al., 2012). It was therefore 
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considered important to determine the differential expression profile for these 
and associated proteins within the cell lines being selected for 
characterisation. 
 
Links between PAK4 and pancreatic cancer have also been demonstrated 
through some previous genomic studies (Chen et al., 2008; Kimmelman et 
al., 2008). The PAK proteins are a family of serine/threonine kinases, of 
which there are six isoforms; these are divided into two groups, based on 
structural similarities and sequence homology. Group I is made up of PAKs 
1, 2 and 3 and group II contains PAKs 4, 5 and 6 (Bokoch, 2003; Jaffer and 
Chernoff, 2002). It is well documented that PAKs act as effectors for a wide 
range of signalling pathways and contribute to changes in cellular motility, 
morphogenic processes and cell polarity (Arias-Romero and Chernoff, 2008; 
Bagrodia and Cerione, 1999; Hofmann et al., 2004; Sells and Chernoff, 
1997). As PAK proteins are involved in the regulation of many cellular 
processes, this infers that abnormalities in PAK functioning are likely to 
contribute to a number of disease states including cancer (Dummler et al., 
2009; Kumar et al., 2006; Kumar and Vadlamudi, 2002). However, the 
complete expression profile of the PAK family kinases has not been well 
characterised within pancreatic cancer. Therefore, alongside the other 
proteins, the panel of cell lines was probed for PAK1-6 expression. 
 
This first chapter shows the results from immunofluorescence and western 
blotting studies on a range of pancreatic cell lines. The results gathered 
throughout these initial characterisation studies were used to justify which 
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3.2.1 E-cadherin expression 
Upon first culturing the cells, it was noted that although the HPDE cells were 
selected as they are representative of an epithelial phenotype, they appeared 
to lack the defined characteristics of epithelial cells. They remained as single 
cells, with no monolayer formation being observed and no evidence of 
cell:cell junctions. Thus it was decided to define the epithelial versus 
mesenchymal phenotype of the selected cell lines by testing E-cadherin 
localisation and expression. 
 
To assess the epithelial characteristics of the selected cell lines, all of the 
cells were seeded onto coverslips and stained for E-cadherin. E-cadherin is a 
key component of intercellular junctions, with continued expression and 
functional activity a key requirement in the maintenance of stable junctions 
between cells (Gumbiner, 1996; Li and Mattingly, 2008). It was evident that 
Capan1 (figure 3.1C) and PaTu8988S (figure 3.1D) cells expressed E-
cadherin, with the expression being concentrated at junctions between the 
cells. Although HPDE cells (figure 3.1A) expressed E-cadherin, there was 
no evidence of colony or monolayer formation evident, nor any junctional 
staining. E-cadherin mediated cell-cell adhesions are dependent on 
extracellular calcium (Gumbiner, 1996). This extracellular calcium serves to 
rigidify the extracellular domains of E-cadherin and enables homophilic 
interactions (Kim et al., 2011a; Nagar et al., 1996). Thus, HPDE were seeded 
in the presence of calcium nitrate (1g/L) as the addition of calcium to the 










Figure 3.1:  E-cadherin expression in pancreatic cell lines. HPDE 
(A), dechTERT (B), Capan1 (C) and PaTu8988S (D) cell lines were 
subjected to immunoflourescent staining to observe the expression of 
E-cadherin (green), in combination with DAPI (blue) and actin (red). 
Both Capan1 and PaTu8988S cells express E-cadherin, which appears 
concentrated at the junctions forming between cells within colonies. 
DechTERT cells appear to express no E-cadherin despite this being a 
characteristic of epithelial cells. HPDE cells express E-cadherin, 
although do not form cell-cell contacts. Scale bar = 10μm. 
 
 134 
and induce the formation of cell-cell interactions (Martin et al., 1991). 
 
The HPDE cells responded well to the calcium nitrate treatment and 
displayed a more typical epithelial appearance; E-cadherin was observed at 
the junctions now formed between cells, as highlighted by the white arrow 
(figure 3.2). Unlike HPDE cells, the dechTERT cell line appeared to lack E-
cadherin almost entirely (figure 3.1B). To compliment these 
immunofluorescence studies, western blotting was carried out to examine the 
expression of E-cadherin across the cell lines (figure 3.3A). Whole cell 
lysates from HPDE cells +/- calcium nitrate were produced, but little 
difference in protein expression was observed. It is known that the interaction 
between the cytoplasmic tail of E-cadherin with β-catenin is crucial for 
junctional stability, providing links to the actin cytoskeleton and further 
enhancing junction formation and strength (Conacci-Sorrell et al., 2002; Tian 
et al., 2011a). So, in conjunction with E-cadherin, β-catenin was also probed 
for (figure 3.3A) and the relative density quantified (figure 3.3B).   
 
E-cadherin was expressed only in the two colony forming cancer cell lines 
and the HPDE cells. It was also confirmed that the dechTERT cells 
expressed no E-cadherin, yet had high levels of β-catenin expression. It has 
already been shown that PaTu8988S and PaTu8988T cells have differential 
β-catenin expression (Marques et al., 2009), with PaTu8988S cells having 
observably higher levels. Marques et al also demonstrated that the lack of E-
cadherin expression in the PaTu8988T cells lead to accumulation of β-  
 135 
  
Figure 3.2: Calcium nitrate induces the formation of cell-cell 
contacts in HPDE cells. In order to make HPDE cells for epithelial in 
appearance and behavior, cells were seeded in the presence of calcium 
nitrate (1g/L). This forced cells to form points of contact. These cells 
were stained for E-cadherin (green), DAPI (blue) and actin (red) and it 
could be observed that in comparison to cells seeded without calcium 
that now E-cadherin was concentrated at junctions formed between 




Figure 3.3: Expression of E-cadherin and β-catenin in pancreatic cell 
lines. (A) The expression of E-cadherin was confirmed by western blotting. 
In conjunction with this, the expression of β-catenin was also detected. (B) 
Relative expression was quantified via densitometry where the relative 
density/expression was first normalised to the loading control (GAPDH). 
Blots shown are representative of 3 independent experiments each of 
which was then subjected to densitometry (as described above) for 
quantificational purposes and shown in graphical form (B). 
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catenin in the cytoplasm, whereas PaTu8988S cells had colocalisation of β-  
catenin and E-cadherin at complexes located at the plasma membrane which  
is linked to the invasive potential of the cell lines. The studies carried out as 
part of this characterisation are therefore in line with this previous work 
(Marques et al., 2009). 
 
3.2.2 Further characterisation of the cell line dechTERT 
The dechTERT cell line was immortalised and characterised previously (Li et 
al., 2009). However, during the preliminary characterisation of all pancreatic 
cell lines, it was found that they lacked the classic epithelial marker E-
cadherin (figure 3.3). Further characterisation was therefore carried out 
through immunofluorescent studies to further interrogate the nature of this 
cell line. The dechTERT cells were stained for a range of proteins including 
classical epithelial and tight junction proteins and markers of EMT (figure 
3.4). The expression level of β-catenin had already been demonstrated 
(figure 3.3A) and so the dechTERT cells were stained for the presence and 
localisation. It was noted, that there was an accumulation of β-catenin in the 
perinuclear region. The levels of cytoplasmic β-catenin are usually tightly 
controlled (Olmeda et al., 2003); E-cadherin usually recruits β-catenin to the 
plasma membrane, leading to sequestration and preventing its translocation 
(Orsulic et al., 1999) and so, with the lack of E-cadherin observed an 
accumulation of β-catenin within the cytoplasm is expected.  
 
A loss of E-cadherin is considered to be one of the main molecular events 




Figure 3.4: Protein expression in the duct epithelial cell line, 
dechTERT. To further characterise the dechTERT cell line, cells were 
stained for a variety of proteins including β-catenin, N-cadherin, CK8, 
CK18, vinculin, claudin-1, occluding and ZO-1 (green). Cells were co-
stained with DAPI (blue) and actin (red). High levels of perinuclear β-
catenin were observed as well as high global expression of CK18, 
vinculin and N-cadherin. Very little CK8, claudin-1 and occludin were 
observed. ZO-1 was observed in strands forming between cells. Scale 
bar = 10μm. 
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with epithelial to mesenchymal transition (EMT), which can be considered a 
hallmark of cancer invasion (Onder et al., 2008; Pecina-Slaus, 2003). In 
conjunction with a loss of E-cadherin, there is often a marked increase in the 
expression of N-cadherin observed; this event is known as cadherin-
switching (Hazan et al., 2004; Maeda et al., 2005; Wheelock et al., 2008). As 
no E-cadherin was detected, the expression of N-cadherin was investigated. 
Cytoplasmic N-cadherin was observed in the dechTERT cells which implies a 
less epithelial-like cell.  
 
It is known that pancreatic duct epithelial cells express cytokeratins (CK) 7, 8, 
18 and 19 (Real et al., 1993; Santini et al., 1994) and so the dechTERT cells 
were also stained for the presence of CK8 and CK18. It was observed that 
they had only very low levels of CK8, but it appeared they had relatively high 
expression of CK18. The role of vinculin in cell-matrix adhesions is well 
documented (Zamir and Geiger, 2001; Zamir et al., 2000), but it is also 
known to impact on cell-cell adhesion (Bays et al., 2014; Peng et al., 2010). It 
was found that the dechTERT cells had global expression of vinculin, but 
also localised to adhesion like structures, as observed through the 
immunofluorescence studies. Some other intercellular adhesion proteins, 
which are important components of tight junctions, are claudins, occludins 
and zonula occludens (ZO) proteins (Schneeberger and Lynch, 2004; Tsukita 
et al., 2001). It has also been shown at either the protein or mRNA level that 
HPDE cells express several of these tight junction molecules including 
claudin-1, occludin and ZO-1 (Kojima and Sawada, 2012), so dechTERT 
cells were stained for these to further investigate their expression profile. It 
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appeared that there was no occludin present and only very low observed 
levels of expression of claudin-1. However, ZO-1 could be seen localised at 
finger-like projections, which appeared to form between cells. 
 
3.2.3 Morphology of pancreatic cell lines 
To further characterise the cell morphology of each of the selected cell lines, 
where cells were seeded onto coverslips and subsequently stained for 
paxillin, actin and DAPI (figure 3.5A, B, C and D). HPDE cells were 
maintained in calcium, as before. Each cell lines was seeded onto uncoated, 
fibronectin and collagen (cancer cells only) coated coverslips in order to 
determine if this lead to any substantial morphological changes. Cells shape 
was analysed using ImageJ and the area of the cells was measured from 
three independent experiments. Analysis revealed that there was no 
significant difference between the measured parameters (figure 3.5F).  
 
3.2.4 Characterisation of protein expression in pancreatic cell lines 
In addition to immunofluorescent staining, the panel of pancreatic cell lines 
were analysed for differential protein expression. Whole cell lysates from 
HPDE cells were made from cells that were seeded both with and without 
calcium nitrate in order to determine if this impacted on protein expression. 
 
Under normal cellular conditions, p53 performs crucial tumour suppressor 
functions, through the induction of cell cycle arrest of apoptosis in response 
to various cellular stresses (Brady and Attardi, 2010; Vousden and Prives, 












Figure 3.5:Morphology of pancreatic cell lines. All cell lines being 
used were subjected to immunofluorescent staining in order to 
characterise cellular morphology on different substrates. HPDE (A), 
dechTERT (B), Capan1 (C), PaTu8988S (D) and PaTu8988T (E) cells 
were seeded onto glass (shown), collagen and fibronectin (both data 
not shown). They were stained with DAPI (blue), paxillin (green) and 
actin (red) and the area calculated using ImageJ, which was 
subsequently quantified (F). Results demonstrated that there was no 
significant different in overall cell area between any of the substrates 
used. Images and data were gathered from three independent 
experiments. Scale bar = 10μm. 
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commonly within the p53 gene, many of which result in the expression of a 
stable mutant protein. This subsequent accumulation within the cell is 
considered a hallmark of cancer (Muller and Vousden, 2013; Rivlin et al., 
2011). It has also shown that there is a strong association between p53 
expression and a transformed status (Moro et al., 1995) and so the status of 
p53 expression in the panel of pancreatic cell lines was investigated through 
western blotting (figure 3.6A). It was observed that there was a marked 
increased in p53 expression in the cancer cell lines in comparison to the 
epithelial cell lines, in line with the existing literature. Blots were subsequently 
quantified using ImageJ (figure 3.6B). 
 
c-Met is known to have increased expression in pancreatic cancer (Herreros-
Villanueva et al., 2012; Kiehne et al., 1997; Li et al., 2011a) and can lead to 
upregulation of the PI3K pathway. PI3K is made up of two main subunits, 
P110 and p85. It is known that the P110 subunit is overexpressed in human 
pancreatic cancer tissues and cell lines (Edling et al., 2010). However, within 
this study, the p85 subunit is of particular interest and therefore the 
expression of this protein and c-Met was investigated (figure 3.7A). The 
levels of both c-Met and p85 were increased in the cancer cell lines, in 
comparison to both HPDE and dechTERT epithelial cells. These blots were 
quantified through densitometry using ImageJ (figure 3.7B). 
 
Like c-Met, K-ras is known to be a key component in the development and 
progression of pancreatic cancer (Collins et al., 2012). There are four Ras  
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Figure 3.6: Expression of p53 in pancreatic cell lines. Western 
blotting was used to investigate the status of p53 expression in the 
panel of pancreatic cell lines (A). Both HPDE and dechTERT cells 
expressed virtually no p53 while the expression was greatly increased 
in the cancer cell lines. The blot shown is representative of three 
independent experiments, which were then subject to semi-quantitative 
analysis and densitometry (B), whereby each blot was quantified after 
normalising to the loading control (GAPDH). All three experimental 




Figure 3.7: Expression of c-Met and p85α in pancreatic cell lines. 
Knowing the expression of c-Met in increased in pancreatic cancer, the 
relative expression of both c-Met and p85α (a subunit of PI3K, which 
lies downstream of c-Met) was investigated in order to determine the 
differential expression between normal pancreatic epithelia and 
pancreatic cancer cell lines. Western blotting (A) demonstrated an 
increase in the expression of both of these proteins in the cancer cells 
in comparison to both duct epithelial cell lines, which was confirmed 
through densitometry after normalising relative expression to the 
loading control (GAPDH) (B). Blots are representative of three 
independent experiments and the densitometry from each experimental 
repeat is depicted graphically (B). 
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isoforms (H-ras, N-ras, K-ras4A and K-ras4B), which have a highly 
conserved structure (figure 3.8A), with a C-terminal hypervariable region 
changing between the isoforms (Castellano and Santos, 2011). In order to 
ensure that the cell lysates were specifically blotted for K-ras expression, 
isoform specific antibodies were purchased and tested to check for 
specificity. Whole cell lysates from HEK293 cells, transfected with either myc 
tagged K-, H-, or N-ras, were generated and run in duplicate. Blots were then 
either probed with an anti-myc antibody, or the reported K-ras specific 
isoform antibody. The blots revealed that the antibody specifically recognized 
K-ras and there was no evidence cross-reaction (figure 3.8B). This antibody 
was subsequently used to detect the level of K-ras expression in the panel of 
pancreatic cell lines. Western blotting revealed a large increase in K-ras 
expression with increasing invasive potential (figure 3.8C), with the highest 
level being observed in the highly invasive PaTu8988T cell line. This pattern 
of expression was confirmed by densitometry (figure 3.8D) using ImageJ. 
 
3.2.5 Characterisation of PAK family kinase expression 
Having determined the expression profile of several proteins in the panel of 
pancreatic cell lines, the expression of both group I (1-3), and group II (4-6) 
PAKs was investigated. Although within this study, the main focus is on 
PAK4, all PAK expression was initially looked at.  
 
The group I PAK expression was first investigated (figure 3.9A). There was 
a marked increase in all three group I PAKs in Capan1, PaTu8988S and 
PaTu8988T cells in comparison to both the HPDE and dechTERT cells, with  
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Figure 3.8: K-ras expression in pancreatic cell lines. Within the structure 
of Ras proteins (A), there are several highly conserved regions, including 
those for binding GTP/GDP and downstream effector proteins. There is a 
hypervariable region present on all four Ras isoforms, which contains a 
CAAX motif that is responsible for directing post-translational modifications 
such as farnesylation and palmitolation. (Figure adapted from: Castellano & 
Santos, 2011). Isoform specific antibodies were validated (B) by transfecting 
in myc-tagged Ras isoforms (K-, H- and N-ras) and probed for Myc and K-
ras separately. Western blotting confirmed antibody specificity. This antibody 
was then used to probe the panel of pancreatic cell lines (C) and showed 
increased expression in the cancer cell lines in comparison to the epithelial 
cell lines, which was confirmed by densitometry (D) after normalising relative 





Figure 3.9: Expression of Group I PAKs in pancreatic cell lines. 
Western blotting was used to investigate the expression pattern on 
group I PAKs in the pancreatic cell lines (A). Each isoform had 
increased expression in the cancer cell lines, in comparison to the 
epithelial cell lines. The lowest expression was observed with PAK2. 
The blot shown is representative of three independent experiments, 
which were quantified through densitometry (B). Each experimental 
repeat was individually quantified and represented in graphical form 
after normalising to the loading control (GAPDH). 
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PAK2 appearing to having a relatively low level of expression. Group I PAK 
expression was also quantified through densitometry using ImageJ (figure 
3.9B). The pattern of expression of group II PAKs was markedly different 
(figure 3.10A). While both PAK4 and PAK6 had increased expression in the 
cancer cell lines, PAK5 was expressed in the HPDE cells and both the 
colony forming cancer cell lines. From work in our lab, it has been suggested 
that PAK5 is present in colony forming cell lines and then expression is lost 
as cells become more invasive (unpublished data). The work carried out here 
compliments these previous studies as PAK5 was present in HPDE, Capan1 
and PaTu8988S cells but PaTu8988T cells had no detectable PAK5 
expression. PAK6 has been linked to prostate cancer invasiveness (Wen et 
al., 2009) and an increase in PAK6 expression leads to cell-cell dissociation 
in response to HGF (Fram et al., 2014). Results showed that there was 
increased expression of PAK6 with invasive potential, which compliments 
these previous studies. With regards to PAK4, it is known that it is oncogenic 
when overexpressed (Ahn et al., 2011; Liu et al., 2008a; Qu et al., 2001; 
Wong et al., 2013; Zhang et al., 2011a) and plays a significant role in 
oncogenesis. Therefore, it is not surprising to observe that there is a large 
increase in PAK4 expression in the cancer cell lines in comparison to the 
HPDE and dechTERT cells. The expression of group II PAKs was quantified 




Figure 3.10: Expression of Group II PAKs in pancreatic cell lines. 
Western blotting was used to investigate the expression of group II 
PAKs in the pancreatic cell lines (A). It was noted that PAK5 was 
expressed in both colony forming cancer cell lines (PaTu8988S and 
Capan1) and in the HPDE cell line. PAK6 appeared to have higher 
expression in the invasive PaTu8988T cells in comparison to the 
PaTu8988S cell lines. PAK4 appeared to have the highest level of 
expression in all the cancer cell lines, in comparison to both epithelial 
cell lines. Blots shown are representative of three independent 
experiments, which were quantified through densitometry (B). Each 
experimental repeat was individually quantified and represented in 




In this chapter, a panel of pancreatic cell lines were characterised for cell 
morphology and protein expression patterns in order to determine the most 
appropriate cell lines to use going forward within the investigation.  
 
Of the five cell lines used, there were two epithelial cell lines included within 
these initial studies, HPDE and dechTERT cells. It became apparent that 
these epithelial cell lines did not display typical epithelial cell characteristics 
including the formation of cell-cell junctions and/or the expression of 
epithelial markers. As such, a more thorough investigation was carried out to 
provide a more complete data set and understanding of these cells. Upon 
staining the HPDE cells with E-cadherin, it was shown that no junctional 
formation between cells was present. It was demonstrated though, that the 
addition of calcium nitrate induced the formation of cell contacts, with cells 
beginning to form monolayers. It was also shown that the addition of calcium 
nitrate to cells in culture had little impact on protein expression. The 
dechTERT cells, however, were much more complex. They are a duct 
epithelial derived cell line, which was initially characterised when they were 
first immortalised (Li et al., 2009). The initial studies here showed that they 
had a fairly complex expression profile. These cells expressed no E-cadherin 
and immunofluorescence studies demonstrated that N-cadherin was present. 
This pattern of cadherin expression is characteristic of cells that have 
undergone cadherin switching during EMT (Hazan et al., 2004; Maeda et al., 
2005). Also in line with this data, was the high level of β-catenin expression, 
which was concentrated in the perinuclear region, as is expected of cells not 
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expressing E-cadherin, which retains β-catenin within the region of the 
plasma membrane (Orsulic et al., 1999). It is within this cellular region that it 
aids in the formation of intercellular junctional stability, forming part of the link 
between E-cadherin and the actin cytoskeleton (Desai et al., 2013; Valbuena 
et al., 2012). Once in the cytoplasm, it is known that β-catenin can 
translocate into the nucleus and subsequently partake in Wnt signaling, 
which is involved in cancer progression and cytoplasmic accumulation is 
frequently observed in squamous cell carcinoma (Iwai et al., 2010). It is also 
known that disregulation of the β-catenin pathway can be correlated with 
EMT and invasiveness (Prasad et al., 2008; Schmalhofer et al., 2009). These 
E-cadherin and β-catenin studies therefore indicated that the dechTERT cells 
may not be completely representative of normal panctreatic duct epithelia. 
 
Within the characterisation of the dechTERT cells, they were also shown to 
have expression of some junctional proteins, such as ZO-1 but lacked 
expression of others including claudin-1, both of which were found in another 
hTERT immortalised duct epithelial cell line in previous studies (Kojima and 
Sawada, 2012). They also had high expression of CK18 but not CK8, 
however, both of these cytokeratins can be found in both cancer and duct 
epithelial cells (Real et al., 1993; Santini et al., 1994) and thus may not be 
the optimal epithelial markers to have used within this study. Taken 
altogether, these results suggest a protein expression profile that was not 
necessarily indicative of epithelial cells. However, it has been shown that 
pancreatic ductal cells can dedifferentiate and act as pancreatic progenitors 
and this dedifferentiation can be associated with EMT, with cells co-
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expressing epithelial (cytokeratin7 and cytokeratin19) and mesenchymal 
(vimentin and α-smooth muscle actin) markers (Fanjul et al., 2010). 
Therefore, it could be of interest to investigate the expression of these 
markers in the dechTERT cells, also to include markers of progenitor 
pancreatic cells, such as pancreatic duodenal homeobox factor-1 (Fanjul et 
al., 2010). 
 
Another objective of these preliminary studies was to determine if substrate 
variation lead to any pronounced changes in the cellular morphology. The 
extracellular matrix is a complex structure and formulated from a dynamic 
range of proteins and growth factors (Kim et al., 2011b; Taipale and Keski-
Oja, 1997). This can lead to changes in cellular behavior and/or morphology, 
which is dependent on receptor expression that can vary between cell lines 
(Kiss et al., 2013; Legate et al., 2009). It was therefore decided to test a 
range of matrix substrates and look at cellular morphology on each. Cell area 
was measured after seeing on uncoated and fibronectin or collagen coated 
coverslips. It was found that there was no significant difference in 
morphology or area. From this, it was subsequently decided to perform future 
immunofluorescence/migration assays on a collagen I matrix, as collagen I is 
a prominent component in the extracellular matrix and heavily involved in the 
desmoplastic/fibrotic reaction associated with PDAC (Shields et al., 2011) 
and was also one of the main constituents of the organotypic model which is 
planned for later functional studies. 
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Having established the epithelial relevance of the HPDE +/- calcium and 
dechTERT cells, these cells were subsequently tested against several 
pancreatic cancer cell lines for differential expression of project interest 
proteins. This was to observe how the expression varied between epithelial, 
non-invasive and invasive cancer cell lines. Firstly, HPDE cells were studied 
both with and without the addition of calcium nitrate in order to determine if 
the addition lead to any changes in protein expression. However, there were 
no significant changes in any of the proteins investigated throughout the 
course of these initial studies. Of all the proteins under examination there 
was increased expression in the cancer cells in comparison to the epithelial 
cells lines. Many of these proteins are known to be important players in 
pancreatic cancer, including c-Met and K-ras and so it is expected that these 
would have a higher level of expression in these cancer cell lines.  
 
With regards to PAK expression, there has been much research into how 
they contribute to disease progression and cancer (King et al., 2014). 
However, there is little reported research on the impact of PAK expression 
specifically in pancreatic cancer. Although more recently one study, 
published during this project, did implicate PAK1 as having a role in 
pancreatic tumorigenesis (Jagadeeshan et al., 2014) and tentative links 
between the role of PAK4 in PDAC progression have been made (Chen et 
al., 2008; Kimmelman et al., 2008). 
 
With regards to group I PAKs, it was noted that not only PAK1, but also 
PAK3 appeared to have increased expression. This is perhaps unexpected 
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as PAK3 is primarily expressed in neuronal tissues, playing a crucial role in 
the development of normal brain functioning (Huang et al., 2011) and loss of 
function mutations being linked to mental retardation and/or learning 
difficulties (Dubos et al., 2012; Kreis et al., 2007). However, it has been 
shown that PAK3 is present in thyroid cancer tissue samples and cell lines 
(McCarty et al., 2010). PAK2 appeared to have low expression across the 
panel of cell lines tested, however, there was still an increase in the 
expression of PAK2 in the three cancer cell lines in comparison to the HPDE 
cells. A recent study demonstrated that ovarian cancer cells had increased 
migrational capacity on a collagen I matrix, which was mediated (at least in 
part) by PAK2 (Flate and Stalvey, 2014). As collagen I is known to be one of 
the main constituents of the ECM, which plays a significant role in pancreatic 
cancer (Shields et al., 2011), it would be of interest to investigate whether 
PAK2 has a similar role in pancreatic cancer. 
 
Of the group II PAKs, PAK4 had a notable increase in expression between 
the epithelial and cancer cell lines. It is known that PAK4 plays a major role 
in oncogenesis, being implicated in a number of cancers including breast 
(Callow et al., 2002; Liu et al., 2010b; Liu et al., 2008a; Minden, 2012), 
prostate (Ahmed et al., 2008; Park et al., 2013; Whale et al., 2013), colon 
(Tabusa et al., 2013), ovarian (Davis et al., 2013; Siu et al., 2010a), as well 
as pancreatic (Chen et al., 2008; Kimmelman et al., 2008; Mahlamaki et al., 
2004). It was also demonstrated that PAK5 had expression within the colony 
forming cell lines, but not in the highly invasive PaTu8988T cells. Previous 
work in our lab (currently unpublished) suggests PAK5 displays increased 
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expression in colony forming cells of the bladder and breast as well as the 
pancreas. This leads to the prediction that loss of PAK5 could therefore lead 
to increased invasion of cancer cells, the opposite effect of both PAK4 and 
PAK6. Indeed, western blotting within this study showed that there was an 
increase in PAK6 expression in the PaTu8988T cell line, in comparison to the 
matched, colony forming cells PaTu8988S. This compliments previous work 
from our lab using the prostate cancer cell line DU145, which demonstrated a 
link between PAK6 expression and cancer cell invasiveness, with 
overexpression of PAK6 leading to colony dissemination (Fram et al., 2014). 
 
It was found during these preliminary studies that both PaTu8988T and 
PaTu8988S had the highest level of PAK4 expression across all cell lines 
tested. This lead to the decision to continue using this matched pair 
throughout the course of this investigation. This would allow comparison 
between a non-invasive and invasive phenotype within pancreatic cancer. It 
was decided against using either epithelial cell line as an additional control 
due to the lack of typical epithelial behaviour and protein expression.  
 
In summary, it was confirmed that there was increased expression of key 
components of pancreatic tumorigenesis and high PAK4 expression levels in 
pancreatic cancer. These data support further investigation of the role PAK4 
may play within the development and progression of this disease.  
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3.4 Future Work 
Studies of disease progression are greatly enhanced by the presence of a 
normal/control cell line. Therefore, in the future, if the dechTERT cells were 
to be considered for this use it would be beneficial to further characterise this 
cell line. Due to time constraints, the protein expression profile performed as 
part of the preliminary work is still incomplete. It would be advisable to 
perform further western blotting and immunofluorescence (or an array to 
allow for a larger screen) for additional epithelial/mesenchymal markers to 
build a more complete picture as to the exact nature of these cells. As they 
also do not exhibit the typical epithelial morphology, it may be advised to 
perform some putative random migration assays. 
 
In this chapter, it was also shown that the expression of PAKs 1, 2, 3 and 6, 
as well as 4 were increased in cancer cell lines, in comparison to HPDE and 
dechTERT cells. It could therefore be considered interesting, particularly 
regarding PAK6 where there was increased expression in the invasive cell 
line, in comparison to the non invasive sister cell line or PAK2 which has 
been shown to influence collagen I mediated cell migration, to follow up as to 
whether they play a role in pancreatic cancer in addition to the work done on 
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Chapter 4: Characterisation of PAK4 depletion in pancreatic 
cancer cell lines 
 
4.1 Introduction 
The c-Met proto-oncogene codes for the c-Met protein, which is a receptor 
tyrosine kinase. It is a cell surface receptor, and can be found expressed in a 
range of epithelial cells including those of the prostate, liver and pancreas 
both during development and throughout adulthood (Organ and Tsao, 2011). 
Post-translational, proteolytic processing produces a single-pass, disulphide-
linked α/β heterodimer (Comoglio et al., 2008; Organ and Tsao, 2011). This 
is the receptor for HGF, which is also known as scatter factor (Naldini et al., 
1991; Weidner et al., 1991). Upon binding to c-Met, HGF acts as a pleiotropic 
factor and cytokine leading to promotion of proliferation, cell survival, motility, 
differentiation, morphogenesis and scattering (Boros and Miller, 1995; 
Brinkmann et al., 1995; Zhu et al., 1994). HGF/c-Met signalling is known to 
play an important role in embryogenesis and wound repair through induction 
of cell scattering involving the dissolution of cadherin-based cell junctions 
and increased cellular motility (Chmielowiec et al., 2007).  
 
Upon binding, HGF induces c-Met receptor dimerisation and a 
phosphorylation cascade, leading to the induction of downstream signalling 
(Blumenschein et al., 2012). There are two main arms of HGF/c-Met 
signalling, which are the MAPK and PI3K pathways. The PI3K pathway can 
be activated downstream of Ras activity or can be stimulated either directly 
or indirectly (via Gab1) through the p85 subunit of PI3K binding the c-Met 
receptor (Organ and Tsao, 2011). Activation of the c-Met signalling 
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pathways, leads to the phosphorylation of downstream signalling proteins 
including ERK and Akt (Tanahashi et al., 2013). 
 
It has been demonstrated that PAK1 is overexpressed in pancreatic cancer 
tumour samples and that it plays a key role in PDAC signalling, acting 
downstream of HGF and c-Met to drive cancer cell motility (Zhou et al., 
2014). It is also known that ras activates PAK1 via PI3K-dependent pathways 
(Dummler et al., 2009) and that a reduction in PAK1 expression leads to 
decreased ERK and Akt activity in colon cancer (Huynh et al., 2010). Also 
within colon cancer, it was shown that siRNA induced depletion of PAK4 lead 
to a reduction in Akt phosphorylation (Tabusa et al., 2013), although the 
authors stated that results were not consistent across a range of RNAi 
oligonucleotides tested. Another study provided further evidence supporting 
the hypothesis that PAK4 may lie within the PI3K pathway downstream of 
ras, which demonstrated that in NIH3T3 PAK4 knockout cells there was a 
reduction in Akt phosphorylation at Ser473. This phenotype was rescued 
through the introduction of K-ras V12 (Gnad et al., 2013). 
 
We, and others, have found PAK4 to be overexpressed in pancreatic cancer 
cell lines (Kimmelman et al., 2008). It is also known to contribute heavily to 
oncogenesis, particularly in cancer cell motility and through modulation of the 
actin cytoskeleton, it promotes migration and invasiveness (Whale et al., 
2013). It has been shown that constitutively active PAK4 leads to increased 
invasiveness of pancreatic ductal cells, with siRNA mediated depletion of 
PAK4 within PaTu8988T cells resulting in a reduction of anchorage 
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independent growth (Kimmelman et al., 2008). It has also previously been 
shown that PAK4 interacts with LIMK, enhancing its ability to phosphorylate 
cofilin, inhibiting its actin disassembly function (Dan et al., 2001). This 
interaction is known to be downstream of c-Met in prostate cancer in a HGF-
dependent manner (Wells et al., 2002), with PAK4 depleted prostate cancer 
cells being less responsive to HGF (Wells et al., 2010; Whale et al., 2013). 
 
Although typically the PI3K/Akt pathways has been considered primarily to 
be responsible for survival signalling, there is accumulating evidence to 
suggest that PI3K/Akt signalling contributes to cellular motility, including in 
metastatic cancer cells (Xue and Hemmings, 2013). Although there have 
been more recent publications linking PAK4 with PI3K and K-ras, the nature 
of this relationship within pancreatic cancer has yet to be fully elucidated. 
Therefore, knowing that PAK4 activity is at least in part reliant on c-Met and 
PI3K activity and that both are upregulated in pancreatic cancer, the nature 
of this relationship was further interrogated within this chapter. The chapter 
discusses the impact on HGF on PaTu8988S/T signalling and migration and 
looked to investigate further the effect of PAK4 knockdown on pancreatic 
cancer cell motility, as well as looking at downstream effectors of PAK4 
signalling in pancreatic cancer cells.  
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4.2 Results 
4.2.1 HGF leads to increased AKT and ERK phosphorylation 
Results from the previous chapter reveal an increased expression of the c-
Met receptor tyrosine kinase in both PaTu8988S and PaTu8988T cells. c-Met 
acts as a high affinity receptor for HGF, and signalling through this receptor 
is key to a number of biological processes including development, wound 
healing and morphogenesis (Maulik et al., 2002). HGF/c-Met signalling is 
known to play a significant role in pancreatic tumorigenesis too, acting 
upstream of several signalling pathways including PI3K and MAPK (Maehara 
et al., 2001; Patel et al., 2014; Tan and Yang, 2010). It is also known that 
there are increased levels of circulating HGF in pancreatic cancer patients 
(Kemik et al., 2009), so the effect of HGF stimulation on downstream 
effectors was investigated in the selected cell lines. Both PaTu8988S (figure 
4.1A) and PaTu8988T (figure 4.1C) were serum starved, subjected to HGF 
stimulation for set time point and lysates made. Western blotting revealed 
that upon HGF stimulation, there was an increase in both the 
phosphorylation of Akt and ERK, which was evident after 5 minutes. In both 
cell lines, Akt peaked after 5 minutes, with no further increase in the 
phosphorylation being detected. ERK, however, peaked at 10 minutes. 
These results were confirmed through densitometry (figure 4.1Bi, 4.1Bii, 
4.1D and 4.1Dii).  
 
4.2.2 HGF has no effect on the phosphorylation of group II PAKs 
Until more recently, there was little knowledge on the regulation of PAK4. It 






Figure 4.1: Effect of HGF stimulation on the phosphorylation of 
AKT and ERK. Both PaTu8988S (A) and PaTu8988T (B) cells were 
subjected to stimulation with HGF where cells were starved overnight 
before HGF was added at specific time point. Lysates were separated 
by SDS-PAGE and western blotting revealed that there was an 
increased in the phosphorylation of both AKT and ERK, which was 
confirmed through densitometry (Bi, Bii, Di and Dii). Blots are 
representative of three independent experiments. Each experimental 
repeat was individually quantified using ImageJ and represented in 
graphical form after normalising to the loading control (GAPDH). 
 
 167 
sign of its activation. However, more recent reports suggested that it was 
constitutively phosphorylated at this site and that its regulation was controlled 
by either an autoinhibitory domain, or a pseudosubstrate region within the N-
terminal (Baskaran et al., 2012; Ha et al., 2012). Knowing that the 
PaTu8988T cell line responded to HGF and previous work in our lab 
suggested that PAK4 was activated downstream of HGF (Ahmed et al., 
2008; Wells et al., 2002), it was decided to look at the phosphorylation of 
PAK4 after cells were stimulated with HGF. Western blotting analysis 
revealed that in line with the more recent literature, no change in PAK4 
phosphorylation was observed after stimulating the cells with HGF (figure 
4.2). 
 
4.2.3 HGF leads to an increase in pancreatic cancer cell migration 
Having confirmed that both the pancreatic cancer cell lines (PaTu8988S and 
PaTu8988T) responded to HGF through an increase in the phosphorylation 
of Akt and ERK, the migratory response was next investigated. HGF (also 
called scatter factor) is known to have mitogenic, motogenic and 
chemoattractant activities (Giacobini et al., 2007; Stella and Comoglio, 1999) 
and that both the circulating levels of HGF and its receptor, c-Met are 
increased in pancreatic cancer (Ebert et al., 1994). Random 2D migration 
assays were carried out with both PaTu8988S and PaTu8988T cells. 
PaTu8988S cells form very tight colonies, with high expression of E-cadherin 
concentrated at the junctions between cells. They are also a non-invasive 
cell line. It is known that HGF can lead to dissolution of cell contacts (Royal 
et al., 2000; Wells et al., 2002), however, it appear to have little impact on  
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Figure 4.2: Effect of HGF on the phosphorylation of group II PAKs. 
PaTu8988T cells were subjected to HGF stimulation after being 
maintained in starve media (0% FBS) overnight. Lysates were 
produced after exposure to HGF for set time periods (between 5-30 
minutes). A group II PAK phospho antibody was used and revealed that 
there was no change in the phosphorylation of PAK4 (indicated). 
Additional bands are phospho-PAK6 and phospho-PAK5 which also 
show that there is no change in phosphorylation status after stimulating 
the cells with HGF. 
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Figure 4.3: Effect of HGF on PaTu8988S/T cell migration. Both 
PaTu8988S and PaTu8988T cells were analysed for the change in 
migration rates after the addition of HGF (Experiments were performed in 
serum-containing media +/- HGF). PaTu8988S cells (A) had a very low 
rate of migration with little change observed after the addition of HGF. 
For PaTu8988S cells, N=1. PaTu8988T cells are an invasive cell lines 
and the mean velocity increased after HGF (B). Mean velocities were 
calculated (C) and PaTu8988T cells demonstrated a significant increase 
in velocity after HGF stimulation. Results from PaTu8988T cells are from 
three independent experiments. * P<0.05 
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PaTu8988S cell morphology or colony formation. Cells were tracked and plot 
profiles produced (figure 4.3A) and mean velocity calculated (figure 4.3C). 
PaTu8988S cells migrated very little, remaining in colonies and little change 
was observed after the addition of HGF. PaTu8988T cells are a highly 
invasive cell line (Marques et al., 2009), which was shown within this assay. 
Plot profiles were produced after tracking cells (figure 4.3B) and the mean 
velocity calculated (figure 4.3C).  There was a significant increase of almost 
40% in average cell velocity after cells had been subjected to HGF 
stimulation.  
 
4.2.4 PAK4 knockdown in PaTu8988S and PaTu8988T cells 
Knowing that PAK4 is overexpressed in these cell lines and has been 
implicated in pancreatic tumorigenesis (Chen et al., 2008; Kimmelman et al., 
2008), the effect of depleting these cells of PAK4 expression was next 
investigated. It was originally planned to use an shRNA vector that has 
previously been used in the lab to produce a stable PAK4 knockdown cell 
line (Whale et al., 2013). However, even after adding the antibiotic selection 
and achieving a transfection efficiency of approximately 90%, PAK4 
expression remained unchanged (figure 4.4A). It was therefore decided to 
move to using siRNA in order to knockdown PAK4 in both PaTu8988T and 
PaTu8988S cells. Four different siRNA oligonucleotides were purchased and 
trialed in order to determine which resulted in the greatest reduction of PAK4 
protein expression and how long these effects would be maintained. A non-
targeting control siRNA as well as untransfected/wild type (WT) cells were 





Figure 4.4: PAK4 knockdown in pancreatic cancer cell lines. In the 
first instance, a stable PAK4 knockdown cell line was intended to be 
made. However, despite a high transfection efficiency, no knockdown 
was evident (A). Using four siRNAs targeting PAK4 it was shown that 
knockdown of PAK4 was evident in both PaTu8988S (B) and 
PaTu8988T (D) cells after 24 hours. This effect lasted in excess of 10 
days and it appeared to be greater with siRNA2 and siRNA5. Blots are 
representative of three independent experiments, which were quantified 
using densitometry (C and E), with each experimental repeat for each 
protein of interest being individually quantified using ImageJ and 
represented in graphical form after normalising to the loading control 
(GAPDH) * P<0.03. 
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After transfection, each cell line was lysed at 24 hours, 72 hours and 10 days 
(being trypsinised and reseeded as necessary to avoid cells becoming over 
confluent) and PAK4 expression investigated through western blotting for 
both PaTu8988S (figure 4.4B and figure 4.4C) and PaTu8988T (figure 
4.4D and figure 4.4E). There was an obvious reduction in the expression of 
PAK4 with all four siRNA oligonucleotides even after only 24 hours. The 
expression reduced further after 72 hours and lasted in excess of 10 days. 
These results meant that the production of a stable cell line was not 
necessary in order to undertake assays where longer time frames were used. 
It was noted that out of the four siRNA oligonucleotides used, siRNA2 and 
siRNA5 lead to a greater level of PAK4 knockdown and so it was decided 
that moving forward that these two oligos would be used. 
 
4.2.5 Depletion of PAK4 leads to a reduction in cell area and rounder 
cell shape in PaTu8988T cells 
PAK4 was originally identified as a cytoskeletal regulatory protein (Abo et al., 
1998), affecting both cell morphology and motility and filopodia formation 
(Callow et al., 2002). Thus, characterisation of cell area of each cell line after 
PAK4 depletion was performed. As PaTu8988S cells form tight colonies, 
making morphology studies challenging due to clustering, it was decided to 
look at cell morphology after PAK4 knockdown in the PaTu8988T cells. 
Control and PAK4 knockdown cells were seeded onto collagen coated 
coverslips (figure 4.5A). Following quantification (figure 4.5B), cells 




Figure 4.5: Effect of PAK4 depletion on PaTu8988T cell area. 
PaTu8988T cells were subjected to siRNA knockdown of PAK4 using two 
pre-validated siRNAs. In addition both a control siRNA and WT cells were 
used in morphological studies. Cells were reseeded onto collagen-coated 
coverslips and stained with DAPI (blue) and actin (red) (A). The cell area 
and circularity was then calculated using ImageJ and results quantified 
(B). There was a significant reduction in cell area and cells appeared 
rounder after PAK4 knockdown. Images are representative of three 
independent experiments. Scale bar = 10μm. Statistical significance was 
calculated using Student’s t-test where *** P < 0.0005  
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than WT and control cells. These data were consistent with previous results 
observed in our laboratory using PC3 cells (Ahmed et al., 2008) and in 
HCT116 colon carcinoma cells (Tabusa et al., 2013). 
 
4.2.6 Depletion of PAK4 reduces PaTu8988T cell migration 
As stated, PAK4 is known to regulate actin cytoskeletal dynamics (Abo et al., 
1998), through regulation of actin assembly and interacts with a plethora of 
proteins involved in cell migration including Cdc42, GEF-H1, LIMK and Gab1 
(Ahmed et al., 2008; Callow et al., 2005; Paliouras et al., 2009; Wells et al., 
2010). In particular, it has been shown that PAK4 interacts with LIMK in an 
HGF-dependent manner (Wells et al., 2002). Prostate cancer cells were also 
less responsive to HGF after PAK4 depletion. In addition, PAK4 has been 
shown to associate with Gab1 (a scaffold protein), relocalising to lamellipodia 
in response to HGF/c-Met signalling (Paliouras et al., 2009). Taken all 
together, the vast amount of research already published suggests that PAK4 
plays a significant role in cell migration and metastasis. Although it has been 
shown that PAK4 knockdown leads to decreased pancreatic cancer cell 
migration (Kimmelman et al., 2008), little work has been done to look at the 
possible pathways PAK4 may lie in. 
 
Having shown that PaTU8988T cells have a high migratory potential, which 
increased further after the addition of HGF (figure 4.3), control and PAK4 
knockdown cells were tracked +/- HGF (figure 4.6). Over the course of three 





















Figure 4.6 Effect of PAK4 knockdown on PaTu8988T cell 
migration. PaTu8988T cells were subjected to siRNA-mediated 
depletion of PAK4, reseeded on collagen and used within a random 2D 
migration assay both +/- the addition of HGF. In addition cells treated 
with an off-target control siRNA as well as WT cells were used as 
controls. Cells were imaged over the course of 12 hours, with an image 
taken at 5 minute intervals. Cells were then tracked using the ImageJ 
plugin MtrackJ and plot profiles produced for –HGF conditions (A) and 
+HGF (B) using the chemotaxis and migration tool from Ibidi. N=3 for 
each conditions tested and each data set was quantified (C). Results 
showed that upon depletion of PAK4 there was a significant decrease in 
PaTu8988T cell migration, which was evident with both siRNA2 and 
siRNA5. The same experiment was conducted with the addition of 
HGF, in order to determine whether PaTu8988T cells depleted of PAK4 
had the same response to HGF as WT and control cells. As before, 
there was a significant difference in the average velocity of cells 
between PAK4 knockdown and control cells. However, cells had the 
same level of response to HGF. Statistical significance was calculated 
using Student’s t-test where *** P < 0.0005 
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the ImageJ plugin MtrackJ and plot profiles produced using the Ibidi 
Chemotaxis and Migration tool (figure 4.6A and figure 4.6B). In the –HGF 
conditions, there was a visible change in migration rates and analysis 
revealed a significant reduction in mean velocity (figure 4.6C). Whereby cells 
treated with siRNA2 and siRNA5 lose their migratory capacity in comparison 
to both WT and control cells.  
 
In addition to the –HGF independent experiments, where HGF had been 
added, as previous results showed, there was a significant increase in HGF 
induced cell migration in both the WT and control cells. Cells that had been 
depleted of PAK4 prior to HGF stimulation also had a significant increase in 
cell migration, although these were still significantly reduced in comparison to 
control cells. Previous work has demonstrated that cells were not as 
responsive to HGF after depletion of PAK4 (Ahmed et al., 2008) and 
although the PaTu8988T PAK4 knockdown cells responded to HGF it did not 
completely rescue the knockdown phenotype. PAK4 knockdown cells still 
had a significantly reduced migration rate in comparison to control cells, 
suggesting PAK4 is required for a full migratory response to HGF. 
 
4.2.7 Production of a PAK4 RNAi rescue construct 
As an additional control and validation method of the results observed 
through the use of the siRNA depletion of PAK4, a rescue construct was 
produced. Taking the target sequence of siRNA2 and using site-directed 
mutagenesis a GFP expressing siRNA resistant form of PAK4 was made. To 
ensure it was correct, PaTu8988T cells were subjected to knockdown and 
 179 
transfection with the construct. Whole cell lysates were then produced and 
western blotting used to determine if the expression of the rescue construct 
was correct (figure 4.7A). After using the in house PAK4 antibody, a band at 
both 68 kDa and 95 kDa (PAK4 = 68 kDa + GFP = 27 kDa) can be seen. 
 
Having shown that the construct successfully transfected into PaTu8988T 
cells, the rescue construct was used in random 2D migration assays. To 
perform the rescue experiment, 24 hours after depleting cells of PAK4 using 
siRNA, cells were transfected with the GFP tagged rescue construct before 
being filmed with both brightfield and GFP channels. Only GFP expressing 
cells were tracked. When comparing the migration velocity (-HGF), it was 
evident that cells expressing the GFP construct had a similar mean velocity 
to both WT and control cells with no significant difference being observed.  
 
4.2.8 Reduced AKT phosphorylation in response to PAK4 knockdown 
Having observed the phenotypic effect of PAK4 knockdown, the signalling 
mechanisms responsible for this were next investigated. It is known that 
PAK4 acts downstream of PI3K in epithelial cells (Paliouras et al., 2009; 
Wells et al., 2002) and that PI3K signalling is constitutively activated in 
pancreatic cancer (Bondar et al., 2002). Thus, the effect of PAK4 depletion 
on downstream effectors of the PI3K was investigated. 
 
Previous results within this study have shown that PaTu8988T cells respond 
to HGF with an increase in the phosphorylation of AKT. Therefore the effect  
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Figure 4.7: PAK4 siRNA rescue construct. Through site-directed 
mutagenesis, a PAK4 rescue construct was produced which was tagged 
with GFP. This was transfected into PaTu8988T cells after depleting cells 
of PAK4 using siRNA. Western blotting revealed that PaTu8988T cells 
expressed this rescue construct with a band being evident at 95 kDa (A). 
This rescue construct was then used in random 2D migration assays to 
see if the PAK4 knockdown phenotype could be rescued (experiments 
were not performed in the presence of HGF). Only GFP expressing cells 
were tracked and analysis revealved that there was a significant increase 
in migration after transfection with the rescue construct in comparison to 
knockdown cells. No significant difference was observed between rescue 
and control cells (B). Results from the rescue were gathered over 6 
independent experiments and N=15 cells total due to technical 
difficulties. Statistical significance was calculated using Student’s t-test 
where *** P < 0.0005 
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of PAK4 knockdown on the phosphorylation status of Akt was investigated. 
Whole cell lysates were made after PAK4 knockdown and Western blotting 
used to investigate the level of Akt phosphorylation (figure 4.8A). The results 
show that there is a correlation between the level of PAK4 and Akt 
phosphorylation, which is reduced as PAK4 is depleted. This correlates with 
newly published data in both NIH3T3 and gastric cancer cell lines (Fu et al., 
2014; Gnad et al., 2013). The blot shown is representative of three 







Figure 4.8: Reduction in AKT phosphorylation correlates with 
depletion of PAK4. The level of phosphorylation of potential 
downstream effector proteins of PAK4 was looked at after siRNA-
mediated depletion of PAK4. Western blotting revealed that there was a 
correlation between PAK4 knockdown and the level of AKT 
phosphorylation (A). The results from three independent experiments 
were then quantified through densitometry (B), each experimental 
repeat was individually quantified using ImageJ and represented in 
graphical form after normalising to the loading control (GAPDH). 
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4.3 Discussion 
In this chapter, the sister cell lines PaTu8988S and PaTu8988T were used to 
further interrogate the link between the PI3K pathway and PAK4 within 
pancreatic cancer. To do this, HGF stimulations were used in combination 
with siRNA knockdown of PAK4, in both morphological and migration assays. 
 
Primarily the response of the cell lines to HGF was determined. As an output, 
both the phosphorylation of ERK and Akt were used, as both proteins are 
known to lie downstream of c-Met signalling in response to HGF (Tanahashi 
et al., 2013). Both PaTu8988S and PaTu8988T cells showed a significant 
increase in the phosphorylation of both of these proteins, with a response 
being evident after only 5 minutes. This confirms that HGF/c-Met signalling is 
highly active within these cell lines, reflecting the fact that it is upregulated 
within pancreatic cancer. With regards to PAK4, however, PaTu8988T cells 
showed no change in the phosphorylation status of this protein at Ser474 in 
response to HGF stimulation. As discussed, it was originally thought that 
phosphorylation at ser474 on PAK4 was a sign of its activation (Callow et al., 
2002). However, with more recent literature suggesting that it is constitutively 
phosphorylated at this site (Baskaran et al., 2012; Ha et al., 2012) and 
knowing that PAK4 has been shown to be activated downstream of HGF we 
sought to confirm these results in the PaTu8988T cell line. The results shown 
here, demonstrate that PAK4 is likely to be constitutively phosphorylated at 
this site in this cell line, which is in line with the most current literature 
(Baskaran et al., 2012; Ha et al., 2012). 
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It was also shown that PaTu8988T cells had a significantly increased 
migratory response to HGF. It is known that both MAPK and PI3K/Akt 
pathways are activated downstream of HGF and c-Met, both of which can 
contribute to increased cellular motility. PaTu8988T cells are a highly 
invasive cell line and their migratory capacity was increased significantly after 
the addition of HGF. It is known that pancreatic cancer is a highly aggressive 
disease with for expression of c-Met and circulating levels of HGF being 
greatly increased (Kemik et al., 2009). It has been shown here the impact 
that these increased levels have on cellular migration, with a significant 
increase in PaTu8988T migration in response to HGF. In contrast to the 
PaTu8988T cells, PaTu8988S cells are known to be non-invasive (Marques 
et al., 2009) and it was shown within this chapter that they migrate very little, 
even after the addition of HGF. This is likely due to the high level of E-
cadherin that they express at points of cell contacts, leading to tight colony 
formation, as shown in chapter three. Previous, published, work from our lab, 
which involved optimisation of a scatter assay using prostate cancer cell lines 
observed a similar result. HT29 cells were shown to form tighter colonies in 
comparison to DU145 cells. They did not exhibit the same scattering 
response to the same concentration of HGF and a higher concentration was 
required (Fram et al., 2014).  It was therefore hypothesised that a higher 
concentration of HGF could be required to induce cell scattering in the 
PaTu8988S cell line. Despite have a relatively high expression of the c-Met 
receptor, it could also be speculated that the surface level may not be as 
high and thus preventing observation of a more migratory phenotype. 
However, as the PaTu8988T cell line showed both phosphorylation events 
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and an increased migratory capacity in response to HGF it was decided to 
pursue migration assays using this cell line. 
 
It is known that PAK4 is upregulated in various cancer cell lines and tissue 
samples (Callow et al., 2002; Liu et al., 2008a; Siu et al., 2010a) and that it is 
oncogenic when overexpressed (Wong et al., 2013). Oncogenic PAK4 is also 
known to increase cell survival, motility and invasion (Kesanakurti et al., 
2012; Siu et al., 2010a). Therefore, the effect of PAK4 knockdown in a 
pancreatic cancer setting was investigated. It was initially decided to produce 
a stable knockdown cell line using an already established shRNA vector 
(Whale et al., 2013). However, it was shown that this had little effect of the 
expression of PAK4 within the PaTu8988T cell line. This shRNA was a PAK4 
specific pGIPz lentiviral vector, which uses a CMV promoter (a polymerase II 
promoter). It may be that an shRNA vector with a different promoter could 
prove more successful. U6 is a widely used polymerase III promoter and is 
known to be a strong member of the promoter class (Giering et al., 2008) and 
could therefore be a suitable alternative. It may also be of benefit to design a 
vector that targets a difference sequence within PAK4. However, for the 
purpose of this study, it was shown that siRNA provided an effective way to 
deplete both PaTu8988S and PaTu8988T cells of PAK4. A series of 
experiments, using a range of siRNAs from different companies in order to 
obtain optimal knockdown efficiencies, demonstrated that PAK4 levels were 
decreased after as little as 24 hours after siRNA treatment and lasted in 
excess of 10 days. This could indicate that once depleted, the recovery of 
PAK4 protein levels is difficult. It is known that PAK4 can translocate to the 
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nucleus, which is controlled by three nuclear export signals and two nuclear 
import signals. Within the nucleus it plays an important role in stabilising β-
catenin by inhibiting its degradation (Li et al., 2012). As PAK4 contributes to 
the regulation of this protein, it could be hypothesised that it therefore 
contributes to its own regulation. This could provide some explanation as to 
the reason for the length of knockdown observed within this study, using 
siRNA. Two of the four siRNAs tested proved to be more successful in their 
knockdown of PAK4 and so only these were used in future experiments. 
However, also of note was the apparent increase in PAK4 expression in WT 
cells at later time points. This is most likely due to a confluency effect, where 
after being subjected to siRNA (control or PAK4) cells may have a slower 
rate of growth.  
 
Further application of PAK4 siRNA demonstrated that with PaTu8988T cells, 
cells became smaller and rounder upon depletion of PAK4. This has 
previously been observed in our laboratory, where PC3 prostate cancer cells 
had a significant reduction in spread area after PAK4 knockdown (Ahmed et 
al., 2008). Another previous study showed that human pancreatic ductal cells 
expressing activated PAK4 became more elongated in comparison to control 
cells (Kimmelman et al., 2008).  Therefore, it is likely the converse would be 
true for PAK4 depletion in pancreatic cancer cells overexpressing PAK4, as 
observed here. These observations could be considered to be due to the 
ability of PAK4 to affect actin cytoskeletal dynamics. It was also previously 
shown that PaTu8988T cells that were transfected with siRNA targeting 
PAK4 had a significant reduction in invasion in comparison to control cells 
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(Kimmelman et al., 2008). Within this study, random 2D migration assays on 
collagen were used to investigate the effect of PAK4 knockdown on 
PaTu8988T motility. The results were complimentary to the previous studies 
and demonstrated that depletion of PAK4 lead to significant decreases in 
cellular motility. Taken together, all these results demonstrate the necessity 
of PAK4 in pancreatic cancer cell migration. In addition, PaTu8988T cells 
that had siRNA depleted PAK4 were used in migration assays with the 
addition of HGF to investigate whether cells were less responsive to HGF as 
demonstrated previously in prostate cancer cells (Ahmed et al., 2008). 
Although PAK4 depleted cells still responded to HGF, they still had a 
reduced migratory capacity in comparison to control cells under the same 
conditions. These results suggest that PAK4 may be required to achieve a 
full response to HGF. However, the results may also infer that the reduced 
migratory capacity of PAK4 knockdown cells could be due to HGF-
independent pathways, such as via K-ras/PI3K, and further investigation of 
these pathways would be required in order to make a definitive conclusion. 
 
As an additional control, a siRNA rescue construct was designed and 
produced through site-directed mutagenesis. This was used in random 2D 
migration assays after siRNA mediated depletion of PAK4 and results 
gathered over six independent experiments. However, only a total number of 
15 cells over the course of the experiments could be tracked. This was due 
to cell rounding/death and loss of expression during the time-lapse, with 
these cells being discounted. The other limitation of this experiment is that 
there is no way to test if the cells which are expressing the GFP tagged 
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rescue construct are ones which have also been targeted with siRNA, which 
is unknown with no visual cue. However, despite the limitations, the results 
did show that the use of the rescue construct was able to return cells in the 
PAK4 knockdown background to a normal migratory phenotype. 
 
Having looked at PAK4 knockdown on morphology and migration, the effect 
of PAK4 knockdown on downstream effectors was investigated. Some 
preliminary work within our laboratory had suggested that Akt might be a 
downstream target of PAK4. Further investigation into the level of Akt 
phosphorylation after PAK4 knockdown was determined through western 
blotting. Results showed that there was a correlation between PAK4 
depletion and the status of Akt phosphorylation. While this research was 
being carried out, new published data demonstrated that in NIH3T3 PAK4 
knockout cells there was a reduction in Akt phosphorylation at Ser473 (Gnad 
et al., 2013) and the same has been observed after PAK4 knockdown in 
gastric cancer cell lines (Fu et al., 2014). These results confirm the 
observations in PAK4 depleted PaTu8988T cells. Taken together, these 
results provide evidence that PAK4 could be lying upstream of Akt. 
 
Within this chapter, it has been determined that pancreatic cancer cell lines 
respond to HGF, leading to increased cell motility. It as also been 
demonstrated that PAK4 is essential for pancreatic cancer cell migration. It 
has also provided strong evidence that PAK4 lies upstream of Akt, with the 
phosphorylation of Akt being visibly reduced after depletion of PAK4, thus 
warranting further study of the link between PAK4 and the PI3K pathway.  
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4.4 Future Directions 
One major concern with the results obtained during this chapter was the 
siRNA rescue construct. Due to cell death and loss of expression only a 
small number of cells could be tracked throughout the course of a number of 
experiments. Although the cells that were tracked did show that the PAK4 
knockdown phenotype could be rescued, it would be worth formulating a 
more effective experiment to fully confirm these results. It would most likely 
be best to produce a stable knockdown cell line. This was the original 
experimental plan, however, the existing vector that had been successfully 
used within the laboratory previously (Whale et al., 2013) proved ineffective 
in knocking down PAK4 in the PaTu8988T cells. In order to continue with the 
experiments, it was decided to continue using only siRNA as the effects were 
long lasting. However, it may prove beneficial to use a vector using a 
different promoter to produce a stable PAK4 PaTu8988T cell line, which 
could potentially express a fluorescent protein. If then a rescue construct 
could be designed which was joined to a different fluorescent protein, cells 
co-expressing both vectors could be tracked and a true rescue phenotype 
could be observed. Having a stable cell line could also potentially help avoid 
as much cell death occurring as cells would undergo less stress and 
manipulation prior to the assay commencing. 
 
Within this chapter, the effect of PAK4 knockdown on PaTu8988T cell 
migration was investigated both +/- the addition of HGF. Although there was 
a significant reduction in cell migration after depletion of PAK4 under both 
HGF conditions, there was still an increased migratory response in PAK4 
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knockdown cells after the addition of HGF. It was hypothesised, based on 
these results, that PAK4 may be required for a full migratory response to 
HGF. However, it could also be inferred from these results that an HGF 
independent pathway, such as PI3K, are required for PAK4-mediated 
migration. Further investigation would be required in order to determine the 
pathways required for PAK4-mediated cell migration. Although PAK4 has 
been shown to be activated downstream of HGF in epithelial cells (Wells et 
al., 2002), whether this is the same in pancreatic cancer is unknown. It would 
therefore be advisable to determine whether PAK4 is firstly activated 
downstream of HGF in these cell lines via the use of kinase assays. It would 
also be of interest to use chemotaxis assays such as a Boyden chamber or 
transwell migration assays to investigate a specific response to PAK4 in 
these cell lines before and after PAK4 knockdown. These would likely 
provide more conclusive evidence to support whether or not there was a 
definitive requirement for HGF in PAK4-mediated cell migration. 
 
Although it was shown that PAK4 depletion led to a decrease in Akt 
phosphorylation the mechanism of PAK4 regulation on Akt has not been 
investigated within this study. There are a number of proteins that lie 
downstream of PI3K that can impact of Akt activity. For example, mTOR – 
specifically the mTORC2 complex – is a known regulator of Akt 
phosphorylation (Case et al., 2011; Moore et al., 2011; Tato et al., 2011). For 
full activation, Akt requires phosphorylation at Thr308 as well as Ser473. 
Phosphorylation at this site was not investigated as part of this study and it is 
known that this is mediated via PDK1 (Higuchi et al., 2008). This 
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demonstrates another mechanism through which the relationship between 
Akt phosphorylation and PAK4 could potentially be mediated via another 
protein. Therefore it would be beneficial to investigate whether a) PAK4 
depletion affects Akt phosphorylation at Thr308 and b) whether the 










Results: Part Three 
Investigation of the interaction of PAK4 
with the PI3K pathway 
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PAK4 activity is influenced by PI3K signalling (Fu et al., 2014; Wells et al., 
2002) and more recent research has suggested that there are links between 
ras and PAK4 within pancreatic cancer (Chen et al., 2008; Kimmelman et al., 
2008).  This chapter sought to investigate these protein-protein interactions 
further, with the aims to clarify where PAK4 may lay within this Ras:PI3K 
pathway. It is known that the PI3K pathway can be activated either directly or 
indirectly by c-Met or downstream of Ras (Organ and Tsao, 2011). 
Therefore, whether PAK4 interacted with Ras or solely with PI3K was 
investigated. 
 
Ras proteins are small GTPases, which are known to contribute significantly 
to oncogenesis. K-ras is one of the four ras isoforms (H-ras, N-ras, K-ras4A 
and K-ras4B), which are alternative splice variants of the RAS gene (Lowy 
and Willumsen, 1993; Plowman et al., 2003; Pylayeva-Gupta et al., 2011). 
They have a highly homologous domain structure except for a hypervariable 
region starting at amino acid 165. The N-terminus is identical in all four 
isoforms, with amino acids 32-40 constituting an effector-binding domain and 
provides a site for interactions with various effector proteins and allowing 
participation in a wide range of signalling pathways (Bar-Sagi, 2001; 
Castellano and Santos, 2011). Ras proteins are molecular switches and 
under normal cellular conditions, ras cycles between a GDP bound, inactive 
state and GTP bound, active state. The transition between these two states 
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is regulated via GEFs and GAPs (Biou and Cherfils, 2004; Colicelli, 2004; 
Malumbres and Barbacid, 2003; Vetter and Wittinghofer, 2001). However, K-
ras is frequently mutated in pancreatic cancer, with the mutated form being 
observed in more than 90% of patient tumour samples. The most common 
mutation is on codon 12 to produce constitutively active K-ras (Collins and 
Pasca di Magliano, 2013; Zinsky et al., 2010). This leads to continual 
activation of downstream signalling pathways, including the PI3K pathway. 
 
It is known that K-ras is able to directly activate PI3K. PI3K is a heterodimeric 
protein, consisting of two subunits; a catalytic subunit (P110) and a 
regulatory subunit (p85). It is the P110 subunit that is known to interact with 
ras via its RAS binding domain (RBD) and this is independent of p85 
(Castellano et al., 2013; Gupta et al., 2007; Organ and Tsao, 2011). 
However, PI3K is also activated through association with receptors such as 
c-Met. This interaction can either be direct, whereby the p85 subunit 
associates with phosphorylated tyrosine residues via its SH2 domain, or 
indirectly via the scaffold protein Gab1 (Rocchi et al., 1998; Yu et al., 2001). 
After this association takes place, the catalytic P110 subunit is able to 
transfer phosphate groups to initiate downstream signalling.  
 
PAKs have been shown to interact with the PI3K pathway. PAK4 activity has 
been shown to be dependent on PI3K, with pharmacological inhibition 
resulting in reduced PAK4 kinase activity (Wells et al., 2002). Group I PAKs 
also demonstrate links with PI3K, with a reduction in PAK1 activity being 
observed after inhibition of PI3K in colorectal cancer by LY294002, 
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downstream of gastrins (Huynh et al., 2014). Further to this, LY294002 
mediated inhibition of PI3K in hepatocellular carcinoma cell lines also 
demonstrated reduced PAK1 activity (Xu et al., 2014). Contrary to results 
from the previous chapter where PAK4 was shown to act upstream of Akt, 
impacting on Akt phosphorylation, this study placed PAK1 downstream of 
Akt, with siRNA mediated depletion of Akt also reducing PAK1 activity (Xu et 
al., 2014). These highlight how different PAK isoforms can perform similar 
roles while resulting in differing outcomes. 
 
As stated, pharmacological inhibition of PI3K through use of LY294002 has 
been shown to reduce PAK4 activity in both MDCK cells (Wells et al., 2002) 
and gastric cancer (Fu et al., 2014). However, this more recent study also 
observed that inhibition of PAK4 by PF-3758309 suppressed both PI3K/Akt 
and MEK/ERK signalling (Fu et al., 2014), suggesting these pathways are 
able to reciprocally activate each other.  
 
Currently, there are no known binding partners of the proline rich regions 
within PAK4 (Dart and Wells, 2013). However, these proline residues provide 
putative binding sites for SH3 domain containing proteins (Dart and Wells, 
2013). Previous work within our laboratory suggested that PAK4 could be 
interacting with the PI3K pathway through the regulatory subunit p85α, which 
was highlighted in a screen. However, this interaction wasn’t fully validated 
and so the hypothesis that an interaction between PAK4 and the SH3 
domain of p85α was investigated further within this chapter. In addition, it has 
been shown that Gab1 and PAK4 associate and colocalise within 
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lamellipodia, in response to HGF. This interaction was shown to be via the 
GID domain on PAK4 (Paliouras et al., 2009). Taken together, these results 
and preliminary data provide reasoning for further examination of the 
interplay of PAK4 with the PI3K pathway. There is strong evidence to 
suggest they could play a key role in pancreatic cancer progression and the 
results obtained throughout this next chapter sought to elucidate the nature 




5.2.1 PAK4 interacts with K-ras 
As part of the functional studies, the interaction of PAK4 with various 
components of the PI3K pathway was investigated. There have been links 
between K-ras and PAK4, showing PAK4 to be activated downstream of 
oncogenic K-ras (Chen et al., 2008; Choudhry et al., 2014; Yeo et al., 2014). 
HEK293 cells were transfected with GFP tagged K-ras and utilised in a 
glutathione-S transferase (GST) pulldown assay (figure 5.1). The results 
showed that there was a specific interaction between PAK4 and K-ras with 
no binding observed in the control lane.  
 
5.2.2 PAK4 interacts with the p85α subunit of PI3K 
Knowing that the PI3K pathway can be stimulated through c-Met and not only 
through K-ras (Organ and Tsao, 2011), the interaction between PAK4 and 
PI3K was next interrogated. It has also previously shown that the P110 
subunit interacts with K-ras (Castellano et al., 2013; Gupta et al., 2007) and 
previous work in our laboratory suggests that there may have been an 
interaction between PAK4 and the regulatory subunit of PI3K, p85α. To 
investigate this, GFP tagged p85α was transfected into HEK293 cells and 
GST or GST tagged PAK4 truncated domain mutants were used to pulldown 
the p85α (figure 5.2A). It is known that PAK4 contains several proline rich 
regions and that these provide putative binding sites of SH3 domain 
containing proteins (Dart and Wells, 2013). Therefore, full length PAK4 and 
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Figure 5.1: PAK4 interacts with K-ras. HEK293 cells were transfected 
with GFP:K-ras and subsequently used in a GST pulldown. GST and 
GST tagged PAK4 were used to pull down GFP:K-ras overexpressing 
HEK293 cells. Results demonstrated that there was a specific 
interaction between K-ras and PAK4, with no non-specific binding 
evident in the GST control lane. Blot shown is representative of three 




Figure 5.2: PAK4 interacts with the p85α subunit of PI3K. (A) Full 
length PAK4 domain structure (GBD: GTPase binding domain; PxxP: 
Pro-x-x-Pro amino acid sequence motifs; GID: GEF-H1/Gab1 
interacting domain) and the amino acid regions that constitute the PxxP 
and ΔPxxP domain mutants of PAK4. (B) HEK293 cells were 
transfected with GFP tagged p85α and subsequently used in a GST 
pulldown assay. Domain mutants of PAK4 involving the PxxP region 
were used alongside GST (control) and full length wild-type PAK4. 
Results from the assay showed that there was a strong interaction 
between p85α and both PAK4 and the PxxP mutant. No binding was 
observed when the PxxP region had been deleted. These results 
demonstrated that the PxxP region is necessary for p85α binding. 
Results shown are representative of three independent experiments. 
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truncated domain mutants consisting of the proline rich region (PxxP 
comprising amino acids 31-322) and one with this region deleted (ΔPxxP 
comprising amino acids 1-34 plus 319-591) were produced (figure 5.2A).  
 
These domain mutants would help determine whether p85α was binding 
within the proline rich region of PAK4, as hypothesised. The results from this 
GST pulldown assay revealed that there was binding between PAK4 and 
p85α and also between p85α and the PxxP region. These results were 
observed over three independent experiments. There was no observed 
binding between p85α and the ΔPxxP-truncated mutant (figure 5.2B). The 
results provide evidence for an interaction between p85α and PAK4, which is 
likely to be via the central proline rich region of PAK4. 
 
5.2.3 Interaction between PAK4 and p85α requires SH3 domain 
Having shown an interaction between PAK4 and p85α, with use of various 
domain mutants of PAK4 revealing the interaction to be within the PxxP 
region of PAK4, use of p85α domain mutants were used to further interrogate 
this interaction. It is known that the proline regions on PAK4 provide putative 
binding sites for SH3 domain containing proteins (Dart and Wells, 2013). It is 
also known that p85α contains an SH3 domain (Koyama et al., 1993). 
Therefore, it can be hypothesised that the interaction occurs between the 
PxxP region of PAK4 and the SH3 domain of p85α. In order to investigate 
this, two domain mutants of p85α were created (figure 5.3A). As well as full-






Figure 5.3: Requirement of SH3 domain of p85α for interaction 
with PAK4. Domain structure of p85 (SH3: Src homology 3 domain; P: 
Pro-rich region; BH: BCR homology domain; SH2: Src homology 2 
domain; P110 BD: P110 binding domain). Two truncated p85α 
constructs were made; SH3 consisting of amino acids 1-85 and ΔSH3 
consisting of amino acids 80-724 (A). These were both subsequently 
tagged with GFP. GFP:p85αSH3 was transfected into HEK293 cells 
and GST and GST tagged PAK4 derivatives used to pull down 
overexpressing cells (B). Western blotting revealed that p85αSH3 was 
able to bind to both PAK4 and PAK4PxxP with no binding observed 
between the SH3 domain and PAK4ΔPxxP. Conversely, when GST and 
GST tagged PAK4 derivatives were used to pull down HEK293 cells 
overexpressing GFP tagged p85αΔSH3, no binding was observed (C). 
For both assays, results shown are representative of three independent 
experiments. 
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1-85) and one missing the SH3 domain (ΔSH3, comprising amino acids 80-
724) were created. These were tagged with GFP and transfected into 
HEK293 cells prior to their use in a GST pulldown. As before, in addition to 
GST, the three GST-tagged PAK4 derivatives were used to pulldown the 
GFP-tagged p85α truncation mutants and the results shown through Western 
blotting. The SH3 mutant was shown to bind to full length PAK4 and to the 
PxxP construct, but not to the ΔPxxP construct (figure 5.3B). This confirms 
the previous results, whereby it is most likely that PAK4 is interacting with the 
p85α via its SH3 domain. In contrast, when using the ΔSH3 construct, no 
binding could be observed between any of the PAK4 domain mutants (figure 
5.3C). This further supports evidence for the SH3 domain being vital in the 
interaction between PAK4 and p85α. 
 
5.2.4 Does p85α bind preferentially to one proline rich region of PAK4? 
Within all PAK4 proteins, there are a variable number of core PxxP motifs, 
which are ligands for SH3 domain-containing proteins. However, this central 
PxxP-containing region differs in PAK4 in comparison to other PAK family 
members, containing three proline rich regions (Dart and Wells, 2013). 
However, previous to this study there were no known binding partners to 
these specific sites. Having demonstrated that p85α was able to bind within 
this PxxP region of PAK4, we sought to identify where the possible 
interaction was taking place. In order to do this, through site-directed 
mutagenesis, two full-length point mutation containing PAK4 constructs were 
produced (figure 5.4A). They contained a point mutation within different 
regions of the central, proline rich region of PAK4 (P105,108A and  
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Figure 5.4: Point mutants of PAK4 reveal no preferential binding 
site within PxxP region. Through site-directed mutagenesis two full 
length PAK4 constructs containing point mutations at different sites 
within the PxxP region were produced (A). GST and the GST tagged 
PAK4 derivatives were used to pulldown HEK293 cells overexpressing 
p85α. Western blotting revealed there was no observed change in 
binding between any of the PAK4 constructs (B), suggesting no 
preferential binding site. Results shown are representative of three 
independent experiments.  
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P287,298A). These GST-tagged PAK4 point mutants and GST were used to 
pull down overexpressed GFP-p85α from transfected HEK293 cells. It was 
hypothesised that p85α would bind to one of these regions preferentially over 
the other which would be seen by decreased binding to one of the point 
mutants. However, the results showed that there was no change in p85α 
binding in either point mutant in comparison to full-length, wild-type PAK4 
(figure 5.4B), suggesting no preference in binding site. 
 
5.2.5 Interaction between PAK4 and p85α is dependent on Gab1 
Having shown that there was no preferential binding within the proline rich 
region of PAK4 with p85α, more studies were used attempt to further 
elucidate the interaction between the two proteins. It is known that both 
PAK4 and p85α bind to the scaffold protein Gab1 (Abella et al., 2010; 
Paliouras et al., 2009), thus it was tested whether this protein was necessary 
for the two proteins to bind. Gab1 is an adapter protein that acts as a 
scaffold. It plays a critical role in a variety of signalling pathways, acting as a 
central site of multiprotein complex assembly. It is particularly known for 
acting downstream of c-Met in response to HGF. Activation of c-Met via HGF 
results in recruitment of Gab1 to the receptor and phosphorylation of specific 
tyrosine residues. This subsequently provides docking sites for various 
downstream signaling proteins including p85α (Nguyen et al., 1997; Ponzetto 
et al., 1994; Weidner et al., 1996). It was also more recently shown that 
Gab1 was able to bind to PAK4 via the GID domain (Paliouras et al., 2009). 
The interaction between PAK4 and p85α was therefore interrogated and a 
GST pulldown performed after cells were first treated with a siRNA pool for 
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Gab1. This would show whether Gab1 was necessary for the binding 
between PAK4 and p85α to occur. The assay showed that there was 
reduced binding between the two proteins after Gab1 had been depleted in 
the HEK293 cells prior to transfection with the p85α (figure 5.5), implicating 
a role for Gab1 in the interaction between PAK4 and p85α. 
 
5.2.6 Use of PI3K inhibitor phenocopies PAK4 knockdown 
It was speculated that inhibition of PI3K signaling would also impact on HGF-
mediated responses, previously shown to be influenced by PAK4. LY294002 
is known to be a potent inhibitor of PI3K and previous results from our 
laboratory demonstrated that an inhibition of PI3K using this compound lead 
to a decrease in PAK4 kinase activity (Wells et al., 2002). Therefore, further 
investigation into the effect of this PI3K inhibition on PAK4 was carried out in 
order to further establish the possibility of PAK4 lying within the PI3K 
pathway in pancreatic cancer.  
 
The effect of using the inhibitor on Akt phosphorylation in the PaTu8988T 
cells was first determined (figure 5.6A). PaTu8988T cells were subjected to 
treatment either with 20μM LY294002 or with DMSO as a control. Lysates 
were made from cells in full growth media, starve (0% FBS) media and those 
that had been stimulated with HGF and the level of Akt phosphorylation 
determined through western blotting (figure 5.6A). The results showed that 
there was complete abolition of Akt phosphorylation in all conditions after 
addition of the LY294002. This demonstrates that LY294002 is a potent 
inhibitor of PI3K activity within these pancreatic cancer cells. Subsequently 
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Figure 5.5: The interaction between PAK4 and p85α is dependent 
on Gab1. HEK293 cells were subject to siRNA mediated knockdown on 
Gab1. Subsequently they were transfected with GFP tagged p85α. GST 
and GST tagged PAK4 were used to pull down p85α overexpressing 
HEK293 cells. Western blotting revealed a reduction in binding between 
PAK4 and p85α after Gab1 knockdown. Results shown are 










Figure 5.6: Effect of using the PI3K inhibitor LY294002. (A) The 
effect of using 20μM LY294002 on AKT phosphorylation in PaTu889T 
cells was investigated in grow, starve and after the addition of HGF. In 
all three conditions, upon exposure to the inhibitor there was complete 
ablation of phosphorylation of AKT at Ser473. The migration of 
PaTu8988T cells was also studied after addition of LY294002. Cells 
were tracked for 12 hours with an image being captured at 5-minute 
intervals. Cells were tracked using the ImageJ plugin MtrackJ and plot 
profiles produced (B) using the chemotaxis and migration tool from 
Ibidi. Results were analysed and showed that there was a significant 
reduction in migration upon exposure to the inhibitor (C). Statistical 
significance was calculated using Student’s t-test where ** P < 0.005 
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the effect of adding LY294002 to PaTu8988T cells prior to a random 2D 
migration assay was investigated. As expected, there was a significant 
reduction in cell migration; with cells being tracked using ImageJ and 
trajectory plots produced using the chemotaxis and migration tool from Ibidi 
(figure 5.6B). The mean velocity was calculated and graphed (figure 5.6C) 






In this chapter, multiple GST pulldown assays were performed in order to 
investigate the potential relationship PAK4 has with the Ras:PI3K pathway. 
Various mutants of both PAK4 and p85α were created to analyse the 
possible domain interactions and the effect of pharmacological inhibition of 
PI3K was also investigated. 
 
Previous research has demonstrated a link between K-ras and PAK4 within 
pancreatic cancer (Chen et al., 2008; Kimmelman et al., 2008), and this 
interaction was investigated further within this chapter. K-ras is important in 
the initiation of the PI3K pathway, but it has also been shown within colon 
cancer cell lines, that both PAK4 and PAK1 can impact on K-ras signalling 
independent of this pathway (Tabusa et al., 2013). However, more recently 
published data has shown that in both PAK4 knockout NIH3T3 cells and 
siRNA mediated depletion of PAK4 in gastric cancer cells lines leads to a 
reduction in AKT phosphorylation downstream of PI3K (Fu et al., 2014; Gnad 
et al., 2013). Furthermore, in the observed phenotype in the PAK4 knockout 
cells could be rescued through introduction of constitutively active K-ras but 
not Cdc42 (Gnad et al., 2013), providing additional evidence to support the 
hypothesis that PAK4 is involved within this signalling pathway. 
 
Therefore, it was important to further elucidate the relationship between K-
ras and PAK4. Pulldown assays, where full length K-ras and PAK4 were 
used, demonstrated that there was binding between the two proteins. These 
results establish a K-ras/PAK4 relationship. However, the PI3K pathway can 
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also be activated independent of K-ras activity (Castellano and Santos, 
2011). It was therefore necessary to investigate further the relationship of 
PAK4 with components further down the signaling pathway. 
 
Taking into consideration preliminary data from our laboratory that suggested 
a potential interaction between the regulatory p85α subunit of PI3K with 
PAK4, initially, GST pulldown assays were conducted using the full-length 
constructs of both proteins. It was also hypothesised that binding between 
p85α and PAK4 could be within the proline rich region of PAK4. To date, no 
known interacting partners have been identified, but it is a logical assumption 
that the interaction between p85α and PAK4 involves this region. It is known 
that these proline residues provide putative binding sites for SH3 domain-
containing proteins (Dart and Wells, 2013) and that p85α contains an N-
terminal SH3 domain. Therefore two truncated domain mutants of PAK4 
were created; PxxP, which comprised the proline region only and ΔPxxP, 
that had had this region deleted. These initial studies revealed that there was 
an interaction between PAK4 and p85α and that this appeared amplified 
when only the PxxP region was used within the pulldown. Confirming the 
hypothesis that the proline residues were required for the interaction to 
occur, no binding was evident in the deletion mutant.  
 
Having determined that there was an interaction between the PxxP region of 
PAK4 and p85α, it was sought to confirm which region of p85α was binding. 
As aforementioned, the proline residues provide binding sites for SH3 
domains and it was therefore hypothesised that the interaction was occurring 
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between the PxxP region of PAK4 and the SH3 domain of p85α. In order to 
confirm this, two domain mutants of p85α were produced, tagged with GFP. 
These were the SH3 domain alone and a construct with the N-terminal SH3 
domain deleted. As predicted, there was binding of the SH3 domain to the 
PxxP region of PAK4 and no binding observed after deletion of this domain. 
These data provide strong evidence for this novel interaction between PAK4 
and p85α and heavily implicate the involvement of PAK4 in PI3K signalling. 
 
To further investigate this interaction, two point mutants of PAK4 were 
created through site-directed mutagenesis. These were used to answer 
whether p85α was binding preferentially to one of the proline rich binding 
sites of PAK4. However, the pulldown assay revealed no change in binding 
between either point mutant and wild-type PAK4. Taking these results into 
consideration, the domain mutants of PAK4 were looked at in more detail. It 
was noted that the PxxP mutant was composed of amino acids 31-322, 
which not only encompasses this proline rich region, but also the majority of 
the GID. 
 
It is known that the GID of PAK4 is the site of Gab1 interaction (Paliouras et 
al., 2009) and also that Gab1 is a known binding partner of p85α (Abella et 
al., 2010). It was therefore thought that the interaction between PAK4 and 
p85α may be dependent on the scaffold protein Gab1, with it either being 
involved in a cooperative binding complex or acting as a scaffold. 
Knockdown of Gab1 prior to performing a pulldown revealed that there was 
indeed a reduction in binding after Gab1 had been depleted. These results 
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suggest that Gab1 is therefore necessary for the interaction between PAK4 
and p85α. 
 
However, previous results obtained showed that there was an interaction 
between the SH3 domain of p85α and the PxxP region of PAK4. It is known 
that p85α binds to Gab1 via its SH2 domain (Rocchi et al., 1998; Yu et al., 
2001). Therefore, if Gab1 was necessary for binding between p85α and 
PAK4 how was there an interaction present when the SH2 domain required 
for Gab1 binding was deleted? In response to this issue, it could be that 
PAK4 binds directly to the SH3 domain of p85 via proline residues within the 
PxxP region but also indirectly via Gab1 which p85 binds to via its SH2 
domain. This could go some way to explain as to why there is reduced 
binding after Gab1 knockdown but also why there is binding between just the 
SH3 domain and the truncated PxxP PAK4 construct. 
 
More recently, the mode of PAK4 activation has been under examination. 
One study has identified a pseudosubstrate containing a specific sequence 
(R49PKP) within the N-terminal of PAK4, which binds to the kinase domain 
and results in constitutive autoinhibition. They concluded that this sequence 
was necessary and sufficient to inhibit PAK4 kinase activity, but also that 
there were potentially other regions that may facilitate complete inhibition (Ha 
et al., 2012). Within this same study, they found that Src SH3, but not β-PIX 
SH3, was able to activate PAK4 (Ha et al., 2012). It has been demonstrated 
that the tertiary structure of the binding sites in the p85α and Src SH3 
domains are similar (Koyama et al., 1993) and these two proteins have been 
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observed to have the same substrate in other studies (Shen et al., 1999). It 
could therefore be hypothesised that upon binding to PAK4 that the SH3 
domain of p85α could provide a mechanism to relieve PAK4 autoinhibition.  
 
As discussed, the use of a known PI3K inhibitor (LY294002) has been shown 
to impact of PAK4 kinase activity (Wells et al., 2002). To compliment the 
biochemical studies, it was decided to investigate as to whether this 
pharmacological inhibition of PI3K phenocopied the results observed in the 
previous chapter. After PAK4 knockdown there had been a significant 
decrease in cancer cell motility and after PaTu8988T cells had been pre-
incubated with LY294002, there was also a reduction in cell migration, albeit 
to a greater extent. However, taken together, these results demonstrate the 
requirement for both PAK4 and PI3K signalling within pancreatic cancer cell 
migration.  
 
Within this chapter, a novel interaction between PAK4 and p85α has been 
shown. Although the exact nature of this interaction needs further 
investigation, it may be plausible to hypothesise, based on the results 
gathered, that there is a direct interaction between the SH3 domain of p85α 





5.4 Future Directions 
Many protein-protein interactions are transient. It is known that PAK4 is 
involved in many different signalling pathways and so looking at interacting 
partners at an endogenous level can be difficult. Within this chapter, GST 
pulldown assays were used to successfully identify a number of new PAK4-
interacting proteins. However, there were limitations, as discussed in section 
5.3. Due to time constraints, more in depth analysis could not be completed, 
however, there are a number of ways in which these interactions could be 
further investigated. 
 
Although p85α was newly identified as a PAK4 binding partner, the full nature 
of this interaction requires further interrogation. The PAK4 PxxP domain 
mutant was found to contain the GID, the Gab1 interaction domain. 
Therefore, whether Gab1 is providing a scaffold between PAK4 and p85α 
hasn’t fully been answered. It would therefore be necessary to produce a 
PxxP domain mutant that had the GID entirely deleted. It would also be of 
benefit to produce a construct that had the GID intact, but with the PxxP 
region deleted, and use this to determine if p85α could still be detected. It 
could also be considered of use to look at binding between p85α and Gab1 
after PAK4 knockdown and investigate whether this affected this known 
interaction. These experiments would provide further insight into the interplay 
between these three proteins. 
 
However, ultimately it would be ideal to determine if the interaction between 
PAK4 and p85α was direct as well. This is the limitation with pulldown 
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assays; although they are able to show an interaction, they do not confirm is 
this is direct of indirect. One relatively simple technique, which could be used 
to determine whether there was a direct interaction, would be a far Western 
blot. This is a direct binding assay whereby interacting partners can be 
identified within samples. As opposed to the use of an antibody, purified 
proteins are incubated with the nitrocellulose membrane after SDS-PAGE 
and electroblotting (Johansson et al., 2004). Another method by which to 
study direct protein-protein interactions is the yeast two-hybrid system. 
Within this system, the protein of interest is fused to the DNA binding domain 
(bait). The interacting protein is then fused to the activation domain (prey). In 
short, if the two proteins interact, it allows transcription of the reporter gene 
which can be subsequently detected (Bruckner et al., 2009). Ultimately, it 
would be highly beneficial to determine whether a direct interaction between 
PAK4 and p85α is present. 
 
Also within this chapter it was demonstrated that the SH3 domain of p85α is 
able to bind to PAK4. It was hypothesised that this could ultimately lead to 
increased PAK4 kinase activity through relief of PAK4 autoinhibition. It would 











Results: Part Four 





Chapter 6: An organotypic model of pancreatic cancer 
 
6.1 Introduction 
One of the hallmarks of pancreatic cancer is the formation of fibrotic tissue; 
an event often referred to as the desmoplastic reaction, which is perhaps one 
of the most prominent stromal reactions of all epithelial tumours (Vonlaufen 
et al., 2008b). This tissue is composed of various extracellular matrix proteins 
including collagens and matrix metalloproteinases, an increase in 
myofibroblastic pancreatic stromal cells and the presence of immune cells 
(Bardeesy and DePinho, 2002; Pandol et al., 2009; Schneiderhan et al., 
2007). Stromal cells including pancreatic stellate cells and cancer-associated 
fibroblasts contribute to tumour development and progression through cross 
talk and communication with cancer cells via a number of signaling pathways 
including Hedgehog, Notch and TGFβ (Bailey and Leach, 2012). The release 
of various growth factors also contributes to the formation of fibrotic tissue, 
with the activity of these stellate cells meaning that the rate of extracellular 
matrix deposition is exceeding that of ECM degradation (Phillips, 2012). 
Often the desmoplastic stroma can contribute between 70-90% of the actual 
tumour volume (Erkan et al., 2012a; Hwang et al., 2008).  
 
This characteristic feature of pancreatic cancer and pronounced 
desmoplastic tissue is characterised by dense bundles of collagen, loss of 
basement membrane integrity and invasion of malignant cells into the 
interstitial matrix (Apte et al., 2004; Mahadevan and Von Hoff, 2007). It has 
also been shown to contribute to tumour aggressiveness, with pancreatic 
stellate cells promoting proliferation, migration and invasion of pancreatic 
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cancer cells (Bailey and Leach, 2012; Hwang et al., 2008; Vonlaufen et al., 
2008a). It has also been shown in vivo that nude mice injected with a 
combination of cancer and stellate cells had a higher frequency of tumour 
formation, increased tumour volume, proliferation and desmoplasia in 
comparison to those injected with only cancer cells (Bachem et al., 2005; 
Schneiderhan et al., 2007; Vonlaufen et al., 2008a). It is also well known that 
the exclusive microenvironment observed in pancreatic cancer contributes to 
chemoresistance, due to the reduction in drug penetration (McCarroll et al., 
2014; Michl and Gress, 2012; Whatcott et al., 2012).  
 
Taken together, this highlights that the tumour microenvironment plays a 
significant role in disease progression and influences heavily in pancreatic 
cancer. Therefore research into this complex disease needs to take this into 
consideration. 3D organotypic models are able to bridge the gap between 
simple 2D in vitro assays and far more complex in vivo models. Organotypic 
models are invaluable tools in which to study cancer development and 
progression as they recapitulate the features of the disease and better mirror 
the in vivo environment. They are also more easily manipulated to meet the 
specific requirements of the assay, depending on the exact features under 
scrutiny.  
 
Research has implicated the HGF/C-met signaling axis in promoting the 
desmoplastic reaction (Mahadevan and Von Hoff, 2007) and squamous cell 
carcinoma cells that had been depleted of PAK4 have shown reduced 
invasion in a 3D organotypic invasion assay (Zanivan et al., 2013). Within 
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this final results chapter, an organotypic model of pancreatic cancer was 
used to study the invasion of pancreatic cancer cells after PAK4 knockdown 
and whether this was phenocopied by cells subjected to pharmacological 
inhibition of PI3K. This would enable examination of the role PAK4 plays in 
pancreatic cancer invasion in an environment that better simulates conditions 
found in vivo.   
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6.2 Results 
6.2.1 Distinguishing between pancreatic stellate and cancer cells 
Within the organotypic model, it is important to be able to distinguish 
between the stellate cells and the cancer cells being used. This is in order to 
determine specifically cancer cell invasion. The PS-1 cells are a pancreatic 
stellate cell line, which were isolated, immortalised and characterised 
previously (Froeling et al., 2009). Stellate cells were already known to 
contribute to fibrosis during chronic pancreatitis (Masamune et al., 2009); 
however, they were identified as producers of ECM proteins that are major 
contributors to pancreatic tumour stroma (Apte et al., 2004). Several 
pancreatic stellate cell selective markers including desmin, GFAP and nestin 
as well as α-smooth muscle actin (as a marker of activation) have been 
identified (Apte et al., 2004; Apte et al., 2013). Knowing that activated stellate 
cells are present in the tumour stroma and contribute heavily to growth factor 
and matrix protein production involved in pancreatic cancer progression, α-
smooth muscle actin was chosen as a suitable marker to distinguish these 
cells from the cancer cells used. It is also known that adenocarcinomas of 
the pancreas express cytokeratins and are used to identify cancer cells. 
 
To ensure that these markers were suitable for use within the organotypic 
model, both PaTu8988T and PS-1 cells were seeded onto collagen-coated 
coverslips and stained for these marker using specific antibodies. It was 
shown that PaTu8988T expressed cytokeratin (figure 6.1A) whereas the PS-
1 cells had no expression evident (figure 6.1B). Conversely, PaTu8988T 









Figure 6.1: Characterisation of PS-1 and PaTu8988T cells. Both PS-
1 and PaTu8988T would be used within the 3D organotypic model. To 
enable the two cell lines to be distinguished from each other they were 
subjected to immunofluorescent staining of known stellate/cancer cell 
markers to ensure the antibodies would be appropriate for future use. 
Both cell lines were first subjected to immunofluorescent staining for 
WSS pan-cytokeratin. PaTu8988T (A) but not PS-1 (B) had observed 
expression of this protein. Conversely, when stained for α-smooth 
muscle actin, PaTu8988T (C) lacked expression and PS-1 (D) could be 
seen to have global expression of this marker of stellate cell activation. 
Scale bar = 10μm. 
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cells, which had a high level of expression (figure 6.1D). These results 
confirm that these antibodies were suitable for staining the organotypic 
models with in order for clear identification of each separate cell line. 
 
6.2.2 Optimisation of the organotypic model 
3D organotypic models are easily manipulated to better replicate conditions 
found in vivo and can be altered depending on the specific parameter under 
investigation. These organotypic culture systems involve the generation of a 
synthetic stroma, which are composed primarily of collagen and MatrigelTM 
embedded with fibroblasts or stellate cells. Collagen is known to be one of 
the main components of the ECM and desmoplastic tissue contributing to 
pancreatic cancer progression (Shields et al., 2011) and MatrigelTM has been 
shown to enhance cancer cell invasion in 3D (Nystrom et al., 2005) by 
increasing the diversity of the organotypic matrix (Nurmenniemi et al., 2009).  
 
Two widely used models are the submerged organotypic model and the air-
liquid model. Within this study the air-liquid model was used, where the ‘gel’ 
is raised onto a grid (figure 6.2), which enables the specific study of invasion 
into the matrix. This model has been widely used to study both SCC 
(Gaggioli et al., 2007; Nystrom et al., 2005; Zanivan et al., 2013) and 
pancreatic cancer (Coleman et al., 2014; Froeling et al., 2010; Froeling et al., 
2009). There were a number of parameters within the set up of the 
organotypic, which were tested in order to optimise the procedure. These 
included the brand of collagen used, the number and placement of stellate 





Figure 6.2: Raised air-liquid organotypic model. The raised air-liquid 
organotypic model was used to study pancreatic cancer cell invasion 
within this study. Whereby, a collage/matrigel matrix was produced with 
pancreatic stellate cells also being a main constituent. A 2:1 ratio of 
cancer:stellate cells was subsequently seeded atop the matrix. This 
was then raised onto a collagen membrane covered grid and fed with 
culture media from below to encourage invasion down into the matrix. 
The media was changed every 2 days and after 14 days each gel was 
harvested and sent for further processing. 
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outlined below in table 6.1 where the optimal conditions used for future 
experiments are marked; chosen as they were found to produce the most 




















2:1 cancer:stellate cell ratio with all stellate cells 
seeded on top of gel 
 
Equal number of cancer:stellate cells with half in 









Cells seeded on top and gel raised 24 hours later 
 







Table 6.1: Variables tested for optimizing organotypic model 
 
6.2.3 HGF increases invasion of pancreatic cancer cells in 3D 
organotypic model 
Throughout the course of this study, the impact of HGF on PaTu8988T 
migration and signaling has been investigated. It is well documented that 
levels of circulating HGF are increased in pancreatic cancer (Ebert et al., 
1994) and that is acts as a chemoattractant, enhancing cell migration and 
invasion (Giacobini et al., 2007; Stella and Comoglio, 1999). It was therefore 
decided to investigate the effect of using HGF within the organotypic model 
in order to mimic the elevated levels of HGF that are observed in pancreatic 
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cancer. With the air-liquid organotypic model, the gel is raised onto a grid 
and fed from below to encourage invasion. Therefore, HGF was added into 
the culture media and compared with gels where no HGF was included. It 
was also decided to compare DMEM with 10% FBS and KSFM 
supplemented with EGF and BPE, both +/- HGF, in order to find the optimal 
invasive conditions. It has been shown that the addition of both EGF and 
BPE increased keratinocyte motility (Fang et al., 1998) and therefore whether 
the use of this media increased invasion was investigated. 
 
Of the four conditions tested, it was noted that there was a progressive 
increase in PaTu8988T cells from DMEM minus HGF to KSFM with the 
addition of HGF. This was calculated through measuring the depth of 
invasion at three randomly selected areas (imaged by an independent 
observer) from two independent experiments (figure 6.3A and figure 6.3B). 
The areas of invading cells were calculated after exclusion of non-uniform 
invasion at the edges of the gel. Any areas where obvious artifactual invasion 
had occurred in identifiable areas (that could be due to processing) were also 
omitted (see also section 2.5.1 and figure 2.3 for details on the analysis 
procedure).  
 
From these results it demonstrated that HGF increased the invasion of 
PaTu8988T cells in an organotypic model. It was therefore decided to use 
these found optimal conditions in future assays where the effect of PAK4 









   
Figure 6.3: Addition of HGF promotes invasion of pancreatic 
cancer cells in 3D. Four conditions were tested in order to investigate 
the optimal conditions for pancreatic cancer cell invasion in the 3D 
organotypic model. These involved using DMEM and KSFM both +/- 
HGF to feed the model from below once raised onto the grid. Media 
was changed every two days. After processing, gels were stained and 
the depth of invasion measured at random points along the images 
from two independent experiments. An increase in invasive potential 
was observed from DMEM -HGF to KSFM +HGF. Therefore, it was 
decided to use this media to feed all subsequent gels in future assays. 
Statistical significance was calculated using Student’s t-test where *** P 
< 0.0001   
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6.2.4 siRNA mediated depletion of PAK4 has no significant impact on 
PaTu8988T cellular proliferation 
It has been well documented that PAK4 plays a significant role in embryonic 
development; PAK4 knockout mice are embryonic lethal and die by 
embryonic day 11.5 (Qu et al., 2003). Conditional knockout of PAK4 in the 
central nervous system of mice also showed that PAK4 was required for 
proliferation of neural progenitor cells (Tian et al., 2011b) and it has also 
been shown that PAK4 functions are required for normal development of the 
mammalian heart (Nekrasova and Minden, 2012).  
 
Regarding cancer, it has been shown that a reduction in PAK4 in MDA-MB-
231 cells resulted in decreased proliferation, which was determined by a cell 
growth assay (Wong et al., 2013); a result that was amplified in low serum 
conditions. Overexpression of PAK4 in choriocarcinoma cells increased 
proliferation significantly and siRNA mediated knockdown conversely saw a 
reduction (Zhang et al., 2011a). It has also been shown that siRNA mediated 
depletion of PAK4 in Hep-2 laryngeal carcinoma cells (Sun et al., 2013) and 
pharmacological inhibition of PAK4 by LCH-7749944 in gastric cancer cells 
(Zhang et al., 2012) both resulted in a decreased proliferative rate. PAK4 
regulation of proliferation has also been observed in ovarian cancer (Siu et 
al., 2010a) and colon cancer cell lines (Tabusa et al., 2013). Prior to 
undertaking the investigation of PAK4 depletion on PaTu8988T invasion in 
the 3D organotypic model, whether it had an effect on proliferation in this cell 
line was first studied. 
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More recently is has been shown that PAK4 promotes proliferation of 
pancreatic cancer cells via AKT and ERK activation of the NF-κB pathway 
(Tyagi et al., 2014). Therefore, to study the impact of PAK4 knockdown on 
PaTu8988T proliferation, cells were subjected to siRNA-mediated depletion 
of PAK4 and subsequently replated onto collagen coated tissue culture 
plates. Cells were incubated for 72 hours and an MTT assay conducted 
which detected the number of viable cells. Contrary to previous results, there 
was no significant difference in cellular proliferation observed in PAK4 
knockdown cells when these were compared to both control and WT cells 
(figure 6.4). Although these results were different from those observed in 
other published studies, within our laboratory it has also been observed that 
stable PAK4 knockdown breast cancer cells had little observed difference in 
proliferation. These observed results would mean that if PAK4 knockdown 
has no impact on PaTu8988T cell proliferation, that any observed differences 
in invasion could not be due to a decreased proliferative rate. 
 
6.2.5 PAK4 knockdown reduces invasion of PaTu8988T cells in 3D 
PAK4 is known to regulate the cytoskeleton in response to its interaction with 
Cdc42 (Abo et al., 1998). However, PAK4 is also known to interact with GEF-
H1 (Callow et al., 2005), LIMK (Dan et al., 2001) and Gab1 (Paliouras et al., 
2009). These interactions are, in part, responsible for PAK4 driven cell 
migration and invasion. PAK4 has been shown to be involved in endothelial 
cell invasion in 3D collagen matrices, downstream of Cdc42 (Koh et al., 




Figure 6.4: Depletion of PAK4 has no significant impact on 
PaTu8988T cellular proliferation. After siRNA-mediated depletion of 
PAK4, PaTu8988T cells were subjected to an MTT assay to look at the 
effect of PAK4 knockdown on cellular proliferation. PAK4 knockdown 
cells were compared with both WT and control siRNA cells after 72 
hours. There was no significant difference observed after results 
obtained over three independent experiments were quantified. 
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collagen matrices (Fisher et al., 2009). There are also many studies that 
strongly implicate abberant PAK4 signalling is involved in cancer cell 
invasion, including in endometrial (Lu et al., 2013b), ovarian (Siu et al., 
2010a), glioma (Kesanakurti et al., 2012), gastric (Guo et al., 2014b) and 
breast (Wong et al., 2013) cancers . In addtion, a recent study showed that 
PAK4-depleted A431 cells had significantly decreased invasion in an 
organotypic model (Zanivan et al., 2013). 
 
To investigate the role of PAK4 on pancreatic cancer cell invasion, 
PaTu8988T cells were first subjected to siRNA-mediated depletion of PAK4 
before being used as previously described in the organotypic model. Three 
gels from three independent experiments were analysed to compare PAK4 
knockdown cell invasion with WT and control siRNA treated cells. As before, 
the depth of invasion was measured at three randomly selected areas from 
each experiment, after exclusion of non-uniform or obvious artifactual 
invasion areas of the gel. This thickness of the cell layer is observably less 
after PAK4 knockdown in comparison to both WT and control cells (figure 
6.5A). In addition, the depth of invasion was calculated and demonstrated 
that there was a significant reduction in PaTu8988T cell invasion into the 
matrix after depletion of PAK4 (figure 6.5B). This was apparent with both 
siRNA oligonucleotides used in comparison to control siRNA-treated cells. 
Looking at the interface between the invading cancer cells and the matrix, it 
was also shown that there was an increasingly disorganised architecture at 








Figure 6.5: PAK4 depletion leads to a reduction in PaTu8988T cell 
invasion in 3D. PaTu8988T cells were used in the organotypic model 
after depletion of PAK4. After 14 days the gels were harvested and sent 
for processing. Immunofluorescent staining was used to look 
specifically at cancer cell invasion. Images show staining for DAPI 
(blue) and WSS pan-cytokeratin (green) which is specific to cancer cells 
(A). Results from three independent experiments were quantified after 
measurements at randomly selected points were measured (B). Results 
demonstrate a significant reduction in PaTu8988T cell invasion after 
siRNA-mediated knockdown of PAK4 in comparison to control siRNA-
treated cells. (C) Magnification using a 40X lens imaging the interface 
between the cell:matrix border shows that there is a more disorganised 
cell architecture in control cells in comparison to PAK4 knockdown 
cells, with cell clusters breaking away from the main cell group to 
invade down into the matrix. Statistical significance was calculated 
using Student’s t-test where *** P < 0.0001   
 238 
6.5C), with more cells evidently breaking away and invading as small groups 
of cells down into the matrix although the same pattern on invasion observed 
in preliminary experiments (figure 6.3) was not observed. 
 
It is known that resistance to apoptosis is a key process in oncogenesis and 
it has been shown that PAK4 promotes cell survival via several mechanisms 
(King et al., 2014). It has been shown that cells overexpressing PAK4 are 
able to evade apoptosis (Gnesutta et al., 2001), which can be kinase 
independent through antagonism of caspase 8 activation or kinase 
dependent phosphorylation of the proapoptotic protein Bad (Gnesutta and 
Minden, 2003; Gnesutta et al., 2001). In contrast, PAK4 is also known to 
stimulate the activation of pro-survival pathways induced by TNF-α (Li and 
Minden, 2005). 
 
Knowing that the antiapoptotic functions of PAK4 play a key role in 
tumorigenesis, the organotypic gels were stained for cleaved caspase 3, 
which is a marker of apoptosis. This was to determine if there was any visible 
differences in the number of apoptotic cells present before/after PAK4 
knockdown and whether cell death contributed to the differences in invasion 
observed. The gels for WT, control and both PAK4 knockdown conditions 
were stained with both cleaved caspase 3 and DAPI and the images 
compared (figure 6.6). There was no marked difference in the expression of 
cleaved caspase 3 observed across all four conditions, although staining did 
appear to be weaker in siRNA2 treated cells. However, of note was the 




Figure 6.6: Cleaved caspase 3 staining of 3D organotypic model. 
To investigate whether apoptotic cell death contributed to the observed 
differences in invasion observed after PAK4 knockdown, sections were 
stained for DAPI (blue) and cleaved caspase 3 (green). Of note, was 
the strong staining at the top of the sections. There appeared not to be 
any other observed differences in the number of apoptotic cells 
throughout the section. However, there appeared to be only very few 
cleaved caspase 3 positive cells in siRNA2 treated cells. 
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of the experiment, the exposure of the top of the gel could account for the 
pattern of apoptotic cells observed. 
 
Having investigated the effect of PAK4 knockdown on proliferation via an 
MTT assay previously. The organotypic sections were also stained for Ki67, 
which is a marker of actively proliferating cells. This was used as another 
way of examining whether there could be an observed difference in cellular 
proliferation once cells were used within the organotypic and at a longer time 
frame. There appeared to be only limited observed differences in the 
expression patterns of Ki67 across the four conditions tested (figure 6.7A), 
but after quantification using ImageJ there appeared to be a slight decrease 
in ki67 positive cells after PAK4 knockdown especially siRNA5 (figure 6.7B). 
 
6.2.6 Inhibition of PI3K phenocopies PAK4 knockdown invasion 
patterns 
Throughout this investigation, the links between PAK4 and the PI3K pathway 
have been studied. This has, in part, included the comparison between PAK4 
knockdown and pharmacological inhibition of PI3K via treatment with 
LY294002. Having investigated the effect of PAK4 knockdown in a 3D 
organotypic model, the effect of PI3K inhibition was next studied. 
 
As before, cellular proliferation was first investigated. It is known that the 
PI3K pathway plays a key role in cellular proliferation (Hemmings and 
Restuccia, 2012), therefore it was not unexpected for there to be a significant 





Figure 6.7: Ki67 staining of 3D organotypic model. In addition to the 
MTT assay, Ki67 staining was performed on sections to look at actively 
proliferating cells (A). Sections were co-stained with DAPI (blue) and 
Ki67 (green). WT, control and siRNA2 treated cells appeared to have 
actively proliferating cells throughout the section. Qualitative analysis 
revealed that there were however, only a small number of observed 
ki67 positive cells in siRNA5 treated PaTu8988T cells. N=1 but two 
images from each condition were analysed and quantified using ImageJ 
(B) which confirms a slight decrease in the percentage of ki67 
expressing cells/actively proliferating cells after PAK4 knockdown, 
particularly with siRNA5. 
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assay (figure 6.8A). The PI3K inhibitor has been widely used in the study of 
cellular proliferation, in mouse embryonic stem cells treatment lead to a 
marked decrease in cellular proliferation and cell cycle arrest, with an 
accumulation of cells in the G1 stage of the cell cycle (Lianguzova et al., 
2007). Pharmacological studies have also shown a significant reduction in 
cellular proliferation in bladder (Wu et al., 2011a), nasopharyngeal carcinoma 
(Jiang et al., 2010), ovarian (Hu et al., 2000) and also colon and pancreatic 
cancer cells (Semba et al., 2002) under nutrient starvation conditions (Izuishi 
et al., 2000). Therefore, the significant decrease in PaTu8988T cellular 
proliferation, that was observed, is what would be expected.  
 
Knowing that LY294002 can affect both cellular proliferation and induce 
apoptosis, these factors would be considered upon analysing results 
obtained from the organotypic data set. As before, three independent 
experiments were conducted using the PI3K inhibitor, where LY204002 was 
added to the media feeding the gel from below. As a control, DMSO was 
used as an additive at the same concentration. The same analysis 
parameters were used with regards to the measurements taken to calculate 
the invasive cell depth. 
 
The results were gathered and a significant reduction in PaTu8988T cell 
invasion was observed after cells had been subjected to pharmacological 
inhibition of PI3K in comparison to the DMSO control cells (figure 6.8B). 
Only a very thin layer of cells was apparent in images taken of the PI3K 





Figure 6.8: Pharmacological inhibition of PI3K phenocopies 
invasion patterns of PAK4 knockdown cells. The PI3K inhibitor, 
LY294002, was used to study the impact of pharmacological inhibition 
of PI3K on PaTu8988T cell invasion. (A) An MTT assay was performed 
and demonstrated that there was a significant reduction in cellular 
proliferation after treatment with LY294002 in comparison to DMSO 
control cells. (B) Sections of a 3D organotypic model were analysed 
and quantitative analysis revealed that there was a significant reduction 
in PaTu8988T cell invasion after PI3K inhibition. (C) Sections stained 
for DAPI (blue), WSS pan-cytokeratin (green) and α-SMA (red) 
revealed a reduced invasion into the matrix. Results and images shown 
are data gathered from three independent experiments. Statistical 
significance was calculated using Student’s t-test where ** P < 0.002 
and *** P < 0.0001   
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6.3 Discussion 
Within this chapter, a 3D organotypic model of pancreatic cancer was used 
to study the effect of PAK4 knockdown on PaTu8988T cell invasion. The 
model provides a platform in which to study cellular behavior in an 
environment that better replicates conditions found in vivo. This therefore 
provides a more complete insight into the effects of the chosen variable using 
an assay that is reproducible. The air-liquid organotypic model is a widely 
used 3D model in which to study cancer cell behavior. It has been used in 
numerous studies to investigate cancer cell invasion including pancreatic 
cancer (Coleman et al., 2014; Froeling et al., 2010; Froeling et al., 2009). 
Although, the model has been well characterised, further optimisation 
allowed for the production of more stable gel matrix, which therefore made 
the procedure more consistent and allowed for results to have increased 
reproducibility.  
 
To enhance invasion, initial studies of PaTu8988T cell invasion involved 
using WT cells and altering the culture media used to feed the organotypic 
gel from below. In previous chapters, it has been demonstrated that 
PaTu8988T cells responded to HGF with an increased velocity in random 2D 
migration assay. It was therefore decided to transfer these 2D findings into 
the 3D model, whereby media supplemented with HGF at the same 
concentration was compared to media where no HGF was added. It was also 
decided to test another culture media, KSFM. KSFM has additional growth 
factors used to supplement the media, including EGF, and KSFM +/- HGF 
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was used in addition to the DMEM +/- HGF in order to find optimal conditions 
for promoting invasion of the PaTu8988T cells in the organotypic model.  
 
Across the four conditions, a progressive increase in invasion was observed 
from DMEM -HGF to DMEM +HGF, which increased further in KSFM -HGF 
with the most invasion being observed when KSFM supplemented with HGF 
was used to feed the gel from below. The additional growth factors contained 
within the media therefore must promote invasion. From previous studies and 
work throughout the course of this investigation, it has been observed that 
HGF increases pancreatic cell migration (Ebert et al., 1994; Matsushita et al., 
2007; Ohba et al., 1999). Therefore, it was expected to have a similar result 
when transferred to the 3D model. Although it has not been investigated 
within this study, as well as the HGF receptor C-met being upregulated, 
EGFR is known to be overexpressed in pancreatic cancer (Oliveira-Cunha et 
al., 2011). Numerous studies have also shown that an increase in pancreatic 
cancer cell migration occurs in response to EGF (Liu et al., 2012; Ouyang et 
al., 2013; Stock et al., 2014). Therefore, the results observed here, whereby 
there was an increase in PaTu8988T cell invasion when KSFM 
supplemented with both EGF and the additional HGF, are what would be 
expected. 
 
Prior to using PAK4 depleted PaTu8988T cells in the organotypic model, an 
MTT assay was carried out to investigate the impact of PAK4 knockdown on 
PaTu8988T proliferation. This could therefore be used to determine whether 
any potential differences observed in invasion were due to a decreased 
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invasive potential or due to a decreased proliferative capacity. It has been 
shown in numerous studies that PAK4 impacts on cell cycle progression 
through regulation of the cell-cycle regulatory protein, p21, which plays a 
significant role in controlling the G1 to G2/M transition (Nekrasova and 
Minden, 2011) and also through regulation of spindle positioning throughout 
mitosis (Bompard et al., 2013). As previously stated, it is also known that 
PAK4 depletion or inhibition in various cancer cells leads to a decrease in 
cellular proliferation. This has been studied in breast (Wong et al., 2013), 
gastric (Zhang et al., 2012), ovarian (Siu et al., 2010a) and colon (Tabusa et 
al., 2013) cancer cell lines, among others. Therefore, it was somewhat 
surprising to find that siRNA-mediated depletion of PAK4 in the PaTu8988T 
cells had no significant impact on cellular proliferation/viability after 
quantifying results obtained from a 72-hour cell growth assay.  
 
As the organotypic assays were to be carried out over a period of 14 days, it 
could be argued that 72 hours may not provide a long enough time frame in 
which to study changes in proliferation accurately. However, as 
demonstrated in previous results chapters, knockdown of PAK4 using both of 
the siRNA oligonucleotides is evident after only 24 hours. Therefore, any 
impact PAK4 depletion had on cellular proliferation would most likely be 
evident by 72 hours. In addition, unpublished data using stable PAK4 
knockdown breast cancer cell lines has also shown little change in cellular 
proliferation when conducting the same cell growth assay. It is also noted, 
that the stable PAK4 knockdown breast cancer cell lines could be maintained 
in long term cell culture. In a study of colon cancer, it was also demonstrated 
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that knockdown of either PAK4 or PAK1 impacted on cellular proliferation in 
a cell line dependent manner. Of the seven cell lines used, six showed a 
decrease in cellular proliferation after PAK4 knockdown and only two showed 
a decrease after PAK1 knockdown (Tabusa et al., 2013). A recent study of 
pancreatic cancer, which demonstrated promotion of proliferation through 
PAK4 activation of the NF-κB pathway (Tyagi et al., 2014) had not used the 
PaTu8988T cell line. This could therefore go some way as to explain the 
results observed here and it could be hypothesised that the effects of PAK4 
depletion on cellular proliferation are cell line dependent. 
 
Subsequent to the proliferation studies, the effect of PAK4 knockdown in the 
3D model of pancreatic cancer was next investigated. It has been shown that 
knockdown of PAK4 in A431 cells resulted in decreased invasion (Zanivan et 
al., 2013) in a similar 3D organotypic model. However, to date, the effect of 
PAK4 knockdown using pancreatic cancer cell lines in this system has yet to 
be investigated. The results obtained through these studies showed that 
there was a significant decrease in PaTu8988T cell invasion down into the 
matrix, in comparison to WT and control cells. However, the same pattern of 
invasion as demonstrated in earlier experiments was not reproducible. 
Minimal invasion of cells, either as single cells, strands or clusters was not 
observed at a significant level. Despite MTT assays carried out suggest 
minimal impact of PAK4 knockdown in the PaTu8988T cell line, the results 
observed within the organotypic model imply an effect on proliferation as a 
thinner layer of cells is evident in PAK4 knockdown samples, in comparison 
to both WT and control conditions. This may be due to differences in cell 
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behaviour in 2D assays to the 3D environment of the organotypic model. 
Although some increasingly disorganised architecture at the cell/matrix 
interface was observed, no quantifiable patterns of invasion were observed. 
These results therefore prevent full conclusions as to the effect of PAK4 
knockdown on PaTu8988T cell invasion in 3D environment.  Further 
investigation into the effect of PAK4 knockdown on longer-term proliferative 
effects as well as invasion would therefore be advisable.  
 
For qualitative analysis, sections from each condition were stained for ki67 (a 
marker of actively proliferating cells) and cleaved caspase 3 (expressed by 
apoptotic cells). The four different conditions under examination 
demonstrated similar expression patterns. Regarding the expression of 
cleaved caspase 3, cells with positive expression of this protein appeared to 
be mainly concentrated at the top of the gel. It was hypothesised that due to 
the experimental set up, where the gel is exposed to the environment, cells 
that were atop the gel could be under increased stress and this could 
account for the concentration of cells expressing this marker towards the top 
of the gel. However, taken together, these novel findings highlight that PAK4 
could be heavily implicated in the invasion of pancreatic cancer cells. 
 
In addition to investigating the impact of PAK4 depletion on PaTu8988T cell 
invasion and complimenting previous work, the effect of pharmacological 
inhibition of PI3K by LY294002 was investigated. As with PAK4 knockdown 
cells, an MTT assay was carried out in order to look at changes in cellular 
proliferation/viability. It is known that the use of LY294002 leads to a 
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significant reduction in cellular proliferation and induces programmed cell 
death in various cancer cell lines, including pancreatic (Izuishi et al., 2000; 
Semba et al., 2002). Therefore, the significant reduction in LY294002 treated 
PaTu8988T cells, compared to the DMSO control cells was as predicted as it 
is known that both cellular proliferation and cell cycle progression are PI3K 
dependent in pancreatic cancer and also that this signaling cascade has 
antiapoptotic properties (Perugini et al., 2000). Following the proliferation 
studies, the effect of pharmacological inhibition of PI3K was investigated in 
the organotypic model. Media was supplemented with either DMSO, as a 
control, or LY294002. Following quantification there was a significant 
reduction in the depth of invasion following treatment with LY294002. Having 
previously observed the significant reduction in cellular proliferation the 
difference in invasion is as predicted. In addition, visualization of the stained 
sections revealed a marked decrease in cell number. Again this can be 
explained by the reduction in cellular proliferation and hypothesised increase 
in programmed cell death.  
 
Within this chapter, novel data has shown that there is a requirement for 
PAK4 within pancreatic cancer cell invasion, as observed through the use of 





6.4 Future Directions 
It was observed within this chapter that the depletion of PAK4 from 
PaTu8988T cells had no significant impact on cellular proliferation. It was 
hypothesised that this could be cell line specific as differential responses 
have been observed in other cancer cell lines. It would therefore be 
beneficial to study the effect of PAK4 knockdown in a panel of pancreatic cell 
lines to determine as to whether this hypothesis is correct. However, due to 
the nature of this study, the fact that the depletion of PAK4 had minimal 
effects of PaTu8988T proliferation did infer that alterations in invasive 
capacity was due to the reduction in PAK4 protein levels. However, from 
qualitative analysis of the organotypic images, an effect of proliferation could 
be suggested, contrary to the MTT assay results. This could be due to 
differences in cell behaviour in 3D environments in comparison to 2D. It 
would therefore be recommended to conduct proliferation assays with cells 
embedded in a collagen matrix to provide a similar environment to the 
organotypic model in which to study the effect of PAK4 knockdown on 
PaTu8988T cell proliferation. In addition, it may be advised to study other 
markers of proliferation/cell cycle. Previous studies that demonstrated a 
correlation in PAK4 knockdown and decreased proliferation also observed a 
reduction in cyclin D1 (Siu et al., 2010a; Tabusa et al., 2013; Zhang et al., 
2011a), therefore investigating the levels of this protein in the pancreatic cell 
lines after PAK4 knockdown could be beneficial. 
 
The 3D organotypic model of pancreatic cancer used within this study is an 
appropriate platform in which to study cancer cell invasion and bridges the 
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gap between 2D in vitro cell-based assays and complex in vivo models. It 
would of course be ideal to be able to use in vivo mouse models to 
investigate the role of PAK4 in pancreatic cancer progression as they provide 
an environment in which to study the disease in all its stages in an 
environment that is more comparable to that found in humans. However, the 
long latency periods involved make these sorts of studies costly and they are 
less easily manipulated than the organotypic models. Further use of these 
organotypic models could therefore be advantageous to study 
pharmacological inhibition of PAK4 for example. 
 
Staining of organotypic sections for cleaved caspase 3 was carried out for 
qualitative analysis of apoptotic cells. It would be useful to carry out more 
quantitative analysis of apoptosis. Various caspase assays are commercially 
available which could be used to investigate the effect of PAK4 knockdown 
on programmed cell death within the cell line used to provide further insight. 
 
It is known that cross-talk between stellate cells and cancer cells contributes 
to pancreatic cancer disease progression. It would therefore be of interest to 
investigate whether PAK4 contributes to this too. A coculture model to 
investigate hepatocytes and hepatic stellate cells has been used to 
demonstrate bi-directional crosstalk, resulting in gene deregulation and 
changes to the microenvironment through induction of VEGFA and MMP-9 
(Coulouarn et al., 2012). In addition, studies utilizing conditioned media from 
pancreatic cancer cells have been shown to stimulate pancreatic stellate 
cells and increased production of MMP-2 (Bachem et al., 2005; 
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Schneiderhan et al., 2007). An interaction between PAK4 and MMP-2 has 
been previously reported to be involved in the invasion of glioma 
(Kesanakurti et al., 2012), Therefore it could be hypothesised that this could 
also play a role in pancreatic cancer progression and may be worth further 
investigation. However, the results obtained throughout this results chapter 
have provided novel insight into the role of PAK4 on pancreatic cancer cell 











Chapter 7: Concluding remarks 
In this study it has been demonstrated that PAK4 is overexpressed in a 
range of pancreatic cancer cell lines, which correlates with an increased 
expression of c-Met, K-ras and the p85α subunit of PI3K. Furthermore, using 
the highly invasive cell line, PaTu8988T, it has been shown that these cells 
respond to HGF with both an increase in the phosphorylation of downstream 
effector proteins such as Akt and also an increased migrational response. In 
addition, a novel interaction between PAK4 and components of the Ras/PI3K 
pathway has been established. Of particular interest was the interaction 
between PAK4 and p85α, which has been show to be dependent on the 
proline rich region of PAK4 and how Gab1 may also act as a scaffold 
between the two proteins. In addition siRNA-mediated depletion of PAK4 was 
shown to reduce both 2D migration and 3D invasion, which may be through 
regulation of the downstream effector protein, Akt; these data have also been 
shown to be phenocopied through pharmacological inhibition of PI3K. Thus, 
PAK4 may be involved in the PI3K pathway to promote pancreatic cell 
invasion. 
 
The question posed was how PAK4 was involved within pancreatic cancer 
progression, with particular interest on how it interacts with the PI3K 
pathway. There is already considerable evidence to suggest a role for PAK4 
in metastasis and invasion in other cell types and more recently links 
between PAK4 and pancreatic cancer have been investigated (Chen et al., 
2008; Kimmelman et al., 2008; Mahlamaki et al., 2004). PAK4 is the most 
widely studied of the group II PAKs and has been shown to contribute 
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significantly to cancer cell invasion in gastric cancer (Guo et al., 2014b; 
Zhang et al., 2012), glioma (Kesanakurti et al., 2012), choriocarcinoma 
(Zhang et al., 2011a), endometrial (Lu et al., 2013b), prostate (Ahmed et al., 
2008; Wells et al., 2010), ovarian (Siu et al., 2010a) and breast cancer 
(Minden, 2012; Wong et al., 2013) among others, both in vitro and in vivo. 
PAK4 is able to promote cancer cell invasion through modulation of the actin 
cytoskeleton and microtubules. It is known that this regulation occurs through 
interaction with various proteins including Cdc42, which leads to 
reorganisation of actin in the formation of filopodia (Abo et al., 1998); GEF-
H1 mediated interaction with microtubules allows for increased motility 
(Callow et al., 2005); phosphorylation of LIMK by PAK4 enables inhibition of 
the actin filament disassembly protein, cofilin (Dan et al., 2001); and 
association with the scaffold protein Gab1 leads to modulation of cell 
migration within lamellipodia (Paliouras et al., 2009). 
 
However, how PAK4 may drive pancreatic cancer cell invasion has yet to be 
fully elucidated. Genomic studies have shown that PAK4 can be activated by 
oncogenic K-ras, which is mutated in over 90% of pancreatic tumour samples 
(Chen et al., 2008) and in vitro cell-based assays have shown that shRNA-
mediated knockdown of PAK4 in a pancreatic cancer cell line reduced cell 
migration (Kimmelman et al., 2008). However, the mechanisms underlying 
these findings have not been fully investigated. 
 
Data presented here demonstrate that PAK4 is able to pulldown K-ras; 
although links between K-ras and PAK4 in pancreatic cancer have been 
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established (Chen et al., 2008) and the overlap in signalling networks 
regulated by K-ras and PAK4 investigated (Gnad et al., 2013), this interaction 
has not previously been described. Moreover, an interaction between the 
p85α subunit of PI3K and the proline rich region was established. This novel 
interaction between PAK4 and p85α was found to be dependent on the 
proline rich region of PAK4 and the SH3 domain of p85α. Whether Gab1 was 
involved in this interaction was also investigated, as it is known to bind to 
both the GID of PAK4 (Paliouras et al., 2009) and the SH2 domain of p85α 
(Rocchi et al., 1998; Yu et al., 2001). Results revealed that Gab1 knockdown 
lessened that interaction observed between PAK4 and p85α. However, as 
binding was observed between just the SH3 domain and PxxP region it was 
hypothesised that binding between PAK4 and p85α could be both direct and 
indirect, via the scaffold protein Gab1. The mechanism of PAK4 activation 
has been the subject of intense study. Recently, an N-terminal region 
(R49PKP) was found to act as an autoinhibitory pseudosubstrate. It was also 
found that Src SH3 could activate PAK4 and relieve autoinhibition (Ha et al., 
2012). The tertiary structure and binding partners of the SH3 domains of both 
Src and p85α have shown commonalities previously (Koyama et al., 1993; 
Shen et al., 1999); this therefore provides scope for activation of PAK4 by 
pseudosubstrate autoinhibition release through binding to a SH3 domain 
containing proteins, which could potentially include p85α. 
 
Further to the interaction studies with upstream components of the PI3K 
pathway, how PAK4 was involved with downstream effector proteins was 
also investigated. It was shown that depletion of PAK4 resulted in a reduction 
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of Akt phosphorylation. During the course of this investigation, newly 
published data has corroborated these findings, whereby a reduction in 
PAK4 in both NIH3T3 and gastric cancer cells lines resulted in a reduction of 
Akt at Ser473 (Fu et al., 2014; Gnad et al., 2013). In addition, this phenotype 
was seen to be rescued by expression of constitutively active K-ras (Gnad et 
al., 2013). This further supports the hypothesis of a RAS/PI3K/PAK4/AKT 
pathway, but the comprehensive mechanisms behind PAK4/Akt interplay still 
remains unclear. Whether PAK4 affects phosphorylation of Akt at Thr308, as 
well as Ser473, has not yet been investigated and if the regulation of Akt by 
PAK4 is direct or mediated via other mechanisms requires further study.  
 
Akt is recruited to the membrane by binding of its PH domain to the PI3K 
reaction products PIP2 and PIP3, and this translocation to the membrane is 
crucial for Akt activation (Kohn et al., 1996; Sarbassov et al., 2005). It is 
known that both PDK1 (Higuchi et al., 2008) and the mTORC2 complex 
(Case et al., 2011; Moore et al., 2011; Sarbassov et al., 2005; Tato et al., 
2011) impact on AKT activity through phosphorylation at Thr308 and Ser473, 
respectively, downstream of PI3K.  It has also been shown that PDK1 can 
interact with PAK1 (King et al., 2000; Riaz et al., 2012; Weber et al., 2004). 
Indeed, in NIH-3T3 cells, activated PAK1 increased phosphorylation of Akt at 
both sites, which was shown to be independent of PAK1 kinase activity. It 
was demonstrated that PAK1 served as a scaffold, binding to both PDK1 and 
Akt to promote Akt phosphorylation by PDK1. This interaction was increased 
after growth factor stimulation and was found to promote cell motility (Higuchi 
et al., 2008). PAK1 has also been shown to affect phosphorylation of Akt at 
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Ser473. A study using cardiomyocytes revealed a direct interaction between 
PAK1 and Akt, which resulted in Akt phosphorylation at Ser473 (Mao et al., 
2008; Rauch et al., 2011). Despite differences in sequence homology, PAK1 
and PAK4 share a number of substrates (Dart and Wells, 2013), so it could 
therefore be hypothesised that PAK4 affects the phosphorylation of Akt by a 
similar mechanism. It would therefore be highly beneficial to investigate 
these possible regulatory mechanisms further. 
 
Furthermore, although typically the PI3K/AKT pathways has been considered 
primarily to be responsible for survival signalling and proliferation, there is 
accumulating evidence to suggest that Akt signalling contributes to cellular 
motility, including in metastatic cancer cells (Higuchi et al., 2001; Kim et al., 
2001; Xue and Hemmings, 2013; Xue et al., 2012). A role for Akt in 
pancreatic cancer cell migration has not been previously documented; 
however, results provided within this study provide a strong case for Akt 
involvement. Phosphorylation at both Thr308 and Ser473 is required for full 
activation of Akt, and although within this study only Ser473 phosphorylation 
was investigated, it still provides evidence for a PI3K/PAK4/Akt axis 
involvement in PDAC cell migration. Akt has been shown to induce tumour 
metastasis through Twist1 phosphorylation-driven EMT via crosstalk 
between TGF-β and PI3K signalling (Xue et al., 2012) and activated Akt 
(shown by increased Ser473 phosphorylation), was found to promote 
phosphorylation/activation of components important cell migration including 
actin filaments (Ho et al., 2011). Indeed, phosphorylation of Akt at both 
Thr308 and Ser473 was required for motility of lung endothelial cells 
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downstream of HGF, with pharmacological inhibition of PI3K via LY294002 
treatment leading to reduced phosphorylation at both sites and decreased 
lamellipodia formation (Usatyuk et al., 2014). Furthermore, it has recently 
been reported that the Wnt family member, Wnt5A, promotes 
phosphorylation of Akt at Ser473 downstream of PI3K to promote 
osteosarcoma cell migration (Zhang et al., 2014a), supporting the hypothesis 
that PAK4 regulation of Akt phosphorylation at Ser473 may also be required 
for PDAC cell migration. Whether this is direct phosphorylation of via an 
intermediary requires further study, as does whether there is involvement of 
Thr308 phosphorylation. 
 
However, what has been demonstrated here is the requirement for PAK4 in 
pancreatic cancer cell migration and invasion (summarised in figure 7.1). A 
novel interaction between PAK4 and p85α has provided evidence for the 
involvement of PAK4 in the PI3K pathway. It is thought that this could 
potentially be a mechanism to relieve PAK4 autoinhibition (similar to Src 
SH3), which then serves to promote phosphorylation of AKT at Ser473 and 







Figure 7.1: Proposed model of RAS/PI3K/PAK4/AKT signalling 
module in pancreatic cancer. Data gathered throughout the course of 
this study provides evidence that PAK4 lies downstream of K-ras and 
PI3K to promote pancreatic cancer cell migration. PAK4 has been 
shown to bind to K-ras and to the p85α subunit of PI3K either directly 
via a PAK4PxxP/p85αSH3 domain interaction, or indirectly via the 
scaffold protein Gab1. It is thought that this signalling pathway is 
activated downstream of HGF-mediated c-Met activation and serves to 
increase phosphorylation of Akt at Ser473, which subsequently leads to 
increase both 2D migration and 3D invasion of pancreatic cancer cells. 
It has also been hypothesised that SH3-mediated binding of p85α to 
PAK4 (*) could serve to aid relief of PAK4 autoinhibition. Whether PAK4 
phosphorylates Ser473 directly or through an intermediary (?) such as 
mTORC2 remains to be elucidated, as does the impact PAK4 may have 
on Akt phosphorylation at Thr308. However, it has been shown that 
PAK4 serves to increase pancreatic cancer migration in an Akt 
dependent manner, downstream of a novel interaction with PI3K. 
 
*indicates potential binding that may aid in relief of PAK4 autoinhibition 
? indicates possible intermediary protein between PAK4 and AKT 
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